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   Abstract 
Claire O’Connell 
Dye-doped silica nanoparticles for cancer cell staining and detection 
 
 Cancer is a leading cause of death worldwide, with metastasis responsible for a 
majority of these deaths. Circulating tumour cells (CTCs) present in blood samples can 
be a precursor to metastasis and if detected in low numbers can indicate early stage 
cancer. In this work, fluorescent silica nanoparticles (NPs) were developed to detect 
these CTCs. NPs approximately 40 nm in diameter were doped with two different 
concentrations of Cyanine5 dye molecules, using the reverse microemulsion method. 
The NPs were over 100 times brighter than Cyanine5 free dye and the measured 
fluorescence intensity matched a homo-Förster Resonance Energy Transfer model. NPs 
were conjugated with anti-epithelial cellular adhesion molecule (EpCAM) antibody to 
the NP surface for immunospecific targeting. The NP labels were shown to selectively 
bind to model CTC lines, MCF-7 and LNCaP, a metastatic breast and prostate cancer 
cell line respectively, by targeting EpCAM present on the cell’s membrane.  
In flow cytometry experiments, the NPs were twice as bright as commercial anti-
EpCAM red fluorophore conjugates, APC and AlexaFluor®647 on the MCF-7 cell line. 
This increase was achieved while keeping non-specific binding low with a non-
metastatic cancer control cell line (HeLa). The NPs were also immunospecific in 
fluorescence microscopy experiments. Confocal microscopy was used to confirm that 
the NPs were located on the cell’s surface, matching with the location of the EpCAM 
marker. The NPs were tested in a mixed cell environment by spiking CTCs into lysed 
blood samples where the NPs successfully identified CTCs at different ratios to white 
blood cells.  
Some experiments were also conducted to investigate the use of NPs for 
secondary antibody staining of EpCAM on CTCs. In addition, gold grating plasmonic 
enhanced fluorescence imaging of CTCs was investigated briefly. In summary, the NP 
labels have excellent potential in biomedical applications, particularly in cell labelling 
and diagnostics. 
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Chapter 1: Introduction 
 
1.1  Motivation and context 
Cancer is the second leading cause of death worldwide, with 8.8 million deaths occurring 
in 2015 and it has been predicted that this number is going to rise by 70% over the next 
20 years [1,2]. The majority of cancer deaths are caused from the phenomenon that is 
called metastasis which is the spread of cancer from the primary tumour site to form 
secondary tumours elsewhere in the body. This happens due to proliferation of cancer 
cells from the primary tumour, called circulating tumour cells (CTCs), that can enter the 
blood stream and spread to other organs. The metastasis of cancer makes it very difficult 
to treat, primarily because these cells are found in blood samples at such a low range of 
concentrations. These numbers vary from cancer type and stage but can be as low as 1-
10 in every millilitre of blood, which contains millions of healthy blood cells [3]. The 
attraction of research into these cells is that accurate identification and quantification 
could represent a non-invasive method of assessing cancer patient disease stage or 
evaluation of patient treatment where, usually, patients routinely endure long waiting 
times for scans or invasive biopsies.  
 
1.2   Current detection methods of cancer 
Currently, cancer diagnosis in patients is primarily based on self-reporting, where a 
patient, upon finding a lump or presenting with other symptoms of being unwell, will 
visit their local general physician. The doctor will send the patient for further testing in 
the form of biopsy tests and imaging scans that can be expensive. It is a well-known fact 
that time is of the essence when dealing with cancer, so long waiting lists in hospitals 
for these procedures can increase the mortality rate of the patient. Furthermore, even 
when results are returned, the diagnosis can often be of late stage cancer, for which 
treatment has a high rate of failure.  
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1.2.1 Imaging 
There are many types of imaging systems that can be used to image and detect cancer 
tumours, leading to diagnosis. Irish breast cancer patients with self-reported lumps or 
those in the age bracket of 50-69 that are more prone to the risk of breast cancer, are sent 
for mammograms in order to detect tumours. A mammogram consists of one or two x-
ray images of the breast tissue and identification of a tumour by means of denser tissue 
or some calcification spots which can signify tumour growth [4]. This method can also 
be used to image lung cancer or detect cancer that has metastasised [5].  Current imaging 
techniques can detect tumours that are less than 15mm in size when assessed by a skilled 
radiologist and imaged correctly within 85-90% accuracy [6]. The problem with this 
method is that when the tumour is larger in size, patients have a decreased survival rate. 
When tumours found in patients are greater than 5cm, the patient has only a 70% five-
year survival rate compared with 95% when tumours are found at less than 2cm [7,8]. 
A computed tomography (CT) scan is usually carried out on an organ such as the liver 
or lung and abdomen to detect cancer tumours [5]. CT scans consist of a series of X-ray 
scans taken at multiple angles to form detailed images in either planes of view or even 
to construct 3D images of an organ. As different types of tissue absorb the X-rays to 
varying degrees, the distinction can be made between different tissue types and tumours. 
Positron emission tomography (PET) scans work similarly to CT scans and are usually 
used as a complementary technique to CT scans. Instead of using X-rays, PET scans use 
a radioactive tracer that emits gamma rays [9]. The tracer, usually an isotope with a short 
half-life such as carbon-11, oxygen-15, nitrogen-13, and fluorine-18, when combined 
with certain biological functionality, like fludeoxyglucose, will detect tumours as they 
usually have higher uptake of glucose than regular tissue [9]. The positron emission of 
these radioactive isotopes combines with electrons from surrounding atoms to form a 
pair of gamma rays by annihilation which are then detected by the scanner [9]. This is 
carried out in targeted areas of the body or organs to create high detail images. 
Magnetic resonance imaging (MRI) scans use an external magnetic field, in which nuclei 
with certain spin can be aligned in this uniform magnetic field. Hydrogen atoms have a 
non-zero spin, which encompasses a magnetic and angular momentum, and are found in 
tissues of the body such as fat and water. As radio waves are pulsed into a sample 
containing hydrogen atoms within the magnetic field, they excited the hydrogen nuclear 
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spin and, depending on the difference in relaxation time of the hydrogen in the different 
types of tissue, the technique can be used to distinguish between healthy and cancerous 
tissues [10]. As these scans avoid the use of ionizing radiation, they are primarily used 
for the imaging of the brain and spinal cord [11]. 
1.2.2 Biopsy 
A variety of biopsies can be carried out to investigate the suspicion of cancer depending 
on the type of cancer. Endoscopic biopsies are carried out for forms of cancer such as 
those of the oesophagus, colorectal, lung or urinary tract, to name just a few [12]. 
Another form of biopsy is the needle biopsy, where either fluid or a small sample of 
tissue is extracted from the area of interest for further testing and is usually used for 
cancers such as breast and thyroid or even in an enlarged lymph node [12]. A skin biopsy 
involves the removal of a piece of skin from the patient which is then sent for further 
analysis and usually is for the detection of melanoma. A bone marrow biopsy involves 
a needle insertion into the bone marrow to search for abnormal cells linked with blood 
cancers or metastasis [12]. The last type of biopsy that will be mentioned is a surgical 
biopsy and this type is performed on suspicious areas that cannot be accessed by any of 
the other methods of biopsies. When the fluid, cell or tissue sample has been obtained 
from the patient, this is used for further testing and tissue samples can be thinly cut into 
slices and stained for certain cancer markers which are examined under the microscope 
[12]. In some situations, a pathologist will examine the cell samples to determine the 
particular stage or type of cancer. One thing that is common to all these biopsies is that 
they are extremely invasive for a patient as well as introducing a risk of infection from 
having the procedure. Stress induced from waiting time of tests and results can have 
detrimental effects on patient, especially when this can be up to 25 weeks for brain 
magnetic resonance imaging (MRI) for public patients in the Republic of Ireland [13]. 
If it were possible to reduce these wait times using a simple blood sample test then this 
would be a huge achievement. This is another reason to strive for non-invasive detection 
systems of cancer diagnosis. 
 
1.3  Significance of detection of CTCs 
As CTCs are a precursor to metastasis, research into their enumeration and link to cancer 
stage is of great importance, as it requires only a blood draw which could be incorporated 
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into a patient’s routine check-up. Low number detection rates of these CTCs, ≤5 per 
7.5mL of blood, has been shown to have huge impact on mortality rate of patients 
whereby patients with higher than 5 CTCs had a predicted overall survival time of 8.2 
months compared with 18 months to patients with a count less than 5 [14]. This study 
was carried out using an FDA approved CTC detection instrument called CellSearch 
(Menarini-Silicon Biosystems Inc., CA, USA) which is an expensive system that 
removes CTCs from a blood sample with the use of immuno-magnetic beads followed 
by a staining procedure to verify that the cell is a CTC. The technique is discussed in 
more detail in section 2.6.  Other companies have similar systems for the detection of 
CTCs, some are based solely on fluorescence, such as the CytoTrack instrument, 
(CytoTrack ApS, Lyngby, Denmark) and some are based on the evaluation of size and 
deformation differences between blood cells and CTCs, such as Celsee PREP100 or 
PREP400 (CelSee Diagnostics, MI, USA), after which the cells are stained to verify that 
there are markers present for CTCs on captured cells. 
The focus for this PhD work is to develop a very bright CTC stain using dye-doped silica 
nanoparticles. These particles can incorporate hundreds, and even thousands, of dye 
molecules inside a single particle so that they can be used as a tool to provide a high 
degree of separation, based on photon emission, between positive and negative cell 
populations [15,16]. The proof of concept is to determine whether CTCs can be 
distinguished by using only a nanoparticle based fluorescence stain with conventional 
lab instruments such as a flow cytometer or microscope.  
 
1.4  Overview of work and structure of the thesis 
The work carried out for this thesis focused on successfully using dye-doped silica 
nanoparticles for cell staining to identify CTCs. In order to do this, synthesis and analysis 
of Cyanine5 dye-doped nanoparticles was undertaken. A cell staining method was 
developed in order to evaluate the efficiency of the particles on two cell lines that 
expressed a marker for CTCs; MCF-7 breast cancer and LNCaP prostate cancer, and 
compared to cell lines that did not express EpCAM; cervical cancer cell line, HeLa, and 
healthy prostate cell line, PNT1A. Initial work concentrated on characterising the 
efficiency of the staining using fluorescence microscopy and flow cytometry on the cell 
lines separately. Following this, the EpCAM positive cells were spiked into blood 
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samples to imitate patient blood samples to evaluate the nanoparticles ability to label the 
cells correctly. Secondary antibody staining methods were investigated to improve 
sensitivity and signal and nanoparticles were also used with grating coupled surface 
plasmon resonance for enhanced cell imaging.  
The structure of this PhD thesis comprises of a brief introductory chapter, chapter 1, to 
give context of the project, followed by chapter 2 which provides the theory and 
background behind the various aspects involved within this thesis and also contains a 
section on state of the art nanoparticle synthesis and application in cell staining. Chapter 
3 gives a brief overview of the instrumentation and characterisation techniques used 
throughout the PhD, while Chapter 4 describes the synthesis, characterisation and 
development of the fluorescent nanoparticles. Chapter 5 details the imaging and flow 
cytometry results from using the nanoparticles as a stain and comparison to 
commercially available dyes. Chapter 6 explores the use of nanoparticles to detect the 
CTCs in a mixed blood cell population. Chapter 7 investigates the use of nanoparticles 
as a secondary antibody label and chapter 8 is an exploratory chapter on the use of the 
nanoparticles on gold gratings for surface plasmon resonance enhancement imaging.  
Finally, chapter 9 summarises the work completed in the thesis and details how this work 
could be furthered in the future.  
 
1.5  Research aims and objectives 
Main Aim:  
To demonstrate the specific staining of circulating tumour cells from blood using 
fluorescent silica nanoparticles for cell staining, both in flow cytometry and imaging, in 
comparison to single dye labels. 
 
Objectives: 
1. Synthesize and characterise Cyanine5-doped silica nanoparticles using a 
microemulsion method. 
2. Successfully conjugate antibodies that are specific to markers for CTCs to the 
nanoparticle surface. 
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3. Use the nanoparticles to stain cell lines that represent CTCs specifically, while 
keeping non-specific binding low and characterise the staining using 
fluorescence imaging and flow cytometry. 
4. Spike the cell line CTCs into blood and investigate if the nanoparticles can detect 
them from a mixed blood cell population via flow cytometry and imaging. 
5. Investigate the use of a more sensitive detection assay such as secondary 
antibody labelling to improve signal enhancement.  
6. Investigate the use of the nanoparticles with gold grating surfaces to further 
enhance the signal when imaging for sensitive detection of rare markers. 
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Chapter 2:  Theory, background and 
state of the art 
 
2.1  Introduction 
This chapter describes the fundamental theory behind the work in this thesis relating to 
fluorescence phenomena and includes some background on nanoparticle synthesis, 
antibodies and blood. Included in this chapter is a description of the state of the art on 
the current approaches taken to use targeted dye-doped silica nanoparticles in the 
application of cell staining and flow cytometry for cancer cells. 
 
2.2  Fluorescence phenomena 
2.2.1 Fluorescence and Stokes shift  
Luminescence can be described as the emission of light from a substance and this 
emission can be stimulated in many ways. A summary of the types of light emission can 
be viewed in Fig 2.1. For photoluminescence, there are three primary forms of light 
emission and these are fluorescence, phosphorescence and Raman emission.  
 
Fig  2.1: Summary of some types of luminescence adapted from [1]. 
In the instance of fluorescence, light emission is stimulated by photons from the UV, 
visible or infrared wavelengths of light. Photon emission is only generated when 
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electrons in the fluorophore become excited, from a ground state to a higher electronic 
state, by incoming photons of specific energy or frequency. These energy states, for both 
the excited and ground state, contain discrete vibrational and rotational levels. An 
electron will only be excited to a higher energy state if the energy of the absorbed photon 
is equal to or greater than the energy needed to make the excited electronic transition, as 
shown in the Jablonski diagram Fig 2.2 (left), such that  
ΔE=hν     (Eq.  2.1) 
where E is energy of the photon, h is Planck’s constant and ν is the frequency of the 
electromagnetic radiation/photon. The electron will favour a specific vibrational state 
during electronic excitation. One particular vibrational state will be more likely if it has 
a similar wavefunction to that of the electron in its ground state, as predicted by the 
Franck-Condon principle [2,3]. This is shown in Fig 2.2 (right), which shows 
schematically the processes of photon absorption and fluorescence with relevant energy 
levels. 
When the ground state electron reaches the higher electronic and vibrational state, 
internal conversion happens. This is where vibrational relaxation of the electron occurs, 
with a small thermal energy loss, which happens on the pico-second scale [4]. When the 
electron relaxes back to a lower energy state, it will enter a vibrational state with similar 
wavefunction to that of the excited electron and release the energy in the form of a 
photon with less energy than that of the initial absorbed photons. This process is known 
as fluorescence. The released photon has less energy and, consequently, has a shorter 
frequency and longer wavelength. Therefore, it is usually shifted to the red in terms of 
wavelength compared to its absorption wavelength. 
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Fig  2.2: Simplified Jablonski luminescence diagram (left) and the Franck-Condon principle 
diagram for the excitation of an electron with light. S refers to singlet state excitation. 
Reproduced under Creative Commons CC0 1.0 Universal Public Domain Dedication. 
 
The difference in wavelength between the absorbed and emitted photon is known as the 
Stokes shift of a molecule. In general, it is the difference in wavelength between the 
peak photon absorption and emission of a fluorophore and an example of an absorption 
and emission spectrum can be seen in Fig 2.3 for Cyanine5 free dye. A larger Stokes 
shift allows for a more efficient collection of emission photons, where there is less 
overlap between absorption and emission spectra and is desirable in a dye but not 
necessary to detect emitted photons. 
 
Fig  2.3: Absorption and emission scan for Cyanine5 dye molecule exhibiting a small Stokes 
shift measured on spectrophotometer. 
500 550 600 650 700 750 800
Wavelength [nm]
Cyanine5 absorption and emission scan
Excitation
Emission
Abs rption 
Emission 
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Phosphorescence occurs in a molecule when an electron, which has been excited to a 
higher electronic state and has relaxed to the lowest vibrational state, undergoes 
intersystem crossing and relaxes from a singlet state to the triplet state. When the 
electrons relax from the triplet state, the process is known as phosphorescence. Photons 
that are emitted from phosphorescence are on the microsecond to sub-second scale and 
thus are much longer than for fluorescence processes, which are emitted in nanoseconds 
or less [4]. The dyes used in this thesis luminesce via fluorescence but for completeness 
phosphorescence is also explained.  
2.2.2 Molar absorption 
High molar absorbance is a property that is desirable for fluorescent molecules. Molar 
absorptivity is the measure of the efficiency of photon absorption of a chemical species 
at a specific wavelength. The molar attenuation coefficient ɛ can be calculated using a 
spectrophotometer and Beer-Lambert’s Law. ɛ is inversely proportional to the 
concentration of the dye c, the pathlength l and the absorbance A to form the equation:  
A= ɛcl    (Eq.  2.2) 
Dyes with higher molar absorbance are desirable as they require shorter exposure times 
for detection using imaging techniques, which is an ideal property for the application of 
cell staining. 
2.2.3 Quantum yield   
Simply put, the quantum yield is a ratio of the number of photons emitted compared to 
the number that are absorbed by a fluorescent molecule [4]. The more efficient the 
molecule, the closer the value of the quantum yield will be to 1. When a molecule is 
excited, the energy can dissipate into processes that are radiative, e.g. produce a photon, 
or non-radiative, such as thermal energy loss. The equation to describe these processes 
is given by: 
ϕ=
Γ
Γ+knr
    (Eq.  2.3) 
where ϕ is the quantum yield, Γ is the sum of the radiative rates and knr is the sum of the 
non-radiative rates. 
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2.2.4 Fluorescence quenching 
Fluorescence quenching is the reduction in photon emission due to an increase in non-
radiative energy decay rates. It can be caused by static quenching or dynamic quenching, 
also known as collisional quenching, and can also be induced by energy or electron 
transfer [4]. Static quenching happens upon the formation of a complex between the 
quencher and fluorescent molecule when both are in the ground states, resulting in a 
non-radiative molecule. Dynamic or collisional quenching occurs when the fluorescent 
molecule is excited and, due to a collision with a molecule in solution, has transferred 
its energy to the quenching molecule. Oxygen is a known quenching molecule for 
fluorescent molecules [5]. Quenching can be caused photochemically, because of a 
transition of oxygen from the singlet state to triplet state, which is very reactive, and 
when it comes into contact with the excited fluorescent molecule it can deactivate it. 
Dyes that are not as susceptible to this are known as photostable dyes [6]. Long 
photostability is important for microscopy and analysis of living cells where there may 
be high levels of oxygen present. Also in microscopy, longer exposure times are usually 
needed for imaging with the microscope lamp light compared to the exposure time 
needed with a laser in flow cytometry. This longer exposure time can induce more 
excitation-emission cycles in a fluorophore which lead to photobleaching.  
2.2.5 Förster resonance energy transfer (FRET) 
There are a number of non-radiative processes by which an electron can lose energy. 
Thermal energy loss occurs initially when the excited electron relaxes vibrationally. 
Another process called Förster resonance energy transfer (FRET), can occur when two 
fluorescent molecules have overlapping emission and excitation spectra and are within 
close proximity, on the nanometre scale, to each other [4].  FRET happens when an 
emission photon from one dye molecule, the donor, has enough energy to excite another 
dye molecule, the acceptor molecule. This process can also occur in two adjacent 
fluorescent molecules of the same dye within a close enough radius, and small Stokes 
shift. When FRET happens in this instance, between two of the same molecules, it is 
known as homo-FRET.  The amount of energy that is transferred from the donor to 
acceptor is inversely proportional to the distance to the power of 6 such that 
     E=
R0
6
R0
6+r6
      (Eq.  2.4) 
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where E is the energy of the photon, r is the distance between the donor and acceptor 
molecule and R0 is the Förster radius which is the distance at which there is a 50% energy 
transfer between molecules [7].  For dyes with a large Stokes shift, homo-FRET is less 
likely to occur due to the larger separation between absorption and emission peaks.  
 
2.3  Fluorophores 
There are many types of fluorescent dyes, including those naturally found in proteins or 
chemically synthesised, that cover the ultraviolet, visible and infrared spectrum. Their 
photophysical properties are of significant importance if they are to be useful as optical 
sensors. These desirable properties include a high molar absorbance, high quantum 
yield, large Stokes shift and photostability. For the application of CTC detection, a dye 
with a high quantum yield and large Stokes shift would be an ideal candidate. Dyes that 
fluoresce in the red and near infrared are of interest due to low intrinsic fluorescence of 
biological samples at these wavelengths [8]. In addition, whole blood only has a weak 
absorption within this far-red region. It has been found that far-red dyes make good 
candidates for utilisation in biological applications, more specifically for applications 
where sensitivity is an issue and the background fluorescence can hinder an observable 
result. Some dyes that fluoresce in the red wavelength region, close to 650nm, are 
included in Table 2.1. 
Table 2.1: Fluorescent dyes which emit in the red wavelength of the spectrum 
Dye 
Absorption 
Max [nm] 
Emission 
Max 
[nm] 
Stokes 
Shift 
[nm] 
Quantum 
YieldϮ 
Molar 
attenuatio
n 
coefficient  
[M-1 cm-1] 
Ref 
Allophycocyanine 
(APC) 
650 660 10 0.68 700,000 [9] 
ATTO 647N 644 669 25 0.65 150000 [10] 
DY-649P1 653 672 19 * 250000 [11] 
Alexa Fluor® 647 650 665 15 0.33 239000 [12] 
Cyanine5 646 662 16 0.2 250000 [13] 
*no quantum yield value available.    Ϯ Provided by manufacturer, no medium detailed  
Some of the dyes in Table 2.1 have different advantages over the others. For example, 
allophycocyanine (APC) and ATTO 647N dyes have a very high quantum yield of 0.68 
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and 0.65 respectively but the ATTO 647N has a large Stokes shift which is more ideal 
for easier detection of the emission photons. DY-649P1 also has a relatively large Stokes 
shift. However, no quantum yield information is available for this dye. 
The two most commonly used dyes in the red part of the spectrum are APC and 
AlexaFluor®647. APC is a pigment found in algae and AlexaFluor®647 is a synthesised 
dye. They are favoured over other dyes because they have a relatively high quantum 
yield, as well as being photostable. New labels that emit in the red have more recently 
been established requiring ultra violet or violet excitation from BD Biosciences [14,15]. 
They are known as conducting polymer dyes and have a large Stokes shift, thus, they 
can emit in a broad range of the visible spectrum and even the near infrared.  
APC has a very high molar attenuation coefficient and is followed by DY-649P1 and 
Cyanine5. Although Cyanine5 has a low quantum yield, its molar attenuation coefficient 
is relatively high. Cyanine5 could be used as a CTC stain, although, the signal must be 
amplified and this can be achieved, for example, by encapsulating the dye in silica 
nanoparticles, which was carried out throughout the course of this work.  This dye 
encapsulating method will be discussed in more detail in section 2.7 and the molecular 
structure of Cyanine5 can be seen in Fig 2.4. 
 
Fig  2.4: Chemical structure of cyanine5 NHS ester dye adapted from [13]  
For the work in this thesis, nanoparticles were synthesised with Cyanine5 dye that is 
both absorbs and emits photons in the red and the NPs were benchmarked against both 
APC and AlexaFluor®647 to determine how they perform in the application of cell 
staining and flow cytometry comparatively in terms of brightness. This work could allow 
researchers to use commonly available dyes, such as Cyanine5, with lower quantum 
yields, to close the gap on more expensive, higher quantum yield dye or those excited at 
ultraviolet wavelengths without the need to add a new excitation source as required for 
the conducting polymer dyes. 
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2.4  Zeta potential 
Zeta potential is the indication of surface charge that a particle has at a certain distance 
away from its surface. It is the potential difference between the solution in which the 
particle is placed and the layer of fluid that is attached to the particle. The particle is 
surrounded by an ‘electrical double layer’ comprised of two layers of ions. The Stern 
layer is the innermost layer and is closest to the particle where charged ions in solution 
are greatly attracted to the particle. The next layer is the diffuse layer, where ions are 
attracted to the particle and there are equal numbers of oppositely charged ions in this 
layer. The zeta potential is measured at the outer side of the diffuse layer known as the 
‘slipping plane’; see Fig 2.5 for a diagram of the layers around a charged particle.  
 
Fig  2.5:  Illustration of the electric double layer (diffuse and stern layer) around a charged 
particle from [16]. Reproduced under creative commons licence CC-BY-SA 3.0. 
The mobility of the particles can be measured using the equation 
VD= 
Uq
2π
cos
θ
2
        (Eq.  2.5) 
where VD is the frequency shift of the scattered light, U is the particle mobility,  is the 
scattering angle, q is the scattering vector given by q=4πnSin(θ/2)/λ,  is the wavelength 
of the incident light and n is the refractive index of the medium. This light scattering is 
measured on the dynamic light scattering (DLS) instrument which is discussed in more 
detail in section 3.5. 
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The particle mobility is related to the particle’s zeta potential Z and can be calculated 
from Smoluchowski’s equation 
   Z=
η
ε0εr
U                 (Eq.  2.6) 
where η is the viscosity of the solvent, ε0 is the dielectric constant in vacuum and εr is 
the relative dielectric constant of the solvent [17].  
 
2.5  Antibodies 
Antibodies are part of the immune system in the body. They are proteins in the shape of 
a Y, as seen in Fig. 2.6, and are comprised of different sections. They are produced by a 
subset of B cells called plasma cells to protect the body from invasion from pathogens 
like bacteria and viruses.   
 
Fig  2.6: Antibody schematic of different regions with: (1) Fab region; (2) constant region 
(Fc); (3) heavy chain (blue) comprised of one variable domain (light blue) followed by a 
constant domain (dark blue), a hinge region, and two more constant domains (dark and navy 
blue); (4) Light chain (green) with one variable (light green) and one constant domain (dark 
green); (5) Antigen binding site (paratope) and (6) Hinge regions [18]. Reproduced under 
creative commons license CC-BY-SA 3.0. 
 
2.5.1 Antibody structure 
The two ‘arms’ on the Y shape, called Fab sections, have receptors at the end that can 
interact with pathogens [19]. These are known as paratopes. On the surface of a pathogen 
there are many proteins that are foreign to the body, and are called antigens, and 
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antibodies whose receptors are a complement of the antigens will selectively bind to the 
pathogen. The antibodies can then signal to surrounding blood cells to remove the 
pathogen from the body through the stem part, or constant region, of the antibody which 
is also known as the Fc region [19]. 
Antibodies can be bioengineered to be specific to antigens.  This is done through the use 
of mammals for polyclonal antibodies (multiple antibodies that can bind to the same 
antigen) or hybridoma cells for monocolonal antibodies (one antibody specific to one 
antigen). Polyclonal antibodies are found in the blood of mammals and can be purified 
to harvest them and monoclonal antibodies are secreted by hybridoma cells and purified 
using affinity chromatography.  For direct targeting of an antigen, a monoclonal 
antibody is best suited, as there is only one copy of antibody for which there is a known 
affinity to the antigen. This reduces variability between tests. 
2.5.2 Bioconjugation of antibodies 
In order to target antigens on cells, a bioconjugation method was developed to produce 
efficient antibody attachment to the surface of the nanoparticle. There are many 
regions on an antibody which can be used to attach to the nanoparticle and the most 
commonly used include:  
1. Amine group regions. These are found on the lysine residues of the antibody and are 
found dispersed on all chains of the antibody (see Fig 2.7). They are the most abundant 
groups that are available for modification on the antibody [20]. There are a number of 
these groups found on the antigen binding region and because of this, there is a 
possibility that the binding efficiency of the antibody could be reduced. 
2. Disulfide bond regions. These are found on cysteine residues and the disulphide bonds 
are a crucial part of the structure of the antibody, mainly the hinge region, which holds 
the two halves of the antibody together.  Modifying the disulfide bonds in the cysteine 
residues could result in a conformational change to the antibody, causing some regions 
of the antibody to fold incorrectly and thus cause it to denature [20].  
3. Carbohydrate regions. These are found mostly on the constant region of the antibody 
and can be oxidised to make aldehyde groups active for conjugation. This type of 
coupling does not interfere with the antigen binding sites because of its location on the 
antibody. However, this process has more steps than amine conjugation because the 
carbohydrate regions first need to be oxidised [20]. 
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Fig  2.7: Binding groups available on an antibody adapted from [20]. 
The amine groups were chosen for modification to bind to NPs as the disulphide bond 
conjugation can cause denaturation and the carbohydrate conjugation is more 
complicated. Although there is a possibility that the antigen binding region could be 
blocked by the orientation in which it binds to the surface, there will be a large number 
of antibodies on the surface therefore, statistically, there will be some that will be 
correctly orientated and available to bind to antigens.  
2.5.3 Primary vs secondary antibody detection systems 
Secondary antibody systems can be more sensitive than direct binding primary antibody 
systems because it is possible for more than one secondary antibody to bind to the 
primary antibody target, see Fig 2.8 for schematic representation of antibody staining 
methods. Using a secondary antibody system means that the primary antibody is not 
modified through bioconjugation with a label, leaving it unhindered, pristine and most 
importantly, all binding sites open for interaction with target antigen. There are two 
types of secondary staining detection systems. The first is an antibody-antibody system, 
where a primary unlabelled antibody is used to bind to a specific antigen and then a 
secondary labelled antibody is introduced which is specific to the primary antibody, and 
binds to Fc regions of the primary antibody. The second system is a biotin-avidin 
detection system. In this case, an unlabelled biotinylated antibody targets a protein and 
then an avidin modified labelled antibody is introduced that will bind directly to the 
biotin on the primary antibody. 
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Fig  2.8: Schematic of cell staining methods using primary antibody, secondary antibody – 
antibody or secondary biotin – avidin methods. 
.   
2.6  Blood cells and circulating tumour cells 
In the human body, there are many types of cells, that carry out various functions. In the 
blood, there are between 4.2-6.1 million red blood cells per microliter and 5-10 thousand 
white blood cells per microliter [21]. Circulating tumour cells (CTCs) are cells that have 
dissociated from a primary cancer tumour somewhere in the body and have entered 
either the blood stream or lymphatic system. They are the cause of metastasis in cancer 
patients, as mentioned earlier. This particular cell population is extremely rare in the 
blood in terms of numbers among patients, especially at early stage. It has been estimated 
that there are 1 to 100 circulating tumour cells (CTCs) in 109 blood cells [22]. It is clear 
there are a substantial number of cells from which CTCs must be differentiated. Efforts 
have been made to detect CTCs based on physical parameters such as size and density 
on microfluidic platforms but as these parameters are not so distinct from normal cells, 
the separation has not been unambiguous [23-25]. One way to distinguish CTCs from 
blood cells is through their surface markers. As these cells originated from the 
epithelium, they exhibit surface antigens that are related to this area of the body and 
express markers that are not present on blood cells. This largely includes the expression 
of epithelial cell adhesion molecule (EpCAM), cytokines or e-cadherin [26]. Some 
CTCs express a surface protein, EpCAM, which is a 40 kDa glycoprotein antigen (one 
made of both oligosaccharides (glycans) and a protein) and is also known as cluster of 
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differentiation (CD) 326.  Epithelial originating CTCs also express particular cytokines, 
which are intermediate filaments for cytoskeletal structure, and include K8, K18 and 
K19. E-cadherin is a protein that supports epithelial structural adhesion and prevents it 
from detaching. It is also used for the identification of non-blood cells [26]. A 
combination of these markers in conjunction with markers to identify white blood cells 
are used to correctly isolate and identify CTCs. This can be done using 
immunomagnetics and fluorescence recognition. An FDA approved detection platform 
called CellSearch (Menarini Silicon Biosystems Inc, CA, USA) uses a combination of 
these principles to detect CTCs in patient whole blood [27]. Anti-EpCAM magnetic 
beads are used to select EpCAM positive cells, which are then stained with cytokeratin, 
anti-CD45 and DAPI stains to verify if CTCs have been captured.  Some microfluidic 
platforms have been developed with a similar workflow as the CellSearch by using 
immunomagnetic and fluorescence staining of cells to achieve the same outcome by 
taking advantage of surface markers [28]. In the work presented in this thesis, for 
simplicity and proof of concept of tagging CTCs with NPs, EpCAM was chosen as the 
targeting surface receptor on a model CTC line.  
Monoclonal antibodies have been engineered specifically to the EpCAM antigen and are 
commercially available to adhere to EpCAM positive cells. For this project, two cell 
lines were used to investigate a system of detection. One cell line was EpCAM positive 
and the other EpCAM negative. The EpCAM positive cells that were used for this 
project were MCF-7 and LNCaP cells which are a breast cancer and prostate cancer 
adenocarcinoma.  The EpCAM negative cells used were HeLa, a cervical cancer cell 
line that does not express EpCAM, and LNCaP, a normal, non-cancerous, prostate tissue 
cell line. All cell lines were grown by adherent growth methods throughout this work. 
 
2.7  Nanoparticle synthesis  
Silica nanoparticles can be synthesised mainly by two methods; the Stöber method and 
the microemulsion method. The Stöber method, first published in 1968, involves the 
hydrolysis of alkyl silicates, usually tetraethyl orthosilicate (TEOS) with ethanol, and a 
condensation reaction occurs in the presence of a catalyst to form monodisperse silica 
nanoparticles in the range of 50nm - 2µm [29]. The growth mechanism has been 
investigated by Masalov et al. and it was concluded that the silica nanoparticles form 
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through aggregation of primary particles, ~5nm in size, and when there is not enough 
polymer left to form these primary particles, the polymer forms a thin coat around the 
aggregated particles to produce a smooth silica particle for particles up to ~160nm in 
size, see Fig 2.9 [30]. Upon the addition of further amounts of TEOS, larger particles 
form and coat the smooth, <160nm, particle. This repeats itself upon the addition of 
more TEOS until the particles reach micron size.  
 
Fig  2.9: Growth of silica nanoparticles via Stöber method adapted from [30] 
The reverse microemulsion method of producing silica nanoparticles is a system that 
can produce particles in the range of 20-500nm and entails the use of water in a solvent, 
such as cyclohexane or hexane, with a silicate and a number of surfactants in order to 
control the size and shape of the nanoparticles [31,32]. In this method, the hydrolysis of 
silica and the condensation reactions occur at the interface between the water and oil 
phase. This water and oil phase consists of water micelles that are surrounded by 
surfactant in an oil medium.  
2.7.1 Dye doped nanoparticles 
Hydrophilic dye can be encapsulated in silica NPs using the reverse microemulsion 
method when added to the water phase of this method. However, when using this system 
to produce dye-doped nanoparticles with hydrophobic dyes, it can fail to form proper 
micelles, due to aggregation of the dye and cause insufficient dye loading of the particles 
[33]. Previous work has shown that it is possible to incorporate hydrophobic dyes into 
nanoparticles using the reverse microemulsion method by first conjugating an N-
hydroxysuccinimide (NHS) ester dye molecule to a silane 
(aminopropyltrimethoxysilane also known as APTMS) and using an additional 
negatively charged surfactant such as dioctyl sulfosuccinate sodium salt (AOT) 
alongside nonionic surfactants like polyoxyethylene (5) nonylphenylether (NP-5) to 
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form micelles (see Fig 2.10 below for a schematic representation of how dye-doped 
nanoparticles form) [33,34]. This method is known as a quaternary method as it involves 
a combination of four solvents and/or surfactants; APTMS, cyclohexane, NP-5 and 
AOT. This was the formulation for nanoparticle synthesis used throughout this thesis to 
incorporate Cyanine5 hydrophobic dye into nanoparticles and is referred to as the 
quaternary method. If there were a combination of three solvents and surfactants, this 
would be a tertiary system.  
 
Fig  2.10: Dye-doped silica nanoparticle synthesis method with dye-conjugated TEOS. © 
Robert Nooney 2015. Reproduced with permission. 
2.7.2 Surface functionalisation design considerations 
Surface compatibility for bioconjugation is necessary for targeted cell staining. Silica is 
readily able to bind and interact with proteins without the need for functionalization of 
the nanoparticles. This passive adsorption of protein on the nanoparticle surface has been 
analysed and discussed by a number of groups [35-39]. This inherent affinity of the 
proteins and silica is not a strong bond and as such is unsuitable for use in antigen 
targeting where the antibody to nanoparticle bond should be strong enough to bind the 
particle to the analyte. Covalently conjugating the antibody to the surface circumvents 
this. A typical approach is to attach a layer of amine groups through hydrolysis to the 
silica surface of the nanoparticles. This is done so that the surface is readily available 
for further modification. There are a wide range of molecules available to be used as 
linkers between nanoparticle and protein but they mainly fall into two sub headings: 
linear or branched linkers. An investigation carried out by Gubala et al. showed that 
branched linker molecules, or multivalent linkers, as referred to in the paper, are more 
efficient for protein binding and they also increased the particle stability [40]. For this 
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reason, an 8-arm PEG linker was used in the nanoparticle synthesis step to bind to the 
surface after amine functionalisation (see Fig 2.11 below, with modified NHS ester end 
groups). The NHS ester groups allow for reactivity of the PEG molecule to amine groups 
on an antibody.  
 
  
Fig  2.11: 8-arm PEG multivalent linker molecule adapted from [41]. 
One of the challenges in using NPs for targeted cell imaging or staining is high non-
specific interactions between the cells and particles followed by endocytosis. The 
internalisation of NPs by cells can be useful for investigating pH, toxicity and drug 
delivery applications [42-44]; however, for the work presented in this thesis, it is 
imperative that the nanoparticles do not get adsorbed or up taken non-specifically. Key 
parameters to prevent non-specific binding include a negative zeta potential, 
polyethylene glycol (PEG) functionalisation and protein stabilisation of NPs [37,45,46]. 
It has been reported that, to prevent NPs from crossing the cell membrane, the NPs need 
to be negatively charged because phospholipid membranes of the cells are also 
negatively charged leading to electrostatic repulsion, whereas positively charged NPs 
are more regularly up taken [45,47]. PEG has been used to increase circulation times of 
NPs in vivo due to reduction in aggregation of opsonins and proteins from blood serum 
on the surface of NPs that cause endocytosis [48,49]. In a detailed study, Rampazzo et 
al. investigated the use of PEG molecules on the surface of silica NPs with different 
charged functional groups to reduce particle up take in cells [49,50]. Results indicated 
that PEG only nanoparticles had reduced up take in the cell compared to positively 
charged amino-PEG-NPs, but that overall the highly negative carbo-PEG-NPs were least 
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effective at entering the cell membrane, emphasising the point that the overall negative 
charge of the NP helps to prevent its endocytosis. It has been shown that proteins help 
to stabilise NPs by creating a protein layer around the particles, also known as a protein 
corona, that helps to prevent aggregation sterically in protein rich sample media such as 
serum [37,46,51]. Lesniak et al. have shown that, without serum, NPs are internalised 
by cells much more effectively because of the lack of protein in solution, and similarly 
Kim et al. have shown that at low concentrations of protein, NP uptake is greater than at 
higher concentrations [61,63].  
NP size is another aspect which must be considered when using silica NPs before 
experimentation for biomedical applications with cells. A great deal of research has been 
carried out recently in relation to this, particularly for cell cytoxicity in the presence of 
different size silica nanoparticles [52-55]. Nanoparticles of different sizes, ranging from 
20-200nm, were analysed in the presence of three different cell types at different time 
points [52]. It appeared that 20,60 and 200nm silica nanoparticles at a concentration of 
100µg/mL or less are not cytotoxic and do not induce cell death. They found that 20nm 
particles over 24 hours caused damage to intracellular structures upon uptake, that the 
60nm NPs were uptaken the most over this time frame but the 200nm NPs that were 
endocytosed resided in the mitochondria [52]. The high particle uptake for 60nm size 
NPs agreed with another study that found similar results for this size particle [54].  
60nm dye-doped silica NPs had previously been developed in the optical sensors group 
at Dublin City University. Their synthesis was a well understood process and they had 
been used sucessfully with immunoassays. For this thesis, part of the investigation and 
exploratory work was to determine if they could be used for surface antigen detection 
on cells despite known particle uptake by cells at this size nanoparticle.  
Taking all these factors into consideration, a ~60nm negatively charged PEGylated NP, 
that is colloidally stable due to protein adsorption, for specific targetting of EpCAM 
markers on the surface of the MCF-7 cells was developed. 
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2.8  Nanoparticles for cell staining and flow cytometry - state of the 
art  
Cell imaging and flow cytometry has been used in the field of biomedical diagnostics 
for decades in relation to the detection of many disease markers and has contributed to 
the study of histology and oncology.  These experiments have been carried out using 
various fluorescent probes including dyes and nanoparticles for the detection of cancer 
either targeted or untargeted. These fluorescent probes include but are not limited to: 
quantum dots [56-58], carbon dots [59,60], polymer dots [61-63] and dye doped silica 
nanoparticles [64,65]. 
Dye-doped silica nanoparticles have been used for biomedical applications such as cell 
imaging and immunoassays previously [64-66]. They have advantages over other 
nanoparticles due to their high dye doping ability, biocompatibility and relative non-
toxicity [67]. Their easily functionalised surface allows for the conjugation of bio 
recognition units to the NP such as antibodies and DNA which can transform the NPs 
into biosensors [68,69]. It has been demonstrated that the NPs can encapsulate a  
versatile range of dyes including hydrophobic and hydrophilic dyes such as fluorescein 
isothiocyanate (FITC), tris(bipyridine)ruthenium(II) chloride (Rubpy), Cy5TM and 
AlexaFluor®750 to name but a few [68-74]. These NPs can be used to detect pH, oxygen, 
glucose and ion species in cells intracellularly by doping them with metal complexes 
such as Ruthenium complexes or pH sensitive dyes [64,75,76]. However, the brightness 
and photon emission of the NPs is limited by a number of factors that were mentioned 
previously in this chapter in section 2.2 such as the quantum yield of the dye and the 
effects of Forster resonance energy transfer between dye molecules in close proximity. 
Despite this, enhancements of over two orders of magnitude have been achieved when 
comparing free dye to NPs that have encapsulated the same dye [34,68].  
In sections 2.8.1-2.8.3, specific and non-specific targeting of cells using dye doped silica 
nanoparticles in cell imaging and flow cytometry is discussed. Primarily, these NPs were 
made using the microemulsion method, although some NPs synthesised using the Stöber 
method are included as well.  For cell staining using NPs, there are usually two types 
mentioned: specific and non-specific staining. The more common and easiest to 
implement is non-specific staining. In this case, cells are incubated with NPs that have 
no biological recognition receptors on their surface but are either completely bare or 
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have the addition of some functional groups on their surface such as amine, thiol etc. 
Non-targeted cell staining can also be useful in determining if surface charge or certain 
surface groups on the NP induce a greater/lesser uptake in the cell or are toxic to it. 
However, the real challenge lies within targeted NP staining of cells and NP stability. 
Some of these factors which must be considered are NP stability in cell media, correct 
design of antibody-nanoparticle conjugation and NPs entering through the cell 
membrane through cell mediated pathways to name just a few. Reduction of non-specific 
binding is an important step in optimisation of the use of the NPs as cellular labels and 
also as labels for fluorescence-based immunoassays and DNA assays where low limits 
of detection (LOD) and a high signal to noise ratio are required.  
2.8.1 Untargeted silica nanoparticle cell staining 
It is important to know the fate of the NPs once incubated with cells, for example, in cell 
staining when detecting surface markers, to ensure that the targeting antibody is 
functional and not endocytosed by the cell, or in drug delivery, if the drugs are targeting 
a specific cell organelle. This can be useful when investigating the toxicity of the 
nanoparticles to the cells in question. A study carried out by Al-Rawi et al. showed that 
70nm silica NPs labelled with FITC end up in the lysosomes of HeLa cells. However 
larger particles of 200-500nm diameter were located in endosomal compartments within 
the cytosol of the cell due to the time frame of the study [77]. In general, particles will 
eventually migrate to the lysosome of a cell [78]. They also reported that the 70nm 
particles were toxic to the HeLa cells without the presence of serum. 
Different microscopy methods can be used to identify where the NPs are located. For 
example, Ye et al. used a transmission electron microscopy (TEM) method for the 
investigation of 50nm unfunctionalised silica NPs across the blood-brain and intestine-
endothelial barriers [79]. In another study, Lesniak et al. used both TEM and confocal 
analysis to determine the fate of dye-doped unfunctionalised silica NPs in A549, 
adenocarcinomic human alveolar basal epithelial cells [80]. 
2.8.2 Targeted silica nanoparticles for cell staining 
A number of papers have been published in which is described the surface 
functionalisation of dye doped silica NPs with a bio-recognition structure, such as an 
antibody, and used to successfully identify a target protein on a cell population. Below 
are a few examples of these studies. 
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Woolley et al. used anti-CD41 conjugated nanoparticles to image platelets [81]. They 
doped NIR-664 dye into silica particles using the reverse microemulsion method and 
could image the surface of the platelets. They achieved good specificity when compared 
with either bare NPs or IgG conjugated NPs incubation with platelets. They confirmed 
the location of the NPs using a combination of scanning electron microscopy and 
confocal microscopy. A study by He et al. was carried out to investigate two sets of NPs 
prepared by microemulsion method, either anti-carcinoembryonic antigen (CEA) FITC 
NPs or anti-CK19 Rubpy doped NPs. They were developed to detect MGC-803 gastric 
cancer cells [82]. Both antibodies can detect a different marker for gastric cancer cells 
and, using the two dye-doped NP labels, they could use different fluorescent channels 
in confocal microscopy to image the cells. They also obtained xenograft primary gastric 
cancer tumour cells from mice and showed that the NPs could successfully label these 
cells. Another study was carried out in which HepG liver cancer cells were recognised 
using FITC doped NPs that were synthesised using the reverse microemulsion method 
[83]. Using anti-HAb18 monoclonal antibody that was conjugated to the NPs, the liver 
cancer cells were distinguished with good specificity. Another study by Tiernan et al. 
investigated NIR664 doped silica NPs synthesised using the microemulsion method for 
targeting colorectal cancer cells [84]. They conjugated anti-CEA antibody via a 
branched dendrimer linker molecule to the NPs. They were successful in identifying 
LS174T, LoVo and HCT116 colorectal cancer cell lines using the NPs in confocal 
microscopy applications and showed that the particles could also be used to detect 
xenografts of colorectal tumours in mice in vivo. 
Some groups have carried out work using dye-doped silica nanoparticles for the 
identification of a single protein on a cell line within a mixed cell system [69,85]. Tao 
et al. identified EpCAM positive colo205 colon cancer cells from EpCAM negative 
sw480 colon cancer cells using Rubpy doped silica NPs that were synthesised via the 
microemulsion method [69]. First, they used single cell line populations in cell imaging 
and flow cytometry to ensure specificity of the NPs. They then used a mixed cell 
population of the EpCAM positive and negative cell lines together and visualised this 
mixed cell population by microscope, but not by flow cytometry. Another mixed cell 
population study, by Peng et al., has looked at the detection of BEL-7404 liver cancer 
cells from MCF-7 cells that were transfected with green fluorescent protein (GFP). They 
spiked the BEL-7404 cells into MCF-7s and incubated them with galactose conjugated 
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Rubpy-doped NPs, synthesised by the microemulsion method. Initially the cells were 
analysed using confocal microscopy and after the NPs displayed specificity, this was 
followed by spiking the liver cancer cells in to the MCF-7s at a range of different ratios. 
The mixed cell populations were then monitored via flow cytometry where they 
achieved high specificity and were able to detect the liver cancer cells with the NPs 
down to 1% of cell population [85]. In this same paper, they also looked at the detection 
of the liver cancer cells from white blood cells. They detected the BEL-7404 liver cancer 
cells using the same galactose Rubpy doped silica NPs as previous and, via confocal 
laser microscopy, could distinguished them from white blood cells [85].  They did not 
carry out flow cytometry on these mixed cell samples. 
2.8.3 Targeted silica nanoparticles for flow cytometry. 
Another application of dye-doped silica NPs is for use with flow cytometry. As the two 
methods of detection, cell staining and flow cytometry, largely overlap in studies, below 
are some examples of work that solely relate to flow cytometry. 
Estevez et al. utilised a biotin-avidin secondary labelling system with FITC doped silica 
NPs that were made via the Stöber method for detection of cells. Using a sgc8-polyT10-
biotin aptamer that was allowed to incubate with the cells first and introducing 
neutravidin conjugated NPs, the NPs showed large specificity to CEM cells, also known 
as human acute lymphoblastic leukaemia cells, compared to the Ramos human Burkitt’s 
lymphoma control cell line using flow cytometry [68]. They repeated these experiments 
using confocal microscopy to image the cells and also stained the same cells with Rubpy 
NPs, synthesised using the microemulsion method, which showed good specificity for 
the cell line. They then used a mixed cell population consisting of CEM cells spiked into 
Ramos cells at different percentages and, after incubation with FITC NPs, detected them 
using flow cytometry.  More flow cytometry analysis was carried out using an antibody-
antibody secondary system where this time biotinylated anti-PTK7 was first incubated 
with cells and then neutravidin coated FITC or Rubpy doped NPs were added. They 
achieved a 100-fold increase in signal compared to a primary anti-PTK7 
AlexaFluor®488 antibody and this large increase can partly be attributed to comparing 
a primary antibody system to a more sensitive secondary one.  
One group recently published a study on the effect of the orientation of conjugated 
EpCAM antibodies on Stöber synthesised Cy5 doped NPs in relation to cancer cell 
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detection. [86]. NPs were first conjugated with protein G, a protein which only allows 
antibodies to bind via their constant region, thus allowing only one orientation, facing 
outwards. The NPs were then incubated with anti-EpCAM, to allow binding to the NP, 
which were used to detect colorectal HK 29 cells through flow cytometry and 
interestingly found that the orientated NPs were over 10 times more sensitive than anti-
EpCAM NPs that were prepared using the commonly used EDC-NHS chemistry. 
Yun et al. targeted blood cells to enumerate subsets of leukocytes with FITC doped NPs 
that have implications for HIV and AIDS monitoring [87]. Using FITC doped silica 
nanoparticles that were synthesised using the microemulsion method they targeted 
CD45 and CD4 proteins on the surface of leukocytes. Interestingly, although targeting 
two proteins, they could detect the second CD4 protein using only one type of dye doped 
NP. Due to the substantial increase in fluorescence from the additional NPs bound to the 
second protein they could view this fluorescence increase from only one channel. This 
was measured on a microchip based flow cytometer that was built in house and used 
with a diode laser. 
It appears that dye-doped silica nanoparticles for the detection of CTCs from blood cells 
on a flow cytometry system has not been carried out previously. 
 
2.9  Grating coupled surface plasmon resonance 
There has been much emphasis in the literature on high resolution imaging of cells using 
confocal microscopes, stimulated emission depletion microscopy (STED) and other 
complex imaging systems [88] and some work has been reported on cell imaging using 
plasmonic substrates [89]. This brief feasibility study focused on assessing the suitability 
of plasmon active grating structures for cell imaging. These substrates were developed 
and fabricated as part of a separate project and provided here for this exploratory 
imaging project. More details on the development of these substrates can be found in a 
paper published earlier this year [90].  
2.9.1 Principle of plasmonic enhancement of fluorescence 
A plasmon is a quantum of plasma oscillation, where a plasma oscillation is the 
collective oscillation of free electrons in a conducting material such as a metal. A 
plasmon is analogous to a photon, which is a quantum of light as alluded to earlier. 
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Surface plasmon resonance (SPR) occurs under certain conditions when light interacts 
with metal at a particular wavelength which resonates with the oscillations of the 
electrons, hence producing plasmons. Photons interact with the plasmons to form surface 
plasmon polaritons (SPPs), which travel along the dielectric / metal interface. This is the 
basis of the widely used technique of SPR, a label-free detection technique using, 
usually, planar gold surfaces on which the molecule to be detected is bound [91-93]. In 
order to achieve coupling, the momentum of the light must match the momentum of the 
surface plasmons which can be achieved using Kretschmann or Otto geometry for prism 
coupled SPR [94,95] or by using metal grating coupling as is used in this thesis. 
A localised plasmon occurs when nanoparticles smaller or of similar size to the 
wavelength of incident light are used to trap or confine the plasmons and prevent them 
from propagating through the metal / dielectric interface.  This can occur when metal 
nanoparticles are purposely deposited on a surface, such as a prism, or due to the intrinsic 
random surface roughness of the coated metal. The surface plasmon resonance causes 
the electric field near the surface to become enhanced due to the oscillating electron 
density but decays rapidly as a function of distance from the surface. Fluorophores that 
are within this metal enhanced electric field have enhanced signals and modified excited 
state lifetimes [96]. This can be explained by the reflected far-field radiation from the 
fluorophore back on itself which can induce a reduced excited state lifetime and an 
increase in the radiative decay rate thus producing enhanced fluorescence [97]. This 
effect depends on many parameters e.g. size, shape and composition of the nanostructure 
and dye-metal separation [98-101].  Incident light can be efficiently coupled into a metal 
grating to excite SPPs, which, in turn, can interact with fluorescent molecules to produce 
enhanced fluorescence. This principle is used here to explore grating enhanced cell 
imaging where the cells are bound to a plasmonic grating substrate which is mounted on 
a standard inverted epifluorescence microscope 
2.10  Summary  
This chapter discussed the theory behind the photo physical phenomena that were used 
in this thesis and detailed the rationale behind choice of nanoparticle design during 
synthesis steps. Also included in this chapter was a state-of-the-art on current 
fluorescence nanoparticles used for cell imaging and staining.  
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Chapter 3:  Instrumentation 
 
3.1  Introduction 
A range of instruments were used in this largely multidisciplinary work in various 
aspects of the project. In this chapter, the instrumentation used throughout the work is 
described and the methods of operation explained in detail.  
 
3.2  Microscopy 
3.2.1 Transmission electron microscope 
Transmission electron microscopy (TEM)  is used to image samples at the low-micron 
and nano scale. There are a number of components in a TEM that distinguish it from 
optical microscopes, and these are described in conjunction with the theory of operation 
of a TEM. TEMs make use of electrons instead of photons for imaging samples. An 
electron gun, that can consist either of a heated filament or field electron gun, is used as 
the ‘illumination’ source. The electrons are accelerated towards an anode. While 
accelerating, the electrons pass through a number of magnetic fields which act like an 
objective lens in an optical microscope, whereby they focus the electron beam onto the 
sample specimen being investigated. The electrons pass through the sample and through 
another ‘condenser lens’ or magnetic field to focus the scattered electrons  onto a screen, 
where they are collected and converted into images. Depending on the type of TEM, 
some will have more condensers than others.  
TEM micrographs were obtained in this work using a Tecnai Transmission Electron 
Microscope (FEI, Oregon, USA). The FEI Tecnai F30 TWIN field emission gun was 
operated at 300 kV with a Twin lens, a field emission gun and a Gatan Ultrascan 895 
CCD camera (Gatan, Oregon, USA). Specimens were prepared by dropping ethanol 
solutions of the nanoparticles onto a formvar carbon coated copper grid. 
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3.2.2 Fluorescence microscope  
The light microscope has been used to view cells on the micron scale. This has been 
possible with the use of objective lenses, whose numerical aperture is the limiting factor 
for optical focusing, the smaller the aperture the shorter the wavelength needed to enter 
the objective. Organelles inside the cell and other submicron sized objects can be viewed 
using the optical microscope with the use of water or oil immersion lenses to change the 
refractive index and bend the light into the lens. A fluorescence microscope uses the 
same lenses as those used in the light microscope. However, they are usually inverted, 
lying below the sample so as to excite the sample and allow the collection of the emitted 
fluorescence through the same lens. These are called inverted microscopes.  To allow a 
range of fluorescent dye imaging, the sample is illuminated with a lamp which first 
passes through a filter cube before illuminating the sample. Each filter cube has an 
excitation filter which functions much like a band pass filter allowing light of a certain 
bandwidth through and once the light has passed through this it then encounters a 
dichroic mirror. This dichroic mirror reflects light up to a certain wavelength and after 
the cut-off point transmits the light through the mirror instead. The initial excitation 
wavelength light is reflected up through an objective lens of the microscope which then 
focuses the excitation light on the sample. The sample fluoresces and the light passes 
back through the objective lens where it goes through the dichroic mirror and passes 
through the emission filter, which prevents unwanted light from reaching the CCD 
camera, see Fig 3.1 below for a schematic of this.  
  
Fig  3.1: Schematic of optical set up of an inverted microscope with filter cube.  
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There are a broad range of fluorophores which can be used in the visible spectrum for 
cell imaging and, depending on the excitation and emission wavelengths of these 
fluorophores, filter cubes can be tailored to suit each one. The cubes can be added or 
removed from the microscope easily.  
Fluorescence imaging was performed on an Olympus IX71 (Tokyo, Japan) inverted 
epifluorescence manual microscope with a JVC TK-1460 colour video camera 
(Yokohama, Japan) and using an Excelitas X-Cite series 120 excitation lamp 
(Technologies Corp, MA, USA). Images were taken at 20x magnification and using a 
4',6-Diamidino-2-phenylindole (DAPI), FITC or Cy5 filter cube. The Olympus DAPI 
filter cube set had an excitation wavelength transmission of 352-402 nm and emission 
at 417-477 nm with the dichroic mirror at 409 nm. The FITC filter had an excitation 
wavelength transmission of 460-495 nm and emission of 515-550 nm with a dichroic 
mirror at 505 nm. The Cy5TM filter cube set had an excitation range of 604-644 nm and 
emission of 672-712 nm with the dichroic mirror at 660 nm. 
 
3.2.3 Confocal fluorescence microscopy 
Confocal microscopy operates similarly to fluorescence microscopy except the 
excitation source is a laser instead of a lamp and, importantly, uses a pinhole in the 
collection optics to obtain high resolution images. Mirrors in the system are rotatable 
and are used to focus the lasers on a sample or to be scanned over an area. Any collected 
light passes up through the objective and through a dichroic mirror onto photomultiplier 
tubes (PMTs), where the signal is amplified. This method allows for scanning through 
cell specimens and a number of scans can be compiled in the Z axis to form a 
reconstructed 3D image of the sample. Confocal microscopes employ the use of a 
pinhole on the conjugate focal point so as to prevent unfocused photons from hitting the 
PMT which allows for better resolved images than from fluorescence microscopy alone 
[1]. As fewer photons reach the PMT than with a normal fluorescence microscope, an 
improved light source is required, such as a laser, for illuminating the specimen. See Fig 
3.2 for a schematic representation of a confocal microscope. 
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Fig  3.2: Configuration of a laser scanning confocal microscope [1] © IOP Publishing.  
Reproduced with permission.  All rights reserved. doi:10.1088/0953-8984/19/11/113102 
Confocal microscopy was carried out using a Leica Microsystems TCS SP8 microscope 
(Leica Microsystems, Wetzlar, Germany) using an 86x oil immersion lens and hybrid 
detectors. The excitation source was a Leica tuneable white light laser which is a pulsed 
IR-fibre laser that takes advantage of an acousto-optical filter that allows user orientated 
selection of excitation wavelengths [2]. 
 
3.3  Microplate reader (photospectrometer) 
Microplate fluorescence measurements were performed using a Infinite® M200 PRO 
microplate reader (Tecan, Männedorf, Switzerland). For Cyanine5 dye doped 
nanoparticles, the excitation wavelength was set at 649 nm and the emission wavelength 
set at 679 nm. This particular micro plate reader operates without the use of  filters but 
instead uses a monochromator. 
A typical monochromator uses a Xenon flash lamp which is directed onto condenser 
optics  after which it is focused back through a slit. See Fig 3.3 for a visual aid behind 
the operation of the microplate reader. The light then is incident on the  monochromator 
grating which disperses the light into its component wavelengths. This light then passes 
through a 2nd slit to narrow the bandwidth of light selected after which the light is 
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dispersed once again on a 2nd monochromator and finally passes through an exit slit that 
is incident on the sample in the plate reader. The emission collection is done by passing 
the light through an entrance slit to prevent stray light and noise entering the detector. It 
then is incident on a 3rd monochromator, where the light is dispersed again and passes 
through another slit to select a bandwidth containing the desired emission 
wavelength.The light is dispersed once more on the 4th and final monochromator where 
the light goes through the last slit at the selected wavelength onto condensor optics which 
focus it onto a photomultiplier tube.   
Fig  3.3:The optical setup of the Quad4 MonochromatorsTM in the Tecan Saphire Infinite PRO. 
Excitation optic setup (left) and collection optic setup (right) © Tecan 2012. Reproduced with 
permission. All rights reserved [3]. 
 
3.4  UV-vis photo spectrometer 
UV-Vis photospectrometers are used to measure the absorption of photons through 
samples in liquid phase or for thin film solid samples. Light of a broad spectrum, 190 -
840 nm in some spectrophotometers [4], is passed through the sample in a cuvette of a 
certain length. The amount of light transmitted is calculated to give the number of 
photons that were absorbed by the sample across a range of wavelengths. Using the 
Beer-Lambert equation, A=ɛcl (Eq. 2.2), the sample concentration can be determined. It 
can be used to determine where the absorption maximum is and where fluorescent dyes 
should be excited. The spectrophotometer can determine protein, DNA or ribonucleic 
acid (RNA) concentration based on a ratiometric value of absorption at 280 nm [5,6]. It 
can also be used for colorimetric protein assays such as the Pierce bicinchoninic acid 
(BCA) test at 562 nm [7]. It is not recommended for use with samples that are highly 
    
                                                                               46 
coloured and concentrated due to inner filtering effects or for highly scattering samples 
which could skew the results.  
In this research, UV-Vis spectra were obtained of Cyanine5 and Cyanine3 free dye, 
synthesised Cyanine5 nanoparticles and dye labelled antibody conjugates. They were 
measured with a Nanodrop 2000c UV-Vis photo spectrometer (ThermoScientific, 
Delaware, USA) with a spectral range of 190-840 nm and used with a 1cm cuvette path 
length or the nanodrop function for dye labelled antibody with a 1 mm path length [4]. 
 
3.5  Dynamic light scattering instrument 
A dynamic light scattering instrument (DLS) is capable of measuring the size of particles 
in a solution sample and/or their zeta potential. With the use of a monochromatic light 
source, such as a laser, the light is first polarised before entering the sample. The 
scattered light then exits the sample, is collected and passes through a second polariser 
after which the light is focused onto a photo multiplier tube (PMT) detector. The 
scattered light gives rise to interference patterns, bright spots for constructive 
interference and dark spots corresponding to destructive interference. An initial pattern 
is recorded of the sample at t=0 and taken at successive time points after this. As time 
progresses the interference pattern will change with the scattering of light due to the 
movement of particles. The movement is caused by Brownian motion. Smaller particles 
will create larger changes in the pattern as they move faster than larger particles and thus 
the instrument can correlate these changes to sizes of particles in solution using photon 
correlation spectroscopy. 
Zeta potential can be measured by the electrophoretic light scattering. Laser light is 
directed through the particle suspension where the light will be scattered. A frequency 
shift occurs in the scattered light that is proportional to the velocity of the particles in 
solution (See section 2.4 for the theory of zeta potential). Because the frequency shift of 
the light is proportional to this velocity, the electrophoretic mobility of the particles can 
be measured [8].  
All particle size and zeta potential measurements of samples in solution phase were 
performed on a Delsa™Nano C from Beckman Coulter. All samples were measured at 
a concentration of 0.3 mg/mL. The optical setup for zeta potential measurements is 
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shown in Fig 3.4, in which there are two lasers, one used as the incident beam that passes 
through the sample and one as a reference beam. 
 
Fig  3.4: optical set up of a DelsaTM Nano C particle analyser for zeta potential. © Beckman 
Coulter 2011. Reproduced with permission. All rights reserved. [8]. 
 
3.6  Flow Cytometer 
Flow cytometers have been used for more than 50 years for cell analysis [9]. Their 
function is to measure cell size and granularity alongside protein expression using 
fluorophores. There has been a huge investment in the technology over this time and 
what initially started out as a one colour fluorescence cell cytometer, has now 
dramatically increased to counters that are capable of detecting 20 colours [10].  All 
cytometers contain at least two lasers; blue 488 nm laser and red 635 nm laser. However, 
more recent cytomers are capable of housing five lasers. These can include an ultraviolet 
laser at 355 nm, a violet laser at 405 nm and a green laser at 561 nm. This allows more 
fluorophores to be used when carrying out flow cytometry as the lasers are spatially 
separated by their positioning in the instrument. This means the photons will reach the 
detectors at different times and will prevent crossover between two fluorophores which 
have the same emission wavelength but different excitation wavelengths. As well as cell 
analysers, there are cell sorters, instruments capable of separating cell populations based 
on distinguishing between different fluorophores on the cells. But for the basis of the 
experiments carried out for this project, only a cell analyser was needed. Different 
systems from SonyBiotechnology, Beckman Coulter, BD Biosciences and Merck 
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Millipore offer different configurations with regards to laser, microfluidics and optical 
collection set up. 
A Merck Millipore Guava EasyCyteTM 8HT analyser was used for the duration of this 
work. This cytometer has a 75mW 488 nm blue laser and 40mW 635 nm red laser [11]. 
It is capable of measuring 6 fluorescence channels as well as forward and side scatter. 
Forward scatter is used to measure the size of the beads/cells and the side scatter 
measures the granularity of the beads/cells. The Guava cytometer uses a microcapillary 
to take samples from a 96 well microtitre plate and at a point along the capillary the red 
and blue laser pass through the sample. Based on the diagram in Fig 3.5, it can be seen 
how the Guava can distinguish between different fluorescence emission through the use 
of band pass filters, which only allow light of certain wavelengths through and reflects 
the rest of the light onto a photomultiplier and photo diode. InCyteTM software allows 
manipulation and analysis of data to focus and separate certain populations of cells from 
background noise based on forward scatter and fluorescence of cells. The first four 
bandpass filters are for use with the blue laser and the last two for the red laser. 
 
Fig  3.5: Guava EasyCyteTM benchtop flow cytometer laser excitation and photon collection 
system. © Merk Millipore. Adapted from [11]. 
 
3.7  Haematological analyser 
Haematological analysers are very useful tools in blood laboratories owing to their rapid 
testing, high throughput and accurate cell counting. The haematological counter used in 
this thesis was the Coulter AcT diff2 analyser (Beckman Coulter, CA, USA). This 
particular blood analyser counts the blood cells based on the Coulter Principle for cell 
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counting and sizing. This method measures the change in resistance across a circuit when 
blood cells suspended in fluid pass through two electrodes and from this change in 
resistance both the size and number of cells can be obtained [12]. This is possible as the 
cells are suspended in a conductive fluid and cells are insulating, the resulting impedance 
is related to the volume of the particle that has passed through an aperture which are 
connected to electrodes. As several types of cells have varying sizes, the distribution 
pattern of impedance can be correlated to blood cell sub-types. 
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Chapter 4:  Nanoparticle synthesis and 
characterisation 
This chapter describes the synthesis and characterisation of Cyanine5 dye-doped silica 
particles. Measurements were made to evaluate their size, stability, fluorescence and 
biological affinity, all of which are fundamental to understanding their properties. 
  
4.1  Introduction 
Dye-doped silica nanoparticles have previously been used for biomedical applications 
such as cell imaging and immunoassays [1]. They have advantages such as ability to 
carry hundreds of dye molecules, chemical stability, hydrophilicity, biocompatibility 
and relative non-toxicity [2]. Their facile surface chemistry means that targets such as 
aptamers, antibodies and DNA can be conjugated to the NPs to allow them to function 
as biosensors [3,4]. The NPs have been shown to easily incorporate a range of dyes 
across the spectrum including Rubpy, FITC, Cyanine5 and Cy7, to name but a few [3-
7]. Models of fluorescence ratio of dye-doped NPs in comparison to the free dye 
molecule at the same concentration have shown that an increase in signal can be 
achieved of up to at least two orders of magnitude, despite the effects of homo-Förster 
Resonance energy transfer (h-FRET) which limits the dye loading of NPs [5]. Dyes in 
the red and near infrared spectrum (650–950 nm) have become increasingly popular for 
use in biological detection systems. At these wavelengths, there is less inherent 
autofluorescence because light absorption of blood and tissue are minimal and for this 
reason these dyes are good candidates for use in cell staining and imaging [8]. 
Key parameters to prevent non-specific binding include a negative zeta potential, 
PEG functionalisation and protein stabilisation of NPs, as discussed in section 2.7.2. It 
has been reported that, to prevent NPs from crossing the cell membrane, they need to be 
negatively charged because phospholipid membranes are also negatively charged, 
leading to electrostatic repulsion, whereas positively charged NPs are more regularly up 
taken [9,10]. PEG has been used to increase circulation times of NPs in vivo due to 
reduction in aggregation of opsonins and proteins from blood serum on the surface of 
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NPs that cause endocytosis [11,12]. It has been shown that proteins can help to stabilise 
NPs by creating a protein layer around the particles, also known as a protein corona, 
which aids in preventing aggregation sterically in protein rich sample media such as 
serum [13-15]. Taking all these factors into consideration, I have developed a negatively 
charged PEGylated NP, that is colloidally stable, for specific targetting of EpCAM 
antigens on cancer cells. 
 
4.2  Materials and methods 
4.2.1 Materials 
Cyanine5-NHS ester dye (Cyanine5) was obtained from Lumiprobe GmbH (Hannover, 
Germany). Formvar grids for TEM were purchased from Agar Scientific (United 
Kingdom). 8-arm PEG (10,000 mW) was purchased from Nanocs (Boston, MA, USA). 
Anti-EpCAM purified monoclonal antibody was obtained from BioLegend (SanDiego, 
CA, USA). All other materials were obtained from Sigma-Aldrich, unless otherwise 
stated. 
4.2.2 NP synthesis: 
The theory behind NP synthesis has been described in section 2.7. Cyanine5 was 
incorporated into silica nanoparticles at two different weight percents using the reverse 
microemulsion method as described previously [6]. In brief, dye was added at a 
concentration of 0.108mg and 0.218mg to give theoretical yields of dye at 0.5% and 1%, 
respectively. The dye was conjugated with aminopropyltrimethoxysilane (APTMS) in a 
molar ratio of 5:1 to achieve covalent attachment to the silica. This conjugate was added 
to 10mL of cyclohexane, 260mg of dioctyl sulfosuccinate sodium salt (AOT), 230mL 
of polyoxyethylene nonylphenylether (NP5), 80μL of tetraethyl orthosilicate (TEOS), 
70μL water and 60μL of ammonium hydroxide for 24 h. The resulting emulsion was 
broken using ethanol and the NPs washed three times with ethanol using centrifugation. 
After this, the yield of NPs was calculated from drying and weighing 1 mL solutions.  
From TEM, the size of NPs was determined and subsequently the weight of one NP 
found using a density of 1.6g/cm3 for silica [16]. Knowing the dried weight of NPs and 
the corresponding weight of one NP, the number of particles in solution was also 
determined.  
The initial synthesis step was followed by the addition of a double silica shell coating 
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using the Stöber method, in order to obtain a uniform silica surface to functionalise [17]. 
Firstly, 20μL of TEOS was added to 5.2mg of NPs in ethanol and water solution 
followed by 100μL of ammonium hydroxide and left for 24 h. Another 20μL was added 
after this time to coat a second shell. Following this, an amine layer was coated onto the 
surface of 6mg of particles in ethanol using 20μL of bis(3-triethoxysily) propylamine 
(dipodal APTES). 
4.2.3 Functionalisation and antibody conjugation: 
Methods used for conjugating DNA to the surface of NPs described by Kelleher et al. 
were modified to conjugate EpCAM to the surface of NPs [18]. In short, 2mg of 8-arm 
PEG10,000 was incubated with 2mg of NPs for 24 h in 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) pH 4.7 and 50mM 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and purified in ethanol. Post PEGylation the 
carboxyl groups on the NPs were reactivated with 50mM EDC and 12.5mM N-
hydroxysulfosuccinimide sodium (NHS) salt in MES pH 4.7 buffer for 15 min and were 
then left to react with antibody in 0.1 M MES pH 7.2 buffer for 24 h. After this, the NPs 
were resuspended into phosphate buffer saline (PBS) containing 1% Bovine Serum 
Albumin (BSA) for 24 h before being washed in PBS three times and finally placed into 
PBS containing 1% BSA, 0.05% Tween®20 and 0.01% sodium azide for short term 
storage at 4 °C. This solution was chosen, as previous studies of colloidal stability of 
silica nanoparticles indicated that this was an optimal solution [19]. The sodium azide 
was added to prevent the growth of microbes. 
4.2.4 Fluorescence characterisation methods: 
4.2.4.1 TEM size analysis 
Transmission electron microscope (TEM) size measurements were carried out using a 
FEI Tecnai F30 (FEI, Oregon, USA) twin field emission gun operated at 300 kV with a 
Twin lens and an Ultrascan 895 CCD camera (Gatan, Oregon, USA). See section 3.2.1 
in relation to the operation of a TEM. NP diameters were determined by analysis of 
images on Image J software from the National Institutes of Health (Bethesda, MD, USA) 
on 100 NPs on Formvar grids.  
4.2.4.2 Modelling dye-loading and number of dye molecules per NP  
Models were produced using MATLAB (MathWorks Inc, Natick, MA, USA). Two 
programmes were modified from previous NIR dye molecules models [20]. The first 
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programme was run to produce the Förster radius for FRET between two Cyanine5 dye 
molecules, required for Eq. 2.4 in section 2.2.5. The Förster radius can be calculated by 
equation 4.1 and the programme that was run can be found in Appendix A1. 
R0
6=
9ln10
128π5Na
κ2QD
n4
J    (Eq.  4.1) 
where Na is Avogadro’s number, κ is the dipole orientation of the dye molecules, QD is 
the fluorescence quantum yield, n is refractive index and J is the spectral overlap 
between the absorption and emission of dye molecules. A value of 0.2 is used for QD, 
2/3 for κ and 1.5 for n. The code for the second programme, to find the effects of FRET 
within a nanoparticle, was theoretically calculated using Eq. 2.3 for NPs with different 
radii and the code for that programme can be found in Appendix A2. Weight percent 
loading of dye in the NP was calculated by dividing the mass of one NP by the mass of 
the dye inside it. The molecular weight of the dye used in this calculation is 616.19 
g/mol. The brightness ratio was a comparison of the photon emission of one NP 
compared to one cyanine5 free dye molecule. 
4.2.4.3 Experimental determination of dye loading and number of dye 
molecules  
The dye loading and number of dye molecules per NP were determined experimentally 
by measuring the absorption on the UV-vis of dissolved NPs. NPs at 0.5 mg/mL were 
placed in a silica dissolving buffer at pH 10 containing 0.5% sodium dodecyl sulphate 
and the absorbance of the NPs was measured every minute until t=60 min using a 
Nanodrop 2000c (ThermoScientific, DE, USA). See section 3.4 in relation to the optical 
range of this particular instrument. It was apparent that the dissolution had finished at 
t=60 mins as the absorbance at short wavelengths ~400 nm, due to the silica scattering, 
had stopped decreasing. The absorbance graphs were background subtracted and the 
absorbance at 650 nm was used to calculate both the weight percent and number of dye 
molecules.  
4.2.4.4 Fluorescence comparison to single dye molecule 
Fluorescence properties of the NPs were measured on an Infinite 200 microplate reader 
(Tecan, Männedorf, Switzerland). See section 3.3 regarding the optical setup of the 
microplate reader. By making a cascade dilution of the two sets of NPs in ethanol, and 
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also of Cyanine5 free dye, the fluorescence enhancement could be determined when 
comparing the concentration of NPs to the concentration of free dye.  
4.2.4.5 DLS size and zeta measurements 
Size and zeta measurements of the NPs were taken on a dynamic light scattering 
instrument (DLS) Delsa Nano C from (Beckman Coulter, CA, USA). See section 2.4 
and 3.5 in relation to zeta potential theory and DLS optical setup. All measurements 
were carried out at the same concentration (0.3 mg/mL) using a glass cuvette for size 
and a disposable flow cell for zeta measurements. 
4.2.5 Protein-dye labelling and quantitative measurement of the number of 
antibodies on a nanoparticle 
Human IgG was labelled with sulfonated Cyanine3 dye (Lumiprobe GmbH, Hannover, 
Germany). 1 mg of dye was added to 0.5 mg of human IgG which was buffer exchanged 
into MES pH 7.2 and left to react for 2 hours. The molar ratio of dye to antibody was 
20:1. The dye conjugate was then filtered into MES pH 7.2 for reaction with PEG coated 
nanoparticles. The actual dye to antibody ratio was calculated using a corrected 
absorbance concentration of the dye molecule compared to the antibody and is given by  
[Dye]=
AMax
Molar coefficient
   and [Antibody]=
A280-(0.08xAMax)
Ab molar coefficient
     (Eq.  4.2) 
where AMax is the absorbance maximum of the Cyanine3 dye found at 551nm, the molar 
coefficient is the molar extinction coefficient found to be 162,000 M-1cm-1 for Cyanine3, 
A280 is the absorbance of the IgG protein and 0.08 is the correction factor for the 
absorbance of Cyanine3 at 280nm and Ab molar coefficient is the molar attenuation 
coefficient for IgG which is 210,000 M-1cm-1. The final dye to antibody ratio is given 
by [Dye]/[Antibody]. Using A551=0.130, A280=0.271, measured from absorbance, and 
molar coefficients mentioned above, a dye labelling of 0.675 dyes was obtained per 
antibody.  
A calibration curve was obtained for both the Cyanine3 labelled antibody and Cyanine5 
PEG coated NPs. This was done using a cascade dilution of known concentrations of 
antibody and NPs and measured on the microplate reader exciting at 546nm for 
Cyanine3 IgG and 649nm for cyanine5 NPs. PEG coated NPs were incubated with 
different concentrations of labelled IgG overnight before the supernatant was measured 
the next day in the microtitre plate reader. The NPs were measured fluorescently, 
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directly from the sample, and compared to a fluorescence vs concentration calibration 
curve previously generated for the NPs to obtain the concentration of NPs in the sample. 
Based on the fluorescence of both the NPs and the IgG the concentration of both could 
be back calculated and was determined. 
 
4.3  Results and discussion 
Two sets of NPs with ab initio Cyanine5 dye loadings of 0.5% and 1% were 
characterised using TEM, fluorescence and absorbance measurements, the results of 
which are presented in the following pages. 
4.3.1 Nanoparticle size analysis: TEM  
From TEM images, the nanoparticles, as synthesised, had an average radius of 23.2 ± 
2.0 nm and 20.4 ± 1.0 nm for 0.5% and 1% respectively (n= > 100 in all measurements 
and see Fig B1 in appendix B for 1% TEM images). The smaller particle size for higher 
dye loadings is due to classic nucleation theory where changes in supersaturation point 
directly affect the number of nucleation points. When the concentration of the 
hydrophobic dye increases, it leads to lowering of the supersaturation point resulting in 
more nucleation points and smaller NPs [21]. After synthesis of the bare NP, the 0.5% 
NPs were analysed at every step in the functionalisation process using TEM. As 
expected, the NPs increased significantly in radius after the addition of a TEOS shell 
and surface amination to 31.8 ± 1.5 nm. Upon PEGylation and antibody conjugation no 
further size increase was observed within standard deviation (see Fig. 4.1). Also the NPs 
were of similar size between the two sets after PEGylation with 0.5% NPs measured to 
be 33.3 ± 1.6 nm and 1%, 29.0 ± 1.3 nm.  
It is interesting to note the difference in appearance of the antibody conjugated NP set 
(Fig. 4.1(d)). The NPs in this image show a surface roughness when compared to Figs 
4.1(a)-(c) which is indicative of the presence of the antibody layer. Previously published 
TEM pictures of mesoporous silica NPs coated with monoclonal antibodies do not 
appear to show this roughness [22]. However, these particles were synthesised using a 
templating method which produces a hexagonal structure on the surface, so it is difficult 
to compare to the NPs reported here. In another previous study, TEM images of iron 
oxide NPs conjugated with antibodies show much clearer definition between antibody 
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and NP due to the better contrast between the electron-poor antibody and the electron-
rich oxide particle [23]. The monodispersity of the NPs could not be implied from TEM 
due to aggregation of NPs during preparation of TEM grids but was investigated later 
using DLS. 
 
Fig  4.1: TEM images of 0.5% NPs at different steps throughout the synthesis method: (a) as 
synthesised, 23.2 ± 2.0 nm radius; (b) amine functionalised, 31.9 ± 1.5 nm radius; (c) 
PEGylated, 33.3 ± 1.6 nm radius; and (d) antibody conjugated, 30.0 ± 3.5 nm radius. The scale 
bar is 100 nm in each image. Previously published by author [24]. 
 
Table 4.1: Characterisation of 0.5% (w/w) and 1% (w/w) Cyanine5-doped NPs using TEM.  
NP set 
Radius as synthesised 
[nm] (from TEM) 
Radius + amine layer 
[nm] 
Radius + PEG 
layer [nm] 
Radius + anti-
EpCAM layer [nm] 
0.5% 23.20 ± 1.96 31.8 ± 1.5 33.3 ± 1.6 30.0 ± 3.5  
1% 20.38 ± 1.00 N/A 29.0 ± 1.3 N/A  
 
4.3.2 Colloidal stability: Nanoparticle hydrodynamic radius and zeta potential 
To investigate the colloidal stability and if the dye-doped silica NPs were 
monodispersed, the NPs hydrodynamic radius and zeta potential were measured at each 
functionalisation step. In most cases, NPs were analysed at a concentration of 0.3 mg/mL 
in deionised water. However, antibody coated NPs were also measured in conditions 
that were reported previously for the stabilisation of NPs in immunoassays; PBS 
containing 1% BSA and 0.05% Tween®20 [19]. Fig 4.2 contains data for both 
measurements of the particles at each step and the next paragraph is based on these 
results.  
Newly synthesised dye-doped silica NPs have a negative zeta potential and after the 
addition of two silica shells the potential did not differ significantly. This indicates that 
the dye encapsulated does not interfere with surface charge. They appear to be relatively 
monodisperse and stable in water, as indicated by the low hydrodynamic radius, which 
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is 52.3 ± 13.9 nm for 0.5% NPs and 75.2 ± 18.6 nm for 1%. When the NPs are coated in 
amine groups, there is an increase in hydrodynamic radius which would indicate some 
aggregation of NPs. The zeta potential has also become positive but from the DLS 
measurement the particles are aggregating somewhat in solution. It is most likely, that 
the static repulsion between NPs is not sufficiently positive enough to generate 
stabilisation, via surface charge. After the addition of PEG molecules to the NPs, there 
is a reduction in hydrodynamic radius of statistical significance (P<0.05) for both sets 
of NPs. As the zeta potential remains statistically unchanged it appears that PEG acts as 
a stabilising agent due to the reduced hydrodynamic radius. Upon the covalent 
attachment of antibody and BSA to the surface of the NP, the hydrodynamic radius is 
statistically insignificantly changed (P>0.05) showing stability in both water and PBS 
containing 1% BSA and 0.05% Tween®20 and the zeta potential of the particles has 
become negative. Interestingly, there is a statistically significant difference (P<0.05) in 
zeta potential between the two sets of NPs which were similar at each functionalisation 
step until the antibody was introduced. As the two sets were functionalised in the exact 
same way and the only difference between them is the radius and number of dye 
molecules per NP it is possible that more antibody could attach to the surface of the 
0.5% as they have a larger surface area. Importantly, although they differ significantly 
in zeta potential, the two sets of NPs do not aggregate in the PBS solution which 
indicates that it is a suitable working solution for cell staining and imaging protocols. 
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Fig  4.2: Hydrodynamic radius (top) and zeta potential (bottom) of 0.5% (blue) and 1% (green) 
NPs at different stages in the functionalisation process measured in water on the DLS except 
the Antibody sample in the zeta and NP size graph, measured in PBS containing 1% BSA + 
0.05% Tween®20. 
 
4.3.3 Number of dye molecules per nanoparticle 
To achieve a more accurate estimate of the actual weight percent dye loading in the NPs 
and to calculate the number of dye molecules per NP, the NPs were dissolved using a 
carbonate buffer, to release the dye molecules from the silica matrix. Both sets of NPs 
were placed in a carbonate buffer at pH 10 and, when the silica was dissolved, the 
absorbance of the dye was measured at t=60 min. The results were used to calculate the 
actual weight percentage loading of NPs (see Fig B2 in appendix B). It was found that 
the nominal 0.5% particles actually contained 0.168% dye while the nominal 1% 
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contained 0.279% dye. This indicates that only roughly 30% of dye added was 
encapsulated and is due to the reverse microemulsion synthesis method. Previous work 
to incorporate another red dye, FR664, with a quaternary microemulsion method 
resulted in a less than 20% yield which is lower than the quaternary method used here 
[20]. The dissolution absorbance also allows for a more accurate calculation of the 
number of dye molecules inside each NP. Based on the absorbance, the number of dyes 
inside the two sets of NPs was calculated to be 137 for 0.168% and 155 for 0.279% as 
seen in Table 4.2. 
Table 4.2: Characterisation of 0.5% (w/w) and 1% (w/w) Cyanine5-doped NPs using TEM, 
UV-Vis and fluorescence 
NP set Absorbance 
Actual 
Weight % 
loading 
Dye molecules per NP 
(from absorbance) 
Brightness ratio of 
NPs to Cyanine5 at 
same conc. from 
model 
Brightness ratio of 
NPs to Cyanine5 at 
same conc. 
measured 
0.5% 0.340 0.168 137 ± 7 116 129 
1% 0.566 0.279 155 ± 8 109 113 
 
The brightness ratio of the two sets of NPs was investigated. This is the measure of the 
fluorescence of the NP labels divided by the fluorescence of Cyanine5 dye molecules at 
the same concentration and is a measure of the relative brightness of the NP compared 
to the dye molecule (see Fig B3 in appendix B). The measurements, which were made 
after NP synthesis before addition of shell, yielded a ratio of 129 for the 0.168% to 
Cyanine5 free dye and 113 for the larger dye concentration of 0.279% (see Table 1). 
This data was compared to a previously published h-FRET model of NP dye loading 
that has been modified for Cyanine5 dye (Förster radius of 5.55 nm and a quantum 
efficiency of 0.2) [20]. The model is based on standard Förster energy transfer equations 
in which both donor and acceptor are Cyanine5 molecules and the h-FRET takes place 
as a result of the small Stokes shift of the dye. A reduction in fluorescence happens as 
the dye concentration is increased leading ultimately to saturation of the fluorescence of 
the dye molecules in the silica matrix and causes a decrease in emitted intensity. This is 
illustrated in Fig. 4.3, which represents the theoretical behaviour of the emission of NPs 
of a particular size as a function of dye loading. The y-axis of the graph represents the 
brightness ratio defined above. The predicted ratios for the two dye concentrations are 
116 for 0.168% and 109 for 0.279% compared to measured values of 129 and 113 as 
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seen in Table 4.2. The theoretical maximum ratio is 166 and 118 for the 23 nm radius 
NP and 20.5 nm radius NP respectively, both approximately occurring at 0.41% dye 
loading. From the experimental results, the 20.5 nm NPs (0.279%) are close to the 
maximum ratio. Clearly, the experimental data does not fit exactly to the model, as there 
are a number of assumptions. For example, in the model only nearest neighbour transfer 
is considered, the molecules are assumed to be homogenously distributed in the 
particles, any dye aggregation effects are ignored, and any changes in dye quantum 
efficiency are not taken into account. As noted above, the size of the higher 
concentration NP with larger number of dye molecules, is smaller than that of the lower 
concentration particle. This accounts for the lower predicted ratios which is consistent 
with the measured value and consistent with a larger h-FRET effect in these particles 
due to the closer proximity of the dye molecules. 
 
Fig  4.3: H-FRET model of fluorescence ratio compared with Cyanine5 free dye for 23.0 nm 
and 20.5 nm NPs. Previously published by author [24]. 
4.3.4 Antibody functionality and number per nanoparticle 
It is important to be certain, when using the NPs as biosensors that firstly, the antibody 
is conjugated to the surface of the NP and secondly, the antibody retains its affinity for 
the antigen of interest after conjugation to the surface. 0.5% NPs were tested to ensure 
that the NPs were coated with antibody and also to determine quantitatively how many 
antibodies are on each nanoparticle. Cyanine3 labelled human IgG was covalently 
attached to the NPs as per the protocol described in section 4.2.5. NPs were incubated 
with different amounts of antibody in solution for conjugation. The number of antibodies 
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on each particle was determined through the supernatant once the particles had been 
centrifuged and were in a pellet. In this method, the number of labelled antibodies on 
the nanoparticle is equal to the initial amount of antibody added minus the amount found 
in the supernatant, see section 4.2.5 for methodology.  
 
Fig  4.4: The number of human IgG antibodies per NP based on the µg amount added initially 
at conjugation. Concentrations of cyanine3 labelled IgG were calculated from fluorescence 
based measurements on the supernatant. 0.5mg of NPs added initially, accurate NP 
concentration was measured using fluorescence directly from sample. 
The results in Fig 4.4 reflect the average of three different sets of NPs that were 
conjugated with Cyanine3 labelled human-IgG. Each experiment was carried out with 
0.5mg of NPs. The highest number of antibodies per NP was achieved with the highest 
amount of starting antibody as was expected. The trend appears to be decreasing 
proportionally to the amount of antibody added, the 27µg of IgG having almost half the 
number of antibodies per NP as the 54µg set. It is assumed that, at some point, the surface 
of the NP must reach saturation however, the saturation point does not lie within this 
range of concentration. Accurate calculations of the IgG that was directly on the NP 
surface could not be carried out due to self-quenching effects of the Cyanine3 
fluorophores, conjugated to the antibody, in close proximity to each other. This direct 
sampling method was tested on the 54µg set for comparison purposes and there was 
found to be 16 antibodies per NP using this method, compared with 79 antibodies from 
the supernatant method. The direct fluorescence measurement yields a lower 
concentration of antibody from FRET effects and highlights the importance of using the 
supernatant for analysis. 
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Knowing how many antibodies are on the surface of each nanoparticle is useful 
information, but more relevant information is knowing how many are available to bind 
to an antigen. This is dependent on antibody orientation on the surface of the 
nanoparticle and also assumes that the antibodies do not denature when conjugated to 
the NP. The antibodies are covalently attached to the NP through NH2 groups, which are 
found on lysine residues throughout the structure of the antibody and so the location of 
the amine group bound to the NP cannot be known. To investigate this, two sets of 0.5% 
NPs were conjugated with 27µg of antibody and conjugated with either unlabelled 
human-IgG or unlabelled anti-human IgG as the EpCAM antigen is commercially 
unavailable to purchase. These NPs were incubated with Cyanine3 labelled human IgG 
and the number of specifically bound antibodies determined. The human IgG NPs were 
used to investigate the amount of non-specific binding that occurs on the NPs. The 
experiment was repeated in a high protein media, which was PBS containing 10% FBS, 
to determine the functionality of the particle in a high salt and protein environment. The 
results of this can be seen in Table 4.3. 
Table 4.3: The number of cyanine3 labelled human IgG antibodies bound to anti-human IgG 
NPs or human IgG NPs 
 
Anti-human IgG NPs Human IgG NPs 
No. of h-IgG bound  
(active antibodies) 52 ± 2 2 ± 1 
No. of h-IgG bound- high 
protein (active antibodies) 50 ± 3 2 ± 1 
 
From the work previously presented in this section, Fig. 4.4, 27µg of antibody shows 47 
± 5 antibodies binding to the surface of a NP. The results from the functionality 
experiment show that there were 52 Cyanine3 human IgG antibodies bound to the 
particle, indicating that all antibodies on the particle surface were available to bind to 
the appropriate antibody. This does not necessarily translate for cellular sensing because 
the antigen, on the surface of the cell in this case, will be unable to freely move in 
solution, which should be taken into consideration. With regard to the human IgG NPs, 
it can be seen that two antibodies bound non-specifically to the particle. As the number 
is very low, it implies that the surface of the NP is suitable for the current application. 
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Similar results were obtained for the NPs that were incubated in high protein media and 
this is an indication of how the NPs will react in biological milieu. The conjugated 
antibody on the NP appears to have retained its functionality and to be unhindered by 
the protein in the solution, showing a promising outlook for use in biological 
environments.  
4.4  Conclusion 
Cyanine5 dye-doped silica NPs at two different weight percent loadings, 0.168% and 
0.279% were successfully synthesised and functionalised with antibody. Their size, zeta 
and fluorescence properties have been characterised and they appear stable in water and 
in PBS containing 1% BSA and 0.05%Tween®20, a buffer that can be used for cell 
staining and imaging. The antibodies conjugated to the NP have been verified as 
functional and the number of antibodies on the surface calculated. This knowledge will 
be useful throughout the remaining results chapters of the thesis and an essential 
understanding of the particles has been achieved to move on to the next steps of 
evaluating specificity in the cellular environment.  
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Chapter 5:  Primary antibody 
nanoparticle cell staining 
 
5.1  Introduction 
There are two main techniques to stain cells or detect antigens. They are through primary 
or secondary antibodies (see section 2.5 for more details of the structure of antibodies 
and differences between primary and secondary antibodies). To summarise, primary 
antibodies are easy to work with, as the antibody directly binds to the target antigen. The 
primary antibody is labelled with dye molecules and so fluorescence measurements can 
easily elucidate where the antigens are positioned. Secondary antibodies require two 
steps. The first consists of incubating cells with an unlabelled primary antibody, and 
after a number of wash steps, the fluorescently labelled secondary antibody is introduced 
to the cells that is specific to the primary antibody. To reduce the number of variables, 
a primary antibody detection system was initially employed for use with NPs. 
One of the motivations for carrying out this work is to benchmark the performance of 
the NPs against other dyes to evaluate whether they can be competitive with the 
conducting polymer dyes discussed in section 2.3. These labels require ultra violet or 
violet excitation [1,2].  APC and AlexaFluor®647 are the most common dyes used that 
are excited and emit in the red and in this chapter the performance of the NPs is 
benchmarked against these two fluorophores as they have a similar spectral range and, 
therefore, they do not require adjusting microscope filter sets or laser lines.  
One of the challenges in using nanoparticles for targeted cell imaging or staining is the 
high degree of non-specific interactions between the cells and particles followed by 
endocytosis. The internalisation of NPs by cells can be useful for investigating pH, 
toxicity and drug delivery applications; however, for the work presented in this chapter, 
it is imperative that the nanoparticles are not absorbed or taken up non-specifically [3-
5]. In this work, multiple layers were placed on the surface of the NP to reduce the effect 
of non-specific binding. A PEG layer was placed on the NP because PEG has been 
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shown to aid in reducing endocytosis [6]. In a detailed study, Rampazzo et al. 
investigated the use of PEG molecules on the surface of silica NPs with different charged 
functional groups to reduce particle up take in cells [7,8]. Results indicated that PEG 
only nanoparticles had reduced uptake in the cell compared to positively charged amino-
PEG-NPs but that overall the highly negative carbo-PEG-NPs, were least effective at 
entering the cell membrane, emphasising the point that the overall negative charge of 
the NP helps to prevent its endocytosis.  
As protein also appears to aid in prevention of endocytosis, the NPs were placed in a 
BSA solution after conjugation with antibody. Proteins help to stabilise NPs through the 
formation of a protein corona which blocks non-specific binding through steric 
hindrance. Cedervall et al., Monopoli et al. and Lundgvist et al., to name but a few, have 
studied in detail how proteins adsorb onto and desorb from the surface of NPs and the 
kinetic rates of such processes [9-11]. Lesniak et al. have shown that, without serum, 
NPs are internalised by cells much more effectively because of the lack of protein in 
solution and similarly Kim et al. have shown that at low concentrations of protein, NP 
uptake is greater than at higher concentrations [12,13]. 
Immunospecific direct binding NP cell staining work has been reported previously 
[14,15]. Yun et al. incorporated Fluorescein isothyocyanate (FITC), into silica NPs and 
conjugated anti-CD4 to their surface in order to detect subpopulations of leukocytes on 
a microchip [14]. In another study, by Tao et al., silica NPs were doped with Rubpy dye 
and the efficiency was investigated of the NaIO4 oxidation method of conjugating 
antibodies to the NP compared with the glutaraldehyde method [15]. They investigated 
direct binding NPs as biosensors for the detection of EpCAM in colorectal cancer. 
It is important to know the fate of the NPs once incubated with cells, for example, in cell 
staining when detecting surface markers, to ensure that the targeting antibody is 
functional and not endocytosed by the cell. This is also important in drug delivery, to 
verify that the drugs are targeting a specific cell organelle. Different microscopy 
methods can be used to identify where the NPs are located [13,16]. In this work, confocal 
fluorescence microscopy was chosen to determine the fate of NPs in both MCF-7 and 
HeLa cell lines, as the NPs are highly fluorescent. Staining the membrane with a 
different fluorophore will help identify whether the NPs are on the surface of the cell. 
This method also allows the position of individual and aggregate NPs to be determined 
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as a whole cell is imaged using scans compiled in a z-stack so that any slice through the 
cell can be examined for signs of internalisation.  
 
5.2  Materials and methods 
5.2.1 Materials 
Purified anti-EpCAM, anti-EpCAM AlexaFluor®647, anti-EpCAM APC, were obtained 
from Biolegend. Wheat germ agglutinin (WGA) conjugated Oregon Green®488, 
ProLong® Gold antifade mountant and Hoechst 33342 Stain was obtained from Thermo 
Pierce. All other materials were obtained from Sigma Aldrich.  
5.2.2 Cell culture 
HeLa, MCF-7, PNT1A and LNCaP cells were cultured in 75 cm2 flasks in Dulbecco's 
Modified Eagle's Medium (DMEM) with 10% uninactivated fetal bovine serum (FBS), 
100units/mL penicillin and 100μg/mL streptomycin. Cultures were maintained at 37 °C 
with 5% CO2. Harvesting of HeLa, MCF-7, PNT1A and LNCaP cells was carried out 
by incubation in 5mL 0.25% trypsin/0.1% ethylenediaminetetraacetic acid (EDTA) at 
37 °C for 5 min followed by neutralization with 5mL DMEM culture medium. Cells 
were centrifuged at 300×g for 5 min and resuspended in supplemented DMEM culture 
media. 
5.2.3 Immunospecific cell staining 
Cells were washed twice in PBS before being resuspended into PBS containing 1% BSA 
and 0.05% Tween®20. They were left to incubate in the solution at room temperature 
for an hour while cell counting was performed on a haemocytometer. Cells were 
distributed so as to obtain 125,000 cells per test. Anti-EpCAM labelled NPs were added 
to cells that had previously been suspended in PBS containing 1% BSA and 0.05% 
Tween®20 and were at a concentration of 1mg/mL. 10μg or less of NPs were used per 
test with cells or, depending on the experiment, 3μL of anti-EpCAM AlexaFluor®647 or 
APC. Any other stains that were used such as the Oregon Green® 488- WGA for staining 
the cell membrane or Hoechst 33342 Stain for staining the nucleus were also added at 
this stage. 2μL of each stain (1μg/μL) was added to each test. The nanoparticles were 
left with the cells to incubate for 1 h at room temperature. After this, they were washed 
3 times in PBS and then taken to be analysed either by flow cytometry or microscopy. 
For confocal microscopy, cells were fixed with paraformaldehyde for 15 min after the 
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incubation with NPs and washing steps. They were then washed in PBS, placed on a 
microscope cover slip and mounted in ProLong® Gold. 
5.2.4 Microscopy 
Cells were imaged using an IX71 (Olympus, Tokyo, Japan) inverted epifluorescence 
manual microscope with a TK-1460 colour video camera (JVC, Yokohama, Japan) and 
using a X-Cite series 120 excitation lamp (Excelitas Technologies Corp, MA, USA). 
See section 3.2.2 for the optical set up of the inverted epifluorescence microscope. 
Images were taken at 20x magnification and using a dapi or Cyanine5 filter cube. 
Confocal microscopy was carried out using a Leica TCS SP8 microscope (Leica 
Microsystems, Wetzlar, Germany) using an 86x oil immersion lens and hybrid detectors. 
The excitation source was a tuneable white light laser set at 488 nm for WGA conjugated 
Oregon Green® 488 and at 650 nm for Cyanine5 or AlexaFluor®647 dyes. See section 
3.2.3 on optical set up and operation of a laser confocal microscope. 
5.2.5 Cell imaging analysis 
Images were analysed to quantify the fluorescence using Image J software. For an image 
of a cell in bright field, a region of interest (ROI) was selected that tightly enclosed the 
cell. That ROI was then superimposed over the fluorescent image, and the fluorescence 
measured, ensuring that the ROI in the fluorescent image corresponded to the cell from 
the bright field image. The raw integrated density value of the ROI was measured using 
the “RawIntDen” measurement in Image J, as this measurement is the sum of the grey 
pixel value in the region and prevents dark, background pixels, that may get incorporated 
in the ROI, to interfere with the measurement. A background value for each cell was 
obtained by taking a measurement where no cell was present with the same area as that 
of the measured cell. This background value was subtracted from the original cell value 
to give a normalised value of fluorescence from the cell. 
5.2.6 Flow cytometry 
Flow cytometry was carried out using a Millipore EasyCyte 8HT with loading in the 
form of a 96 well plate. Parameters were kept consistent between each run and include 
the event count 20,000, forward scatter and side scatter gain of 1.0, all fluorescence 
channels were at 8.0 and forward scatter threshold of 30.0. These were unchanged for 
both cell lines. See section 3.6 for the theory behind flow cytometry and the optical 
detection system for this particular flow cytometer. The median values of the measured 
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fluorescence was chosen for comparison purposes as the median values take into account 
the asymmetry or the skewness of the data plots.  
The flow cytometry plots in this chapter are based on the data from the red2 fluorescence 
channel of the flow cytometer and represents the amount of EpCAM expression per cell 
and is found on the x-axis of the plots.  The y-axis represents the number of cells that 
have the same red2 fluorescence/EpCAM expression values. 
 
5.3  Results and discussion 
5.3.1 Immunospecific staining microscopy results 
In this section, antibody conjugated NP labels were incubated with EpCAM positive and 
negative cells to investigate specificity and brightness. The results were compared to 
commercially available anti-EpCAM conjugates AlexaFluor®647 and APC. Initially, the 
optimal concentration of NPs needed per test was determined. Three different 
concentrations of NPs were incubated with 125,000 cells. This optimal particle 
concentration was determined when the non-specific binding of the NPs to HeLa cells 
was minimal and confirmed using flow cytometry (see Fig C1 appendix C for example 
of 0.279% optimisation). As the number of particles in solution with cells increases, 
there is also an increase in non-specific binding, most likely due to particle-particle 
interactions and possibly aggregation of NPs which could effectively stick to the cell's 
membrane. The optimal NP mass needed per test was found to be 10μg of 0.168% and 
7.5μg of 0.279% NPs. Taking the particle size into consideration the number of particles 
in the case of 0.168% NPs equates to 1.2×1011 particles for the optimal number and for 
0.279% NPs, the 7.5μg equates to 1.3×1011 particles. This is comparable to the number 
of antibodies present in 3μL of dye conjugated anti-EpCAM labels where there are 
5.8×1011 antibodies for AlexaFluor®647 and 1.4×1011 for APC. 
Cells were viewed under the microscope to check their performance for the application 
of cell imaging. Both NP and red conjugate labels bound to MCF-7 cells generate high 
fluorescence signals, whereas almost no binding was observed on the HeLa cells (See 
Fig 5.1). Therefore, the NPs show high specificity in cell staining. The NPs appear to 
cluster into specific regions on the cell surface which is consistent with images presented 
by Tiernan et al. who used NIR-664 doped silica NPs to target colorectal cancer cells 
[17]. For the AlexaFluor®647 and, to a lesser extent, the APC conjugated antibodies in 
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Fig 5.1 (f) and (h), an uneven fluorescence emission signal was observed from the non-
uniform distribution of EpCAM receptors. However, signal was also observed across 
the entire surface of the cell. It is not clear why the NP labels do not cover the entire 
surface, since the concentration of NP and dye conjugates added were similar and good 
mixing was used. It could be that the NP are binding preferentially to clusters of EpCAM 
receptors, which would enable more than one anti-EpCAM antibody on the NP to bind 
to more than one EpCAM receptor and therefore increase the overall avidity of the NP 
label [18]. This is because antibodies (~5-15 nm in size) appear quite small relative to 
the size of the NPs and, because of this size difference, could also be causing steric 
hindrance, preventing other NPs from binding to EpCAM receptors within the vicinity 
of the first receptor.  
 
Fig  5.1: Bright field and corresponding fluorescence images of MCF-7 and HeLa cell lines 
incubated with different red dye anti-EpCAM conjugates. The nucleus of the cells (blue) is 
stained with Hoechst 33342. The scale bar represents 50µm. Previously published by the 
author [19]. 
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The performance of the NPs in cell imaging was analysed quantitatively using image 
analysis methods and compared to that of cells stained with the other red conjugates, the 
results of which are summarised in Fig 5.2. The average fluorescence from 
Alexaflour®647 was higher than the other labels but all were similar within statistical 
error given the size of the error bars. The error bars are large because each cell is non-
identical in size, shape and EpCAM expression, which contributes to the variability in 
the fluorescence from each cell. The analysis was carried out on over 50 cells from each 
experiment. This is still a very small sample set and to get a more accurate insight into 
the trend of the whole population of cells, flow cytometry was carried out and discussed 
in section 5.3.2. 
 
Fig  5.2: Image analysis of cell staining using anti-EpCAM red conjugates on two cell lines; 
MCF-7 (EpCAM +) and HeLa (EpCAM -). The analysis was carried out on over 50 cells from 
each experiment. 
Non-specific binding, i.e., the measure of the fluorescence from HeLa cells is low not 
only for the antibody conjugated fluorophores but also for the two sets of NPs. This is 
particularly valuable in microscopy as it allows a very distinguishable positive and 
negative population and leaves little room for misidentification. This low non-specific 
binding is attributed to the functionalisation steps during synthesis and the preparation 
steps of the NPs before incubation with cells, in particular, zeta potential, PEGylation of 
NPs and protein incubation. The potential at the cell membrane for HeLa cells has been 
measured to be −19.4 ± 0.8 mV and is assumed to be due to the phosopholipids and 
proteins found on the cell surface [20]. In order to prevent electrostatic attraction 
between the NPs and cells, the NPs must be negative. This is vital in preventing non-
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specific binding and allowing specific antibody-antigen interactions. Both sets were 
measured and a summary of these can be found in section 4.3.2. To recap, 0.168% NPs 
with antibody had a zeta potential of −25.46 ± 1.85 mV and the 0.279% NPs had a 
potential of −8.95 ± 2.63 mV. The exact reason for variability in zeta potential between 
NP samples of different dye loading is not known. According to Roy et al., far red dyes 
are found in two distinct regions of silica NPs, at or near the surface or in the core of the 
particle [21]. It could be postulated that, at higher loading, the hydrophobic cyanine dye 
nearer the surface reduces the overall zeta potential. However, upon zeta potential 
measurements at the amination step, the results were similar with +8.69 ± 0.88 mV for 
0.168% NPs and +12.29 ± 0.62 mV for the 0.269% NPs and thus does not appear to 
affect the zeta potential. Therefore, further work involving the synthesis of more NPs 
with varied dye loadings is required to understand the origin of these differences. 
 
5.3.2 Flow cytometry results 
Flow cytometry was performed on the Merck Millipore Guava EasyCyte 8HT system to 
obtain a statistically relevant set of results. Originally, the gain was optimised for APC, 
however after testing some NPs at this setting, they were off the scale and this required 
re-optimising so that all the red conjugates could be viewed at the same gain settings. 
Once the different gains were optimised for both cells and NPs, such as forward and side 
scatter, threshold and fluorescence channels, all these parameters were kept constant 
throughout and performed on 20,000 events for both cell lines. NPs or red conjugates 
were incubated with cells using the same methods that were used for cell imaging. 
From the data presented in Fig. 5.3, it is clear that the nanoparticles are both bright and 
specific to the EpCAM positive cell line. If we view the median of the fluorescence 
intensity of the MCF-7 cell population, the NPs clearly outperform the antibody 
conjugates comparing graphs (B) or (C) to (D) or (E). The 0.168% NPs have over twice 
the fluorescence signal compared to APC, which is the brighter of the two commercially 
available conjugates for flow cytometry and the 0.279% NPs show a higher median 
fluorescence to the APC. The fluorescence characterisation measurements indicate that 
the 0.168% NPs are brighter, due to h-FRET effects, and this is reinforced in the flow 
cytometry results. The zeta potential of the NPs, mentioned previously in the cell 
staining section 5.3.1, showed that the 0.279% NPs were less negative than the 0.168%. 
Due to this potential, they are less likely to be repelled by the negative charge on the cell 
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membrane. However, as the difference is small and the antibody-antigen bond is strong, 
this effect is not observed.  
 
 
Fig  5.3: Flow cytometry results for MCF-7 cells and HeLa where the top row (A and A’) are 
cells only and rows B-E and B’-E’ correspond to cells incubated with anti-EpCAM red 
conjugates. MFI stands for median fluorescence intensity value. Previously published by the 
author [19]. 
Assessing non-specific binding with the HeLa cell line, from graphs D’ and E’ in Fig. 
5.3, the cell population lies largely to the left of the region M1 and the median values 
almost match those obtained for APC and AlexaFluor®647. The median value for the 
0.168% NPs incubated with HeLa cells is slightly higher than the 0.279% NPs and this 
is attributed to the brighter particle and does not imply there are more particles adhered 
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to the surface of the cell. As there are roughly 1011 particles in solution with the cell 
sample there is a possibility that some cells will have NPs bound to them and the results 
confirm this as both graphs (D’) and (E’) trail partially to the right. However, despite the 
small amount of non-specific binding, it can be concluded that the NPs are specific to 
the MCF-7 cells and the positive and negative cell lines’ median value lies far enough 
apart that each population can be easily distinguished.  
These results were compared to previous results reported. Yun et al. found that their 
anti-CD4 FITC doped NPs were approximately 50 times brighter than anti-CD4 free 
FITC dye [14]. As they were comparing the dye incorporated in the NPs to an antibody 
labelled version of the dye for analysis of subpopulations of white blood cells, the results 
cannot be directly compared to the work presented in this chapter. However, work more 
similar to this work was published by Tao et al., who conjugated anti-EpCAM to Rupby 
NPs for cell staining using a direct binding method [15]. Their work focused on a new 
antibody conjugation method using a NaIO4 oxidative method compared with 
glutaraldehyde. They observed a tenfold increase in signal detecting the EpCAM marker 
from colo205, a colorectal cancer and another metastatic carcinoma, using NP labels, 
compared with an anti-EpCAM antibody conjugated with FITC. They achieved a signal 
enhancement within the same order of magnitude as is reported here and likewise, they 
also found low non-specific binding with an EpCAM negative cell line.  
It is noted that the flow cytometry results do not exactly match those obtained from the 
cell imaging analysis. In imaging analysis, all red conjugates had a similar fluorescence; 
however, in flow cytometry the 0.168% NPs performed best closely followed by 0.279% 
NPs, then APC and last was AlexaFluor®647. The trend is similar in the imaging results 
for the two sets of NPs and the APC. However, the AlexaFluor®647 does not perform as 
well. Given the significantly higher number of cells that can be analysed, flow cytometry 
is a more statistically relevant measure of the performance of each label. Therefore, flow 
cytometry lends a more complete picture compared with cell microscopy in terms of 
quantification.  
5.3.3 Location of NPs on cells using confocal microscopy  
Confocal microscopy was employed to identify the location of the NPs in/on the cell and 
also to determine whether the NPs were aggregating on the cell surface, as is suggested 
from the cell staining images. If the NPs are attached to the cell surface, as is 
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hypothesised, they should overlap with a stain for the cell membrane. A wheat germ 
agglutinin (WGA) stain was chosen that was conjugated with Oregon Green® 488 dye 
and the cells were incubated with both this stain and the NPs for one hour at the same 
concentration as per the protocol for both flow cytometry and cell staining. Following 
this the cells were fixed and mounted to be viewed in confocal microscopy. The whole 
cell was imaged and reconstructed from the compilation of z-stack images and this was 
carried out to investigate whether the NPs were internalised by the cells in a mechanism 
of endocytosis and/or entrapment in an organelle. 
From the images obtained from confocal, as seen in Fig. 5.4 (1a-d), the red fluorescence 
overlaps strongly with the green, confirming that the NPs are bound to the surface of the 
cell. As there is no red fluorescence in the centre of the cell (1c) there is no internalisation 
of the NPs. In the confocal microscopy images, there are some small regions of 
clustering but also significant distribution of NPs across the whole surface. There is also 
an uneven distribution of EpCAM receptors on the cell surface, comparing the images 
of the cells incubated with AlexaFluor®647 (2a-d) to those incubated with the NPs in 
this case, in agreement with previous microscopy images. In images (3a-d) of a HeLa 
cell incubated with NPs, there are only one or two NPs bound to the cell, see Fig C2 in 
appendix C for enlargement of HeLa cell image (3a). This demonstrates the level of 
nonspecific binding of NPs, which in this case, is very low. If the NPs were aggregating 
non-specifically, in solution phase or to NPs already bound to cell, a much higher signal 
from the one or two NPs that had bound to the HeLa cell would be expected to be 
observes, which is not the case. If this were true, it would also be noticeable in the DLS 
size distribution measurements. Thus, it can be concluded, that 
the NPs are not aggregated on the surface of the cells. 
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Fig  5.4: Confocal images of cells showing the location of NPs or AlexaFluor®647 (red) and 
cell membrane (green) using WGA conjugated Oregon Green® 488, post incubation for one 
hour. Column (a) shows the complete z-stack through the entire cell, (b) slice through the top 
of the cell, (c) slice through the centre of the cell and (d) through the bottom of the cell. Row 1 
is a MCF-7 cell incubated with 0.168% NPs, row 2 is a MCF-7 cell incubated with 
AlexaFluor®647 and row 3 is a HeLa cell incubated with 0.168% NPs. The sample has been 
fixed with paraformaldehyde and cured in ProLong® Gold. Previously published by the author 
[19]. 
5.3.4 Testing of NPs on a prostate cell line 
The NPs were tested on another EpCAM positive cell line to explore their applicability 
for use with other cell lines. This time a prostate adenocarcinoma line (LNCaP) was 
chosen as the EpCAM positive cell line and was compared with a prostate non-cancerous 
cell line, PNT1A. This cancer cell line expresses one third less EpCAM antigens than 
MCF-7 cells. Despite this, a high fluorescence emission signal from cells tagged with 
NPs would be expected [22]. The NPs and cells were tested in flow cytometry, and 
results are presented and discussed in this section. Cells were incubated with either 
0.168% or 279% dye doped (w/w%) anti-EpCAM conjugated silica NPs or anti-EpCAM 
conjugated AlexaFluor®647. The methods used for flow cytometry and cell staining 
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were kept identical to the protocols used for MCF-7 and HeLa cell lines. The results of 
the flow cytometry are presented below in Fig 5.5.  
 
Fig  5.5: Flow cytometry results for PNT1A cells and LNCaP where the top row (A and A’) 
are cells only and rows B-D and B’-D’ correspond to cells incubated with anti-EpCAM red 
conjugates. The median fluorescence intensity value is written below the figure letter. 
The following observations were made regarding the data from flow cytometry. Median 
values for both sets of NPs with LNCaP cells are higher than that of AlexaFluor®647, 
although, not double the signal that is observed when using the NPs with MCF-7 cells. 
This could be due to two main factors, one of which is that the LNCaP cells do not 
express as many EpCAM receptors as their MCF-7 counterparts. A study by Rao et al. 
found that LNCaP cells expressed 336,667 receptors compared with 509,500 on MCF-
7 cells [22]. If the EpCAM receptors have grouped together, then using NPs will be a 
disadvantage, because two receptors in close proximity will either both be bound to one 
NP or another NP will be unable to bind to the second EpCAM receptor due to steric 
hindrance. Cells that express EpCAM in clusters and have low expression of that 
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particular marker will not be able to benefit fully from using nanoparticles. The second 
factor could be that the NPs have photobleached to some extent, but every care was 
taken to try and prevent this.  
In terms of non-specific interactions, it can be observed from the PNT1A data that there 
is a higher signal from the NPs compared to AlexaFluor®647, in particular with the 
0.279% NPs. The median value for PNT1A using the 0.279% NPs is 163.4 and for the 
LNCaP cell line 273.8. This difference is not particularly large and the overlap of the 
two curves would suggest that there is not much specificity from this set of NPs. Such a 
difference from the results of the HeLa and PNT1A cell lines was unforeseen and would 
suggest that several variables have changed. Some of these variables include antibody 
denaturation on the NPs, aggregation of the NPs in the buffer perhaps caused by 
denaturation of BSA in the PBS solution containing 1% BSA and 0.05% Tween and also 
the change in cell line may have required a re-optimisation of the concentration of NPs 
needed per test. Imaging of the cells can provide further insight into this and is 
investigated in Fig 5.6. Some potential tests that could be used to investigate which of 
these variables is at fault include; conjugating antibody to newly PEGylated NPs from 
‘as synthesised’ NPs, re-titrating the concentration of NPs used in the LNCaP test and 
purchasing brand new BSA to use with solutions. All of these would provide an insight 
into what the underlying issue with the LNCaP cell line and 0.279% NPs are in this case.  
The 0.168% NPs, although they have a higher median than would be desired, the median 
fluorescent values between the EpCAM positive and negative lines are large enough to 
distinguish the two populations from each other. This is in line with work carried out on 
the MCF-7 line and appears that the 0.168% can be used for further studies with blood 
samples.  
Some imaging was carried out also to observe the NPs on the surface of the cells and 
investigate whether aggregation is occurring with the 0.279% set of NPs. The 
immunospecific staining results are presented in Fig 5.6. 
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Fig  5.6: Bright field and corresponding fluorescence images of LNCaP and PNT1A cell lines 
incubated with different red dye anti-EpCAM conjugates. The nucleus of the cells (blue) is 
stained with Hoechst 33342. The scale bar represents 50µm. 
 
Images obtained for the prostate lines are similar to those acquired for MCF-7 and HeLa 
cell lines. Again, small clustering spots of NPs and AlexaFluor® labels are observed on 
the surface of the LNCaP cell line but, as it occurs on all samples, it can be concluded 
that they are largely attributed to clustering of EpCAM receptors rather than aggregation 
of NPs. This would support the theory discussed in the previous paragraph that there is 
less of an amplitude in signal from using NPs than AlexaFluor®647 because of this 
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clustering due to steric hindrance between NP labels preventing high NP binding. 
Observing Fig 5.6 (d’), there are several nanoparticles adhered to the surface of PNT1A 
cells, clearly reflecting the results from flow cytometry of high non-specific interactions 
with the 0.279% NPs. The NPs appear not to be aggregating on the surface of the cells 
but perhaps the anti-EpCAM on the surface of the NPs has denatured for this set of NPs. 
There is not a clear-cut reason for this non-specific interaction but further study would 
have to be carried out in order to determine the exact cause. 
 
5.4  Conclusions  
Cyanine5-doped silica NPs were used for the specific tagging of model CTCs using an 
EpCAM surface marker target. The results from flow cytometry show that the NPs are 
twice as bright as the widely-used APC conjugated anti-EpCAM for MCF-7 
experiments. Excellent binding specificity was also observed for the NPs in cell imaging 
experiments for this cell line. From confocal microscopy, it was confirmed that the NPs 
are not endocytosed in the time frame of a number of hours but are located on the cell 
surface and bound via EpCAM antibody to the EpCAM surface marker. Experiments 
with prostate cell lines LNCaP and PNT1A indicated that the 0.168 (w/w%) dye loaded 
NPs are suitable for experimentation with blood samples as they performed well on this 
cell line also. This work shows that the NPs can be used in the application of cell staining 
and could allow researchers to use commonly available dyes, which have lower quantum 
yields than commercial dyes, to synthesize equally bright if not brighter antibody NP 
labels. This could close the gap on UV-excited dyes in terms of brightness without the 
need to add a new excitation source as required for the conducting polymer dyes. 
While the specificity and brightness of the NPs has been established in buffer, the next 
step in this investigation is to test NP performance when incubated with real blood 
samples and to investigate whether the NPs will maintain their CTC targeting ability in 
a protein rich environment and is addressed in chapter 6. 
  
    
                                                                               83 
5.5  References 
 
[1] B. Biosciences, Relative Fluorochrome Brightness, 2016 (2014). 
[2] B. Biosciences, BD Horizon BrilliantTM Dyes, 2016 (2015). 
[3] Y. Gao, S. Gu, Y. Zhang, X. Xie, T. Yu, Y. Lu, Y. Zhu, W. Chen, H. Zhang, H. Dong, P.J. 
Sinko, L. Jia, The Architecture and Function of Monoclonal Antibody-Functionalized 
Mesoporous Silica Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for 
Cancer Metastatic Chemoprevention, Small. 12 (2016) 2595-2608. 
[4] W. Fan, B. Shen, W. Bu, F. Chen, Q. He, K. Zhao, S. Zhang, L. Zhou, W. Peng, Q. Xiao, D. 
Ni, J. Liu, J. Shi, A smart upconversion-based mesoporous silica nanotheranostic system for 
synergetic chemo-/radio-/photodynamic therapy and simultaneous MR/UCL imaging, 
Biomaterials. 35 (2014) 8992-9002. 
[5] B. Korzeniowska, R. Woolley, J. DeCourcey, D. Wencel, C.E. Loscher, C. McDonagh, 
Intracellular pH-sensing using core/shell silica nanoparticles, J. Biomed. Nanotechnol. 10 
(2014) 1336-1345. 
[6] M.I. Papisov, Theoretical considerations of RES-avoiding liposomes: Molecular mechanics 
and chemistry of liposome interactions, Adv. Drug Deliv. Rev. 32 (1998) 119-138. 
[7] E. Rampazzo, R. Voltan, L. Petrizza, N. Zaccheroni, L. Prodi, F. Casciano, G. Zauli, P. 
Secchiero, Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity 
and efficient cell endocytosis, Nanoscale. 5 (2013) 7897-7905. 
[8] V.C.F. Mosqueira, P. Legrand, R. Gref, B. Heurtault, M. Appel, G. Barratt, Interactions 
between a macrophage cell line (J774A1) and surface-modified Poly(D,L-lactide) nanocapsules 
bearing poly(ethylene glycol), J. Drug Targeting. 7 (1999) 65-78. 
[9] M.P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F. Baldelli Bombelli, K.A. 
Dawson, Physical-Chemical aspects of protein corona: Relevance to in vitro and in vivo 
biological impacts of nanoparticles, J. Am. Chem. Soc. 133 (2011) 2525-2534. 
[10] M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, K.A. Dawson, Nanoparticle Size 
and Surface Properties Determine the Protein Corona with Possible Implications for Biological 
Impacts, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14265-14270. 
[11] T. Cedervall, I. Lynch, S. Lindman, T. Berggård, E. Thulin, H. Nilsson, K.A. Dawson, S. 
Linse, Understanding the Nanoparticle: Protein Corona Using Methods to Quantify Exchange 
Rates and Affinities of Proteins for Nanoparticles, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 
2050-2055. 
[12] J.A. Kim, A. Salvati, C. A°berg, K.A. Dawson, Suppression of nanoparticle cytotoxicity 
approaching in vivo serum concentrations: Limitations of in vitro testing for nanosafety, 
Nanoscale. 6 (2014) 14180-14184. 
[13] A. Lesniak, F. Fenaroli, M.P. Monopoli, C. Åberg, K.A. Dawson, A. Salvati, Effects of the 
presence or absence of a protein corona on silica nanoparticle uptake and impact on cells, ACS 
Nano. 6 (2012) 5845-5857. 
    
                                                                               84 
[14] H. Yun, H. Bang, J. Min, C. Chung, J.K. Chang, D.-. Han, Simultaneous counting of two 
subsets of leukocytes using fluorescent silica nanoparticles in a sheathless microchip flow 
cytometer, Lab Chip Miniaturisation Chem. Biol. 10 (2010) 3243-3254. 
[15] L. Tao, K. Zhang, Y. Sun, B. Jin, Z. Zhang, K. Yang, Anti-epithelial cell adhesion molecule 
monoclonal antibody conjugated fluorescent nanoparticle biosensor for sensitive detection of 
colon cancer cells, Biosens. Bioelectron. 35 (2012) 186-192. 
[16] D. Ye, K.A. Dawson, I. Lynch, A TEM protocol for quality assurance of in vitro cellular 
barrier models and its application to the assessment of nanoparticle transport mechanisms across 
barriers, Analyst. 140 (2015) 83-97. 
[17] J.P. Tiernan, N. Ingram, G. Marston, S.L. Perry, J.V. Rushworth, P.L. Coletta, P.A. Millner, 
D.G. Jayne, T.A. Hughes, CEA-targeted nanoparticles allow specific in vivo fluorescent 
imaging of colorectal cancer models, Nanomedicine. 10 (2015) 1223-1231. 
[18] V. Gubala, C. Crean, R. Nooney, S. Hearty, B. McDonnell, K. Heydon, R. O'Kennedy, B.D. 
MacCraith, D.E. Williams, Kinetics of immunoassays with particles as labels: Effect of antibody 
coupling using dendrimers as linkers, Analyst. 136 (2011) 2533-2541. 
[19] C.L. O'Connell, R. Nooney, C. McDonagh, Cyanine5-doped silica nanoparticles as ultra-
bright immunospecific labels for model circulating tumour cells in flow cytometry and 
microscopy, Biosens. Bioelectron. 91 (2017) 190-198. 
[20] O.V. Bondar, D.V. Saifullina, I.I. Shakhmaeva, I.I. Mavlyutova, T.I. Abdullin, Monitoring 
of the Zeta Potential of Human Cells upon Reduction in Their Viability and Interaction with 
Polymers, Acta Naturae. 4 (2012) 78-81. 
[21] S. Roy, R. Woolley, B.D. MacCraith, C. McDonagh, Fluorescence lifetime analysis and 
fluorescence correlation spectroscopy elucidate the internal architecture of fluorescent silica 
nanoparticles, Langmuir. 26 (2010) 13741-13746. 
[22] C.G. Rao, D. Chianese, G.V. Doyle, M.C. Miller, T. Russell, R. Sanders Jr, L. Terstappen, 
Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary 
and metastatic tumors, Int. J. Oncol. 27 (2005) 49-57. 
  
 
 
 
 
 
 
 
    
                                                                               85 
 
Chapter 6:  Detection of CTCs in blood  
 
6.1  Introduction 
The previous chapters have described the functionalisation and development of NPs for 
the detection of antigens on the surface of cells. This chapter will address the application 
of detection of an antigen on a cell population within a mixed cell population, which is 
the next step when addressing the main research objective of the detection of CTCs from 
whole blood. Whole blood is abundant with proteins: in the plasma, on the surface of 
cells and released by cells in the blood. There have been recent  investigations carried 
out on the adsorption kinetics of those proteins onto the surface of functionalised 
nanoparticles [1-5]. As blood is such a complex system, protocols for use with cyanine5-
doped NPs, that were described in the previous chapters, were developed with the aim 
of reducing the complexity of the system. With this in mind, it was decided to lyse red 
blood cells, as they are not necessary for the detection of CTCs and are the largest cell 
population. So, to mimic patient blood samples, laboratory cultured EpCAM expressing 
CTCs, MCF-7s or LNCaPs, were spiked into a healthy lysed blood samples. As there 
are quite a large variation of the number of CTCs in a patient sample depending on stage 
and type of cancer, CTCs were spiked into samples at numerous ratios [6]. 
Some groups have investigated using dye-doped silica nanoparticles for the 
identification of a target cell population in a mixed cell system previously [7-10]. Tao et 
al. identified EpCAM positive colo205 colon cancer cells from EpCAM negative sw480 
colon cancer cells using Rubpy doped silica NPs. They visualised the mixed cell 
population by microscope, but not by flow cytometry, and the NPs were synthesised via 
the microemulsion method [7]. Estevez et al. spiked Ramos human Burkitt’s lymphoma 
cells into CEM human acute lymphoblastic leukaemia cells at different percentages and 
detected them using flow cytometry. This was achieved using a biotin-avidin secondary 
labelling system, whereby they first incubated the cells with sgc8-polyT10-biotin 
aptamer and then introduced neutravidin conjugated FITC doped silica NPs that were 
made via the Stöber method for detection of cells [8].  Another mixed cell population 
study by Peng et al. looked at the detection of BEL-7404 liver cancer cells from green 
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fluorescence protein (GFP) transfected MCF-7 cells. They spiked the liver cancer cells 
at a range of different ratios and detected them with galactose conjugated Rubpy-doped 
NPs, synthesised by the microemulsion method. The cells were analysed via flow 
cytometry, whereby they achieved specificity of the cells down to 1% of cell population 
[9]. Also in this paper, they reported the detection of the liver cancer cells from white 
blood cells (WBCs). They detected the BEL-7404 liver cancer cells using the galactose 
RuBPY silica NPs via confocal laser microscopy and distinguished them from WBCs 
but did not analyse the cells via flow cytometry [9].  It appears that dye-doped silica 
nanoparticles for the detection of CTCs from blood cells on a flow cytometry system 
has not been carried out previously. 
 
6.2  Materials and methods 
6.2.1 Materials 
Purified anti-human EpCAM antibody, AlexaFluor®647 conjugated anti-human 
EpCAM and Fluorescein Isothiocyanate conjugated anti-human CD45 were obtained 
from BioLegend. Hoechst 33342 Stain was obtained from Thermo Pierce. BD PharmTM 
Lyse (10x) and EDTA vacutainers were obtained from BD Biosciences All other 
materials were obtained from Sigma-Aldrich. 
6.2.2 Anti-EpCAM dye-doped silica nanoparticles 
Protocols for the synthesis and conjugation of anti-EpCAM to the surface of the 
cyanine5 doped NPs have previously been detailed in section 4.2.2 and 4.2.3. NPs used 
in these protocols were the previously characterised 0.168% dye-doped NPs. 
6.2.3 Cell preparation and staining 
Cell lines MCF-7 and LNCaP were grown in 75cm2 flasks in DMEM containing 10% 
heat uninactivated FBS as described in section 5.2.2, 1% L-glutamine and 1% penicillin-
streptomycin. The cells were detached from the bottom of the flask using trypsin. Cells 
were centrifuged (300 x g, 5 mins) and resuspended in PBS containing 1% BSA and 
0.05% Tween®20. Following this, cells were counted by the haemocytometer. 
A blood sample was obtained from vein and collected in an EDTA vacutainer. The 
sample was brought to a Coulter AcT diff2 analyser (Beckman Coulter, CA, USA), see 
section 3.8, where blood component analysis was performed. For this application, the 
    
                                                                               87 
WBC count was of interest and following this the red blood cells were lysed as per 
protocol from BD Biosciences [11].The final solution of WBCs and platelets was 
suspended in PBS containing 1% BSA and 0.05% Tween®20 and the volume adjusted 
so that there were 125,000 WBCs per test.  
CTCs, MCF-7 or LNCaP, were spiked at ratios ranging from 1:1-200:1 to simulate 
patient blood samples. 3µL of AlexaFluor®647 anti-EpCAM or 10µg of 0.168% anti-
EpCAM NPs were added to the solution. 3µL of FITC anti-CD45 stain for WBCs were 
added to each test solution as a secondary distinguishing parameter. The samples were 
then made up to 300µL using PBS containing 1% BSA and 0.05% Tween®20. The cells 
were left to incubate for forty minutes before being washed twice in PBS and finally 
resuspended in PBS before flow cytometry analysis or microscopic imaging. 
6.2.4 Flow cytometry 
Cells were analysed using a Millipore Guava EasyCyte8HT instrument and InCyteTM 
software (see section 3.6), with blue laser and green filter, and red laser and red2 filter. 
Gain settings were optimised for MCF-7 and LNCaP and were kept constant throughout 
the run. Forward scatter and side scatter were kept constant at 5.0 and 1.0 respectively 
and a threshold cut off value of below 100. 30,000 events were used for the initial proof 
of concept low ratios and then 15,000 events were counted per test for higher ratios. 
Controls for flow cytometry were used to optimise green and red2 gain settings. The 
green settings were optimised by monitoring WBC and platelet fluorescence in a number 
of scenarios: (i) with no fluorophores and (ii) with only anti-CD45 and the red2 settings 
optimised using CTCs with (i) only anti-CD45 and (ii) with only NPs. 
Flow cytometry plots in this chapter are two parameter plots. Those that are of side 
scatter vs forward scatter represent the relative size and granularity of cells. Where one 
of the axis mentions green fluorescence, this represents CD45 expression on cells and 
for red2 fluorescence, this represents EpCAM expression. 
6.3  Results and discussion 
6.3.1 Low ratio (high CTC number) proof of concept spiking tests 
Experiments were carried out using either 0.168% NPs or AlexaFluor®647 to stain CTCs 
in a mixed cell population of WBCs, platelets and CTCs. Low ratios were tested initially 
to determine whether CTCs can be distinguished from WBCs as a proof of concept. As 
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non-specific binding was a concern, a second stain was introduced, FITC conjugated 
anti-CD45, which will stain only WBCs. This time, during flow cytometry, two 
fluorescence channels were monitored; green and red2. The green channel was 
optimised via a WBC and platelet sample that were stained with anti-CD45 and the red2 
channel optimised using CTCs stained with 0.168% NPs. Initial ratios of 1:1 and 2:1 
WBC to CTC were carried out for both MCF-7 and LNCaP cells. The results of the 
optimised blood, CTC and mixed cell population for MCF-7s can be seen below in Fig 
6.1. 
 
Fig  6.1 Flow cytometry plot results for WBC, platelets and MCF-7 cells incubated with anti-
CD45 FITC and/or anti-EpCAM NPs. 
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Regions were gated in the first column plot of side scatter vs forward scatter (SSC vs 
FSC) to select for white blood cells and CTCs. The second column of SSC vs green 
fluorescence (Green) shows some distinction between CTCs and WBCs. There is some 
overlap between the two, as seen in row 4of Fig 6.1, and this is discussed in detail in 
section 6.3.2. A region was gated on the SSC vs Green plots, visible in Fig 6.1 on the 4th 
and 5th rows, of mixed cell population runs. This region encompasses both CTCs and 
some WBCs and was gated on for cells with low/no expression of anti-CD45. As 
granulocytes have a lower expression of anti-CD45 than monocytes or lymphocytes (the 
three main cell clouds observed in Fig 6.1; column 2, row 1), and there was some overlap 
between CTCs and this population, it was included in the gate to ensure all CTCs could 
be identified [12]. The final column, of green fluorescence vs red2 fluorescence is the 
most important column as it displays the NPs distinguishing between the two main cell 
populations. There are two distinct clouds of cells visible in these plots in row 4 and 5, 
as predicted, and there should be two if the NPs are specific to the CTCs. There appears 
to be some binding of the NPs to the WBCs non-specifically but using a combination of 
the anti-CD45 and NPs has allowed the two populations to be distinguishable, thus 
concluding that the NPs can be used to identify EpCAM positive CTCs at these ratios. 
Listed in Table 6.1 are the numbers and statistics corresponding to the plots in Fig 6.1 
including CTC number and median red2 value and green median value for WBCs and 
CTCs. 
Table 6.1: corresponding flow cytometry data for Fig 6.1 with MCF-7 cells 
Sample 
MCF-7 + 
NPs 
WBC + MCF-7 
1:1 ratio 
WBC + MCF-7 
2:1 ratio 
Total cell count in R1 18755 30000 30000 
CTC count in R2 - 14183 8240 
Theoretical WBC ratio - 1 2 
Actual WBC ratio - 1.12 2.64 
CTC median red2 value 
411.0 ± 
409.8 
330.6 ± 328.1 457.2 ± 471.7 
CTC median green value 5.9 ± 4.9 5.5 ± 4.4 6.2 ± 5.4 
WBC median red2 value in R2 - 19.9 ± 20.1 13.4 ± 21.6 
WBC median green value in R2 - 21.1 ± 4.1 20.6 ± 3.9 
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The total cell count in each case was set to 30,000 cells within region R1, including a 
mixed population of WBCs and CTCs. The number of CTCs correctly identified was 
enumerated from the green vs red2 fluorescence plot, in which the cloud of cells with 
higher red2 median value and lower green value was assumed to be CTCs.  For the 1:1 
and 2:1 ratios, the number of CTCs recovered were close to the theoretical values and 
resulted in an actual ratio of 1.12:1 and 2.64:1. At both ratios, the median red2 value of 
the WBC cloud was 19.9 and 13.4 respectively and compared to the CTC cloud median 
which was 330.6 and 457.2, indicating low non-specific staining. However, what is not 
captured by the median value is the variability in the red2 fluorescence or ‘the spread’ 
of the cloud plot across the red2 fluorescence or x-axis. This is enumerated in the 
standard deviation. Ideally, there would be a dense cloud around one particular spot but 
that was not observed here. Despite this, the two clouds are distinguishable.  The 
corresponding green value of the MCF-7 was similar for the two ratios and also the 
CTCs by themselves indicating that there is little, if no, non-specific staining of the 
CTCs by the anti-CD45. 
 
Fig  6.2: Flow cytometry plot results for WBC, platelets and LNCaP cells incubated with anti-
CD45 FITC and anti-EpCAM NPs. 
The results for LNCaP cells is not so clearly defined as those for MCF-7 cells as seen in 
Fig 6.2. In the third column, of green fluorescence vs red2 fluorescence plots for the two 
ratios, the WBC cloud is almost merged with the CTC cloud and it appears that there are 
fewer WBCs than CTCs. This is verified in the numbers presented in Table 6.2. The 
actual ratios of spiked cells were 0.72:1 and 1.32:1, as opposed to 1:1 and 2:1. The WBC 
cloud is more visible in the 2:1 ratio plot due to the higher numbers of WBCs in the 
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region R2. But, in the case of LNCaPs, there are two clouds that can be distinguished, 
but what is more interesting is how this evolves with higher ratios of WBCs, as explored 
in section 6.3.3. 
Table 6.2: Flow cytometry data for Fig 6.2 with LNCaP cells 
Sample 
WBC + LNCaP  
1:1 ratio 
WBC + LNCaP  
2:1 ratio 
Total cell count R1 30000 30000 
CTC count R2 17466 12919 
Theoretical ratio 1 2 
Actual ratio 0.72 1.32 
CTC median red2 value 315.8 ± 283.1 322.9 ± 289.6 
CTC median green value 9.9 ± 6.5 10.1 ± 6.6 
WBC median red2 value R2 45.4 ± 40.6 34.1 ± 33.0 
WBC median green value R2 19.1 ± 4.4 21.6 ± 4.81 
 
6.3.2 High ratio spiking tests with MCF-7s and comparison of NPs to 
AlexaFluor®647  
Experiments were repeated as in section 6.3.1 with higher ratios of WBCs to CTCs, 
ranging from 5:1-200:1, to identify the lower limit of detection of MCF-7s by the NPs. 
This was compared with anti-EpCAM AlexaFluor®647. WBCs were stained with anti-
CD45 as a secondary parameter check of the correct identification of CTCs. Fig 6.3 
shows how both NPs and AlexaFluor®647 plots were gated to determine the number of 
MCF-7s that were identified. These plots represent a 5:1 ratio of WBCs to MCF-7s. 
Region R1 represents a mix of both WBCs and CTCs. Region R2 encloses MCF-7s and 
some WBCs of similar side scatter. Region R3 represents the CTCs that are considered 
correctly identified due to their higher red2 median values. 
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Fig  6.3: Plots of MCF-7s spiked in blood samples: side scatter (SSC) vs forward scatter (FSC) 
showing the gating of region R1; SSC vs green fluorescence showing gating on region R2 and 
green vs red2 fluorescence showing R3 assumed identification of CTCs. 
Experimental data plots of green vs red2 fluorescence at 5:1-200:1 ratios with spiked 
MCF-7s are shown in Fig 6.4 and corresponding data for NPs and AlexaFluor®647 is 
shown in separate tables, Table 6.3 and 6.4. Two distinct clouds were observed for NPs 
at all ratios, even at ratios as low as 200:1, in the green fluorescence vs red2 fluorescence 
plots. For AlexaFluor®647, the cloud of identified MCF-7s is more clearly visible than 
for NPs. The tables include the number of MCF-7s that were identified and also displays 
the median green and red2 values of these cells. Also included in the tables are the green 
and red2 median fluorescence values for the WBCs that were in region R2 to evaluate 
the specificity of the NPs and AlexaFluor®647. The red2 median for WBCs was 
averaged over all tests with NPs in Table 6.3 and was found to be 128.9, which is almost 
two orders of magnitude higher than the average WBC red2 median for AlexaFluor®647 
in Table 6.4, which has a value of 1.8. This implies that there is a high level of non-
specific binding of NPs. However, despite this, the MCF-7s have a larger red2 median 
fluorescence of 2,088.8, on average, compared with 179.9 for AlexaFluor®647. For NPs, 
the signal from MCF-7 cells is 16 times higher than that of the WBCs and for 
AlexaFluor®647, it is 100 times higher. The issue with non-specific binding needs to be 
addressed to improve the sensitivity of the NPs.  
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Fig  6.4: Flow cytometry green fluorescence vs red2 fluorescence plots for blood spiked at 
different ratios with MCF-7s and stained with either anti-EpCAM Cyanine5 NPs (left column) 
or AlexaFluor®647 (right column) and WBCs stained with anti-CD45. Shown in black and 
white to elucidate a sharper contrast. 
The paper by Peng et al. had a mixed cell population study where they spiked liver 
cancer cells, BEL-7404, into green fluorescent protein expressing MCF-7s and 
incubated RuBpy NPs with the mixed cell population [9]. The cells, analysed via flow 
cytometry, showed the ability of the NPs to detect cells down to 1% spiking of the cell 
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population.  This is comparable with results obtained here where MCF-7 cells can be 
distinguished from WBCs at a theoretical ratio of 200:1, but, in practice, resulted in an 
actual detection of CTCs at 50:1. Putting this in the format that Peng et al. presented in 
their paper, it is equivalent to a 2% detection rate.  
It was observed when the MCF-7 cells were incubated with NPs that they appear to have 
a higher green median than when they were incubated with AlexaFluor®647. This was 
also observed when they were viewed under the microscope, as shown in Fig 6.5. The 
reason for this is inherent in the cyanine5 nanoparticle itself. UV-vis has shown there to 
be a small absorption peak in the region of 460-490nm, (please see Fig D1 in appendix 
D), that is not present in either Cyanine5 free dye or pure silica nanoparticles. This was 
also observed previously in other work and the reason for this peak has been concluded 
to be the interaction and aggregation of dye with surfactants during the nanoparticle 
synthesis process  [13,14]. The blue laser in the flow cytometer excites fluorophores at 
488nm, which lies exactly within this band and produces some fluorescence, as seen in 
Fig D2 in appendix D. 
There appears to be some amount of non-specific binding of the anti-CD45 in 
conjunction with the green emission of the NPs, and is most visible in the 5:1 and 10:1 
plots of AlexaFluor®647 in Fig 6.4, in which some cells are stained both with NPs and 
anti-CD45 as seen in the small clouds above the main MCF-7 cloud. A combination of 
non-specific anti-CD45 and green emission from the NPs contribute to the higher green 
median fluorescence observed for NP samples in flow cytometry. 
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Table 6.3: Data results for spiked MCF-7s using cyanine5 NPs at different ratios 
Sample with cyanine5 NPs 5:1 10:1 50:1 100:1 200:1 
Total Count R1 15000 15000 15000 15000 15000 
Total CTC count R3 2019 1443 501 392 289 
Theoretical WBC ratio 5 10 50 100 200 
Actual WBC ratio 6.4 9.4 28.9 37.3 50.9 
CTC median red2 value 
1550.0 ± 
1304.6  
2204.7 ± 
1603.7 
2229.7 ± 
1634.6 
2438.8 ± 
1697.9 
2020.6 ± 
1526.2 
CTC median green value 
16.9 ±  
14.6 
22.4 ± 
17.0 
25.4 ±  
18.8 
26.8 ± 
19.8 
24.1 ±  
18.0 
WBC median red2 value in R2 
125.9 ± 
94.3 
150.8 ± 
105.8 
119.8 ±  
91.8 
128.9 ± 
98.1 
118.9 ± 
931.2 
WBC median green value in R2 
24.9 ±  
5.4 
22.8 ± 
5.2 
26.4 ±  
5.4 
24.0 ±  
5.1 
23.6 ±  
5.2 
 
Table 6.4: Data results for spiked MCF-7s at different ratios using AlexaFluor®647 
Sample with AlexaFluor®647 5:1 10:1 50:1 100:1 200:1 
Total Count R1 15000 15000 15000 15000 15000 
Total CTC count R3 2937 1858 493 180 117 
Theoretical WBC ratio 5 10 50 100 200 
Actual WBC ratio 4.1 7.1 29.4 82.3 127.2 
CTC median red2 value 
240.4 ± 
174.1 
213.7 ± 
138.7 
181.2 ± 
120.8 
143.4 ± 
87.8 
120.6 ±  
62.8 
CTC median green value 
4.1 ±  
6.6 
 4.3 ±  
6.8 
4.6 ±  
7.6 
4.1 ±  
7.5 
4.4 ±  
7.3 
WBC median red2 value in R2 
2.4 ± 
 1.5 
2.0 ±  
1.3 
1.5 ±  
1.1 
1.6 ±  
1.2 
1.5 ±  
1.1 
WBC median green value in R2 
24.5 ±  
7.3 
25.3 ±  
7.1 
21.3 ±  
6.2 
21.4 ±  
6.3 
19.2 ±  
5.9 
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6.3.2.1 Imaging of MCF-7 spiked blood cells  
Shown in Fig 6.5 are the corresponding brightfield and fluorescence images obtained 
from preparing the cells under the same conditions used for spiked blood flow cytometry 
experiments using MCF-7 cells with NPs and AlexaFluor®647. Images were made of 
5:1, 10:1 and 50:1 samples. The WBCs are shown stained green with FITC conjugated 
anti-CD45 and MCF-7s are in red and their nucleus is shown in blue, stained with 
Hoechst 33342.  
 
Fig  6.5: Images of MCF-7s spiked in blood cells at three different ratios. WBCs stained green 
with FITC anti-CD45 and MCF-7s stained red with anti-EpCAM NPs or AlexaFluor®647. 
Nucleus stained blue with Hoechst 33342 and scale bar is 50µm. 
One of the most interesting features to note in these images is the lack of red stain on 
the WBCs. This is a good thing, because, visually, the WBCs are very distinguishable 
from the CTCs, which of course is the overall aim of this work. The other is the fact the 
MCF-7s, particularly those stained with NPs, appear to be yellow due to the mixing of 
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wavelengths from green and red. This corresponds to the inherent green emission of the 
NPs from the Cyanine5 dye-surfactant aggregation discussed earlier in section 6.3.2 and 
is visible in Fig 6.5 (d) and (h). This can be observed in these images due to the presence 
of the FITC filter cube which has an excitation band of 475 ± 17.5 nm and emission of 
530 ± 21.5 nm. The non-specific staining of the anti-CD45, can be observed most 
notably in Fig 6.5 (h’), in which the AlexaFluor®647 does not emit in the green and most 
likely also contributes to the green emission for NP samples. 
6.3.3 High ratio spiking tests with LNCaP cells and comparison of NPs to 
AlexaFluor®647 
The experiments reported in section 6.3.2 were repeated with a different cancer cell line, 
LNCaP, which were spiked into WBCs and platelets at increasing ratios from 5:1 to 
200:1, as in the previous section. Fig 6.6 shows how both NPs and AlexaFluor®647 were 
gated on R1; SSC vs FSC for WBCs and CTCs, R2; SSC vs Green for CTCs and some 
WBCs and R3; assumed CTCs. 
 
Fig  6.6: Plots of LNCaPs spiked in blood samples: side scatter (SSC) vs forward scatter (FSC) 
showing the gating of region R1; SSC vs green fluorescence showing gating on region R2 and 
green vs red2 fluorescence showing R3 assumed identification of CTCs. 
Fig 6.7 shows plots of green fluorescence vs red2 fluorescence for both NPs and 
AlexaFluor®647 at each ratio 5:1-200:1. For NPs, two clouds can be observed again for 
WBCs and CTCs and a more distinct CTC cloud for AlexaFluor®647. Tables 6.5 and 
6.6 show the data corresponding to the plots in Fig 6.7. The average red2 median for 
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WBCs across all ratios that were incubated with NPs from Table 6.5 is 88.5, which 
corresponds to the level of non-specific binding of the NPs and from Table 6.6 the 
average red2 median fluorescence value was 1.0 for AlexaFluor®647. This is compared 
with the average red2 median value of LNCaPs incubated with NPs of 1349.5 and with 
AlexaFluor®647 119.6. Spiked LNCaPs exhibit a 15.2-fold increase in signal from 
WBCs when using NPs and 119.6 with AlexaFluor®647 which is the same order of 
magnitude difference as was achieved previously in section 6.3.2 with MCF-7 cells.  
As was the case for MCF-7 cells, with LNCaP cells, there is a higher green median value 
due to the emission of the NPs at green wavelengths, which can be seen in the SSC vs 
green plot in Fig 6.6. There is some non-specific staining of the anti-CD45 visible in the 
5:1 and 10:1 ratio plots of Fig 6.7 with AlexaFluor®647 where cells are stained both 
green and red again. 
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Fig  6.7: Flow cytometry green fluorescence vs red2 fluorescence plots of LNCaPs spiked in 
to blood at different ratios stained with anti-EpCAM NPs (left) or AlexaFluor®647 (right). 
Shown in black and white to elucidate a sharper contrast. 
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Table 6.5: Data results for spiked LNCaP cells in blood at different ratios and stained with 
cyanine5 NPs 
Sample with cyanine5 NPs 5:1 10:1 50:1 100:1 200:1 
Total Count R1 15000 15000 15000 15000 15000 
Total CTC count R3 2509 1695 776 408 689 
Theoretical WBC ratio 5 10 50 100 200 
Actual WBC ratio 5.0 7.8 18.3 35.8 20.8 
CTC median red2 value 
1280.2 ± 
940.4 
1363.3 ± 
926.5 
1494.0 ± 
1015.2 
1341.8 ± 
845.2 
1268.4 ± 
840.9 
CTC median green value 
22.0 ± 
13.4 
23.0 ± 
13.0 
24.4 ± 
12.9 
25.5 ± 
12.2 
20.7 ± 
12.3 
WBC median red2 value 
81.6 ± 
62.3 
85.4 ± 
63.6 
98.6 ± 
71.6 
90.5 ± 
66.1 
86.3 ± 
66.2 
WBC median green value 
25.0 ±  
5.4 
24.3 ±  
5.2 
24.9 ±  
5.2 
20.9 ±  
4.8 
21.8 ±  
4.7 
 
Table 6.6: Data corresponding to LNCaP spiked into blood at different ratios and stained with 
AlexaFluor®647 
Sample with AlexaFluor®647 5:1 10:1 50:1 100:1 200:1 
Total Count R1 15000 15000 15000 15000 15000 
Total CTC count R3 2981 1924 486 206 129 
Theoretical WBC ratio 5 10 50 100 200 
Actual WBC ratio 4.0 6.8 29.9 71.8 115.3 
CTC median red2 value 
137.6 ± 
108.0 
135.0 ± 
97.6 
105.8 ± 
77.0 
107.4 ± 
73.4 
112.3 ± 
8.08 
CTC median green value 
9.6 ±  
10.3 
9.1 ±  
10.3 
8.9 ±  
8.2 
9.6 ±  
10.9 
9.8 ±  
7.7 
WBC median red2 value 
1.2 ±  
0.9 
1.0 ±  
0.7 
1.0 ±  
0.7 
1.0 ±  
0.7 
1.0 ±  
0.7 
WBC median green value 
27.4 ±  
7.4 
25.0 ±  
7.0 
25.3 ±  
6.6 
25.1 ±  
6.7 
24.6 ±  
6.7 
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6.3.3.1 LNCaP spiked blood cell images 
Images were obtained for cells that were spiked at 5:1, 10:1 and 50:1 using NPs and 
AlexaFluor®647 to stain CTCs and are presented in Fig 6.8. Again, in these images there 
appears to be no NPs bound to the WBCs. There is some yellow colour appearing in Fig 
6.8 (f) from the emission of the NPs in green. The non-specific staining of the anti-
CD45, mentioned in section 6.3.2, with AlexaFluor®647 is visible, particularly, in Fig 
6.8 (d’) and (f’). 
 
Fig  6.8: Images of LNCaP spiked in blood cells at three different ratios. WBCs stained green 
with FITC anti-CD45 and LNCaPs stained red with anti-EpCAM NPs or AlexaFluor®647. 
Nucleus stained blue with Hoechst 33342 and scale bar is 50µm. 
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6.4  Conclusions 
Staining with 0.168% w/w Cyanine5-doped NPs enabled distinction between white 
blood cells and CTCs via EpCAM surface marker. Initial low ratios looked promising 
for both MCF-7s and LNCaPs that were spiked in with WBCs and platelets. The NPs 
could distinguish the CTCs down to actual ratios of ~50:1 for MCF-7 cells and 20:1 for 
LNCaP cells compared with 127:1 and 115:1 respectively for AlexaFluor®647. Imaging 
experiments show little or no binding on the surface of white blood cells. Further work 
must be done in order to improve specificity of the NPs, but, as it stands, they show a 
good potential for the application at hand for the detection of CTCs from blood. 
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Chapter 7:  Secondary antibody cell 
staining  
 
7.1  Introduction 
Secondary antibody approaches are employed in cell staining when antigens or receptors 
are expressed in low numbers. Secondary assays, in principle, are more sensitive because 
multiple secondary labels can bind to the primary antibody and also the primary antibody 
is not modified through bioconjugation with a label (see section 2.5 for more detail about 
secondary antibody systems). To summarise, there are two types of secondary staining 
detection systems; antibody-antibody systems, and biotin-avidin detection system. As 
the work on conjugation of antibodies to the surface of the NPs has been characterised 
in previous chapters and is well established, an antibody-antibody system was chosen in 
this case. The primary antibody was a mouse anti-human EpCAM, the same as used in 
chapter 5 and the secondary antibody was a goat anti-mouse IgG. NPs were labelled 
with goat anti-mouse IgG as the secondary label and compared with commercially 
available goat anti-mouse AlexaFluor®647. 
Previous nanoparticle work in relation to secondary antibody staining has been carried 
out by a few groups to detect cancer cells. Chen et al. doped silica nanoparticles with 
FITC or rhodamine B isothiocyanate and conjugated goat anti-rabbit IgG on their surface 
to detect a rabbit-anti-EpCAM antibody on the surface of Sk-Br-3 breast cancer cells 
[1]. They used cells incubated with NPs and no primary antibody as a control but did 
not compare their staining capabilities to commercially available dyes. 
Estéves et al. used fluorescein or Rubpy dye-doped silica NPs coated with NeutrAvidin 
to detect T-cell leukemic CEM cells [2]. Cells were incubated with biotinylated anti-
PTK7 antibody first and NeutrAvidin NPs were added to detect the antibody. The NP 
label had a signal increase of two orders of magnitude compared to a primary antibody 
anti-PTK7 AlexaFluor®488 control stain. As the work presented in this chapter 
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compares secondary labelling to a secondary stain control, it is not expected that the 
same level of enhancement will be observed in these experiments.   
 
7.2  Materials and methods 
7.2.1 Materials 
Purified anti-human EpCAM antibody, purified goat anti-mouse IgG antibody and 
AlexaFluor®647 labelled goat anti-Mouse IgG were obtained from BioLegend. Hoechst 
33342 Stain was obtained from Thermo Pierce. All other materials were obtained from 
Sigma-Aldrich. 
7.2.2 Goat anti-mouse IgG NPs 
Following the same protocol reported in chapter 4.2.2 and 4.2.3 for the synthesis of dye 
doped NPs and coating with antibody, the NPs were coated with goat anti-mouse IgG 
for use in secondary analysis. 2mg of PEGylated NPs were reacted with 50 mM EDC 
and 12.5 mM sulfo-NHS in MES pH 4.7 buffer for 15 min and were then left to react 
with 214µg of antibody in 0.1 M MES pH 7.2 buffer for 24 h. After this, the NPs were 
resuspended in PBS containing 1% BSA for 24 h before being washed in PBS three 
times and finally placed into PBS containing 1% BSA, 0.05% Tween®20 and 0.01% 
sodium azide for short term storage at 4 °C. 
7.2.3 Direct binding immunoassay 
Cascade concentrations of mouse anti-human EpCAM were completed using serial 
dilution in PBS beginning at a concentration of 20mg/mL. 50µL of each concentration 
were then added to each well of a 96 well Maxisorb™ black Nunc™ assay plates. The 
plate was then tapped at the side to ensure the solution filled across the bottom of each 
well.  To enable attachment of the antibody to the bottom of each well the plate was 
incubated in the oven for 1 hour at 37.5°C. The plate was then tapped to remove excess 
anti-EpCAM. Plate blocking solution, comprised of PBS with 1% BSA, 10% Tween®20, 
was added to each well. The plate was then returned to the oven at 37.5 °C for another 
hour. To remove any non-adsorbed antibody and excess block, the plate was then rinsed 
three times with PBS containing 0.1% Tween®20 and then three times with PBS. 
Following this, 50µL aliquots of goat anti-mouse IgG NPs (1mg/mL concentration) in 
PBS containing 1% BSA and 0.05% Tween®20 were added to each well for one hour 
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(no spin down or wash steps of NPs before adding to the assay plate) and further 
incubation at 37.5 °C for another hour. The plate was then rinsed three times with PBS 
containing 0.1 % Tween®20 and then three times with PBS and placed in the Tecan 
microplate reader for further analysis. The experiment was carried out in triplicate. A 
similar protocol for sandwich assay detection was used previously [3]. 
7.2.4 Cell preparation and staining 
Cell lines HeLa, MCF-7, PNT1A and LNCaP were grown in 75cm2 flasks in DMEM 
containing 10% heat uninactivated FBS, 1% L-glutamine and 1% penicillin-
streptomycin. The cells were detached from the bottom of the flask using trypsin. Cells 
were centrifuged (300xg, 5 minutes) and resuspended in PBS containing 1% BSA and 
0.05% Tween®20. Following this, cells were counted on the hemacytometer and the final 
solution was adjusted so that there were 125,000 cells per test. Primary antibody, anti-
human EpCAM (CD326) was added at 1.25mg per test and incubated for an hour with 
cells. After this, cells were centrifuged and washed twice in PBS and finally resuspended 
in PBS containing 1% BSA and 0.05% Tween®20. Anti-mouse IgG conjugated NPs or 
anti-mouse IgG conjugated AlexaFluor®647 were added to cells and NPs were added at 
1µg per test and 3µl of AlexaFluor®647. The cells were left to incubate for another hour 
before being washed twice in PBS and finally resuspended in PBS before flow cytometry 
analysis. 
7.2.5 Flow cytometry 
Cells were analysed using a Millipore Guava EasyCyte8HT instrument and InCyteTM 
software with red laser and red2 filter. Gain settings were optimised for MCF-7 and 
HeLa cell lines and LNCaP and PNT1A cell lines separately and were kept constant 
throughout testing.  A red2 gain value of 2.08 was used for MCF-7 and HeLa and a gain 
of 2.0 was used for LNCaP and PNT1A. Forward scatter and side scatter were kept to 
1.0 and a threshold cut off value of below 100. 20,000 events were counted per test.  
 
7.3  Results and discussion 
7.3.1 Secondary antibody functionality 
Before carrying out secondary antibody cell staining work with goat anti-mouse IgG 
NPs, their avidity to the mouse anti-EpCAM antibody was investigated. A direct binding 
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assay was carried out in triplicate, consisting of the anti-EpCAM antibody coated on a 
96 well plate at increasing concentrations, from 10-10,000ng/mL, and the addition of 
goat anti-mouse IgG NPs at 50µL of NPs (1mg/mL concentration). The response of the 
NPs was measured on the microplate reader and the results are shown in Fig 7.1. 
 
Fig  7.1: Secondary antibody immunoassay to evaluate the activity of the anti-mouse IgG on 
the surface of 0.168% and 279% NPs. 
The data presented in Fig 7.1 shows the fluorescence from NPs in the 96 well plate, 
which were incubated with increasing concentrations of anti-EpCAM antibody for one 
hour. As the fluorescence increases comparably with the concentration of the antibody, 
it can be concluded that they are binding to the anti-EpCAM antibody. If a flat line was 
obtained, then the NPs would be bound non-specifically to the plate instead. This 
information allows the continuation of secondary antibody staining with confidence that 
the NPs will bind to the anti-EpCAM primary antibody. 
7.3.2 Flow cytometry and image analysis with MCF-7 and HeLa cell lines 
Secondary antibody labelling of cells was performed with NPs using EpCAM positive 
and negative cells, MCF-7 and HeLa cell lines. 
Cells were prepared by placing them in PBS containing 1% BSA and 0.05% Tween®20 
and counted on the haemocytometer. Following this, the cells were incubated with anti-
EpCAM primary antibody, washed and then the NPs or AlexaFluor®647 secondary 
antibody added to the cells. The cells were then washed again and brought to the flow 
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cytometer or imaged under the microscope for analysis. The results from flow cytometry 
are presented below in Fig 7.2 and the cell imaging in Fig 7.3. 
 
Fig  7.2: Flow cytometry results for secondary antibody staining MCF-7 cells and HeLa where 
the top row (A and A’) are cells only and rows B-D and B’-D’ correspond to cells incubated 
with anti-EpCAM red conjugates. The number in each graph is the median value for that 
experiment. 
Looking at the MCF-7 cell line, from Fig 7.2, there is a high signal from all red-dye 
conjugates, indicating binding to the EpCAM primary antibody. Viewing the data for 
the HeLa cells shows that there is a relatively low signal from the two sets of NP 
secondary conjugates. However, the median value for AlexaFluor®647 appears to be 
unusually large, indicating non-specific binding (Fig 7.2 B’) and can be visualised in 
Fig 7.3 (f’). This is surprising, as AlexaFluor®647 appears to perform the best for the 
MCF-7 cells, giving a median value that is three times the value for 0.168% NPs, or 
twice the value of the 0.279%, but the non-specific binding is higher than that of the 
NPs. Typically, the commercially available standard has almost no incorrect staining 
when compared with NPs (from chapter 5). Initially, non-specific binding from 
AlexaFluor®647 was thought to be caused by oversaturation of the cells with the 
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fluorophore. Control tests were carried out with flow cytometry in tandem to the tests 
shown in Fig 7.2 and the results are shown in Fig 7.4. 
 
 
Fig  7.3: Bright field and corresponding fluorescence images of MCF-7 and HeLa cell lines 
incubated with goat anti-mouse IgG red dye conjugates. The nucleus of the cells (blue) is 
stained with Hoechst 33342. The scale bar represents 50µm 
 
MCF-7 and HeLa cell control tests were measured by incubating cells with secondary 
antibody conjugates only, without primary antibody, to determine whether the 
fluorophores were non-specifically binding to the cells. Protocols were followed as 
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stated in section 7.2.4, without the addition of the primary antibody. The results are 
shown in Fig 7.4. 
 
Fig  7.4: Flow cytometry data of cells incubated with AlexaFluor®647 or 0.168% NPs without 
prior incubation with primary antibody. The value is the median fluorescence value of the 
cells. 
It is clear from the data presented in Fig 7.4 that the primary antibody plays a role in the 
large non-specific signal from the HeLa cells. The median fluorescence values of the 
AlexaFluor®647 are the same as for cells only, indicating that the fluorophore does not 
stain the cells non-specifically but that the primary antibody is causing the adherence of 
the dye labelled secondary antibody to the cells. Searching the literature has not led to 
any satisfactory explanation as to why this might be the case, as the mechanism of how 
the non-specific binding of the primary antibody can occur is unclear. One suggestion 
by Jackson Immuno Research Laboratories is to block the cells with goat serum rather 
than BSA as there may be some cross reactivity between the goat-anti-mouse and bovine 
IgG proteins that may have contaminated the BSA [4]. As there were no interactions, 
observed from the flow cytometry data, between secondary antibody and cells that were 
in solution containing BSA, this would seem to be an unlikely reason for the effect.  
Image analysis was carried out on images of the cells in Fig 7.3 and on control NP tests 
and a summary of the results can be viewed in Fig 7.5.  It would appear from the image 
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analysis that the NPs and AlexaFluor®647 are specific to EpCAM positive cells, as the 
signal in all cases is higher for MCF-7 cells than HeLa cells, even when the signal from 
HeLa cells was high. Statistical significance testing, in the form of the student t-test, was 
performed on all sets of data and it was found that, for all anti-EpCAM red conjugates, 
the mean values of MCF-7 compared to HeLa were statistically significantly different 
to each other (P<0.05), except for the case of the 0.168% NP control, for which no 
primary antibody was incubated with the cells, in which case the means were not 
significantly different to each other (P>0.05). This result is positive, as the control group 
should have similar means which implies that the level of non-specific binding for NPs 
is similar for both cell lines and does not interfere with specific targeting of the cells. 
 
Fig  7.5: Image analysis of MCF-7 and HeLa cells incubated with secondary goat anti-mouse 
IgG NPs or AlexaFluor®647. The 0.168% NP control set have not been incubated with 
primary antibody previously. 
To conclude, it appears that the NPs are specific to the primary antibody but for reasons 
currently unknown, the AlexaFluor®647 has a high binding efficiency to the control cell 
line, HeLa. Despite this, the difference between EpCAM positive and negative cell lines 
is more than enough to distinguish the different populations in flow cytometry and image 
analysis methods conclude that the differences in mean between cell lines is statistically 
significant. Therefore, it can be said that NPs can be used in a secondary antibody 
EpCAM detection system for MCF-7 and HeLa cell lines.   
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7.3.3 Flow cytometry and image analysis with LNCaP and PNT1A cell lines 
Secondary antibody protocols were carried out on prostate cancer cells to investigate 
whether comparable results can be obtained for another EpCAM positive cell line, 
LNCaP. The PNT1A cell line was used as the control cell line. Cells were incubated 
with secondary goat anti-mouse IgG NPs or AlexaFluor®647 after they had been initially 
incubated with anti-EpCAM primary antibody. The results of these experiments from 
flow cytometry can be viewed in Fig 7.6. 
 
Fig  7.6: Flow cytometry results for secondary staining with LNCaP and PNT1A cells where 
the top row (A and A’) are cells only and rows B-D and B’-D’ correspond to cells incubated 
with anti-EpCAM red conjugates.  
Addressing the data for LNCaP cells firstly, there appears to be three cell populations 
within the graph of the LNCaPs Fig 7.6 (B-D), most notably in Fig 7.6 B, in which cells 
were incubated with AlexaFluor®647. The majority of the cells in the largest peak appear 
to have a median fluorescence value of approximately 800, the second shoulder to the 
left of the main peak has a value in the region of 100 and the third is a small number of 
cells under the value of 10. The last peak most likely represents cells in the population 
that do not express EpCAM and the shoulder peak represents cells that have lower 
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expression than most of the cells. It is interesting to note that these three populations can 
be seen in the cells which have been incubated with 0.168% nanoparticles. However, 
the distinction when cells are incubated with 0.279% NPs is not quite so clear and the 
small population of non-EpCAM expressing cells is almost non-existent. The median 
value for all three fluorophores is similar and appears to be specific to the primary 
EpCAM antibody.  
Interpreting the data for the PNT1A cells, there appears to be some amount of non-
specific binding in the cases of all fluorophores. Interestingly, the signal for 
AlexaFluor®647 is much lower than that from HeLa cells that was observed in the 
previous section 7.3.2 and the 0.168% NPs also have a similar median fluorescence 
value. However, the 0.279% NPs have a much higher non-specific signal to that found 
with the direct binding anti-EpCAM conjugated NP system of section 5.3.4. It possible 
that the problem lies with the nanoparticles themselves, but they appear to perform well 
with the HeLa cell line, which would suggest that it is to do with the cell lines. It is 
possible that the PNT1A cells may have a different surface charge than the other cells 
that were used and could attract the NPs if they have enough charge. Cells have been 
known to vary greatly in zeta potential, even just changing temperature or enzyme 
treatment [5,6]. As the nanoparticles, 0.168% and 0.279%, also have different zeta 
potentials (-26mV and -9mV respectively) this could play a role in the larger non-
specific binding of 0.279% NPs with PNT1A cells. 
Overall, the AlexaFluor®647 and 0.168% NPs appear to be a successful working 
secondary antibody system. The NPs do not achieve as bright a signal from LNCaP cells 
as the AlexaFluor®647 in this case, combined with the higher non-specific binding. 
However, they do have a large enough median population difference. In Fig 7.7 are the 
corresponding images taken for the flow cytometry data. Image analysis was also carried 
out for these cells and is summarised in Fig 7.8. 
    
                                                                               115 
 
Fig  7.7: Bright field and corresponding fluorescence images of LNCaP and PNT1A cell lines 
incubated with secondary antibody red dye anti-EpCAM conjugates. The scale bar represents 
50µm. 
The data from image analysis agrees with data from flow cytometry. In Fig 7.7 (f’) for 
PNT1A cells with AlexaFlour®647, the image appears brighter than the signal from cells 
with either set of NPs, similar to those images obtained with HeLa cells in section 7.3.2. 
Data analysis revealed that the means of LNCaP and PNT1A cells for each set of red 
dye conjugate were significantly different (P<0.01) except for the control NP group, to 
which no primary antibody had been added, for which the mean difference was not 
significant. Also, similarly to HeLa non-specific binding, the PNT1A for 0.168% NPs 
with and without primary antibody incubation was not statistically significantly 
different, again implying that the level of non-specific binding does not hinder the 
staining methods in the secondary antibody staining system, concluding that the 0.168% 
NPs could be used to stain EpCAM antibody in an LNCaP and PNT1A cell system. 
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Fig  7.8: Image analysis data of LNCaP or PNT1A cells incubated with goat anti-mouse IgG 
NPs or AlexaFluor®647. The 0.168% NPs control sample have not been incubated with 
primary antibody before addition of NPs. 
 
7.4  Conclusions 
Secondary antibody NPs were successfully functionalised with goat anti-mouse IgG. 
The antibody was specific to mouse anti-EpCAM antibody as was tested via a direct 
binding assay. Flow cytometry tests with MCF-7 and HeLa cells have shown that both 
sets of NPs were specific to the anti-EpCAM antibody and that the 0.168% NPs were 
specific for the LNCaP and PNT1A cells. However, problems with non-specific binding 
of the AlexaFluor®647 have hindered a direct comparison of their performance to the 
NPs which is most likely due to some interactions between the primary and secondary 
antibody. Further work is required to determine the exact cause and also to investigated 
if the zeta potential of the cells interferes with the 0.279% NPs binding to PNT1A cells. 
The overall conclusion of the secondary antibody approach is that, for reasons stated 
above, there are no sensitivity advantage using NPs or indeed AlexaFluor®647 
secondary staining over the primary antibody approach presented in chapter 5.  
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Chapter 8:  Metal enhanced fluorescence 
 
8.1  Introduction 
In this chapter, the use of surface plasmon-based fluorescence enhancement to improve 
cell imaging is investigated. This follows on from earlier chapters in which cell imaging 
using high brightness silica NPs, or single red dye fluorescent labels, was reported. The 
motivation is to capitalise on ongoing work in the research group on the use of gold 
plasmonic diffraction grating substrates for enhanced fluorescence-based bioassays and 
to explore the use of these grating substrates for enhanced imaging of cells using an 
epifluorescence microscope [1]. The preparation of the grating substrates for cell 
adhesion, the imaging data and an interpretation of the results are presented herein. 
As discussed briefly in Chapter 2, surface plasmon resonance (SPR) is a phenomenon 
which describes the coupling of incident light into a metal-dielectric interface producing 
surface plasmon polaritons (SPPs), also known as surface plasmon waves, which include 
and electric and magnetic component [2,3]. Light will only couple into the SPPs when 
it is polarised parallel to the plane of incidence (p-polarised) and the momentum of the 
vector in the X direction (KLx) matches the momentum of the polaritons (Kspp), (see Fig 
8.1) [4].  
 
Fig  8.1: Production of surface plasmon resonance from light p-polarised parallel to incident 
light that matches the required angle and momentum conditions within a prism 
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 The coupling condition for SPR strongly depends on the complex dielectric function of 
both the metal and dielectric medium and is given below in equation 8.1 and 8.2: 
  𝐾𝐿𝑥 = 𝐾𝑆𝑃𝑃         (Eq.  8.1) 
𝐾𝑠𝑝𝑝 =
2𝜋
𝜆
𝑠𝑖𝑛𝜃𝑖 =
2𝜋
𝜆
√
𝜀𝑀𝜀𝐷
𝜀𝑀+𝜀𝐷
     (Eq.  8.2) 
where λ is the wavelength of incident light, θi is the angle between the incident light and 
the normal of the substrate and εM and εD are dielectric functions of the dielectric and 
metal, respectively [3].  
There are different optical set ups that can be used in order to achieve coupling. Prism-
coupled SPR, can use either the Kretschmann or Otto geometry, which both use a prism 
to modify the dielectric function so that incident light momentum can be matched to that 
of the plasmon [5,6]. The Kretschmann configuration requires metal to be deposited onto 
the side of the prism where light is incident on the metal from inside the prism. The 
opposite side of the metal is the sensing side [5]. For the Otto configuration, light is also 
incident through the prism but there is a gap between the prism and the metal [6]. 
Grating-coupled SPR can be used as a method to couple incident light into the metal, 
whereby the metal is periodically structured. In this configuration, the periodic structure 
can be used to modify the in plane component of the light vector through the addition or 
subtraction of the grating vector. This optical setup has many advantages, but mainly it 
has a higher coupling efficiency and a simple optical setup [7,8]. 
In grating coupled SPR, the coupling angle can be controlled by the period and pitch of 
the grating. The momentum needed to match that of the SPPs is now defined as: 
               𝐾𝐿𝑥 ±  𝐾𝑔 = 𝐾𝑆𝑃𝑃    (Eq.  8.3) 
where Kg is the momentum introduced by the grating. For a periodic metal layer with a 
grating pitch of Λ, the matching conditions are described by the following equation [1]: 
 𝐾𝑆𝑃𝑃 =
2𝜋
𝜆
𝑠𝑖𝑛𝜃𝑖 ± 𝑛
2𝜋
𝛬
=
2𝜋
𝜆
√
𝜀𝑀𝜀𝐷
𝜀𝑀+𝜀𝐷
                                            (Eq.  8.4) 
Usually, the pitch of the grating is selected so that θi is small enough that this coupling 
angle is covered by the angle at which incident light will fall onto a grating through a 
microscope lens. 
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Some groups have previously used silver coated plasmonic gratings for the amplification 
of fluorescence from labelled cells [7,9]. Typically, silver provides a better SPR signal 
as both the real and imaginary parts of the dielectric function are better suited to plasmon 
generation compared to gold, so enhancements similar to those found with silver would 
not be expected [10]. Cui et al. used silver coated gratings for imaging cells on an upright 
microscope with 40x lens [7]. Using this set up, an 8-fold increase in the signal from 
cells was achieved when compared to a cell on a silver substrate and 24-fold 
enhancement between the gratings and cells on a glass substrate. This increase was 
measured from the grey value from a line scan of a stained cell. Tawa et al. also used 
silver coated gratings for the enhancement of cell imaging. Human embryonic kidney 
cells (HEK) were dyed with AlexaFluor®647 membrane while being cultured on a 
grating embedded dish and was compared with a normal glass bottom dish. Using an 
upright fluorescent microscope, they observed a 14-17-fold increase in signal as 
compared to the glass bottom dishes. However, this report did not include a comparison 
to plane silver surfaces [9]. Enhanced fluorescence of fluorescent molecules using gold 
gratings has been carried out by Byrne et al. and simulated the fluorescence enhancement 
to penetrate anywhere from 20nm-200nm above the grating surface at certain points [1]. 
Previous studies using gold gratings for cell imaging have been carried out with LED 
light sources at 875nm and were used to capture and detect human Jurkat T lymphocytes 
in an enzyme linked immunosorbent assay format as a present or absent test [11,12]. 
This was not compared to non-grating surfaces. The results that were obtained for cell 
fluorescence enhancement using gold grating substrates are reported in this chapter.  
 
8.2  Materials and methods 
8.2.1 Materials 
Anti-EpCAM AlexaFluor®647 was obtained from BioLegend (CA, USA).  DY647-P1 
was obtained from Dyomics (Jena, Germany). Gold coated plain plastic and grating 
plastic substrates were chosen to test for cell imaging due to an ongoing project in the 
group. They were synthesised by Dr. Daragh Byrne from the School of Physical 
Sciences Dublin City University. 0.279 (w/w%) Cyanine5 doped silica NPs were 
synthesised in house as described in chapter 4. All other materials were obtained from 
Sigma Aldrich. 
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8.2.2 Plasmonic gratings 
Plasmonic gratings were produced using an interference laser lithographic beam 
previously reported [1]. In brief, gratings were fabricated using a KR1801C TEM00 
HeCd laser (Kimmon Koha, Japan) in SU8 resist, followed by polydimethylsiloxane 
(PDMS) replication. The master grating was produced via interference lithography using 
a Lloyd mirror configuration. In this configuration, a divergent beam is used to 
illuminate the photoresist coated substrate and mirror, which are at right angles to each 
other. The light is reflected from the mirror onto the sample, creating an interference 
pattern at the substrate surface as shown in Fig 8.2 below. The grating period can be 
adjusted by altering the angle between the two interfering beams. The pitch of the grating 
Λ is governed by the equation: 
𝛬 =
𝜆
2 sin 𝜃
    (Eq.  8.5) 
where λ is the wavelength of the beam and θ is the angle between the two beams. 
 
 
Fig  8.2: Laser interference set up for creating master grating in SU8 on silicon using Lloyd 
mirror adapted from [13]. 
The master grating surface on the silicon wafer (see Fig 8.3 below for an atomic-force 
microscopy (AFM) image of a typical resultant grating) was then used as a template for 
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PDMS replication. These PDMS moulds were used to create epoxy resin casts which 
were subsequently coated in gold using a vacuum evaporator.  
 
Fig  8.3: Typical grating surface of Si wafer after interference lithography in SU-8 photoresist 
adapted from [1]. 
Dye coated substrates were prepared by spin coating with a dye doped polyvinyl alcohol 
(PVA) mixture containing 1% w/w PVA and 0.008% w/w DY647-P1. 
 
8.2.3 Cell preparation  
The MCF-7 cell line was grown in a 75cm2 flask in DMEM containing 10% heat 
uninactivated FBS, 1% L-glutamine and 1% penicillin-streptomycin. The cells were 
cleaved from the bottom of the flask using trypsin. Cells were centrifuged (300xg, 5 
minutes) and resuspended in PBS containing 1% BSA and 0.05% Tween®20. Following 
this, cells were counted on the haemocytometer and the final solution was adjusted so 
that there were 125,000 cells for staining with either anti-EpCAM AlexaFluor®647 or 
0.168% anti-EpCAM NPs. Stains were added either 3.0 µL of AlexaFluor or 10.0 µL of 
NPs (1mg/mL concentration) to cells and incubated for 40 mins. After this, cells were 
centrifuged and washed three times in PBS and finally resuspended in ~30 µL of PBS. 
Then 7 µL of solution was added to either a glass, gold or grating substrate after which 
a cover slip was applied and sealed. The cells were left to attach to the substrates for 30 
mins before imaging. 
 79.57 mV
 0.00 mV
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8.2.4 Imaging of dye coated or dye labelled cells on substrates 
Imaging was initially performed on an Olympus IX71 inverted microscope that was 
described in section 5.2.4 and referred to as the manual microscope. The second imaging 
system used was an Olympus IX81 inverted microscope with IX2-UCB motorised XYZ 
stage control and motorised lenses (Olympus, Tokyo, Japan). A Hamamatsu ORCA-ER 
CCD camera (Hamamatsu Photonics K. K., Hamamatsu, Japan), MT20 illumination 
source (Olympus) and Cell R imaging software (Olympus) were used with the inverted 
microscope. It is referred to as the Hamamatsu microscope. A Cy5 filter cube set was 
used when imaging all cells in this chapter. 
All gains were set to zero and an integration time was chosen so as to achieve near 
saturation of the CCD camera when imaging the highest concentration sample, or that 
which should be the brightest i.e. the samples on gratings. Once this integration time 
was determined, it was applied to all other samples and no parameters were changed. 
For the manual microscope, this was a 5s integration time with a 20x lens and for the 
Hamamatsu system this was 50ms using a 20x lens.  
Images acquired were analysed using Image J software (NIH, USA), whereby the 
fluorescence from a region of interest, usually the cell, was measured and compared to 
background fluorescence from a region where no cells were situated. 
 
8.3  Results and discussion 
8.3.1 Adhesion of cells to gold coated substrates. 
As the microscope system was an inverted system setup, an investigation was carried 
out as to the adherence of cells to the surface. This is particularly important as the 
modified electric field from the generation of surface plasmons decays exponentially 
with distance from the metal surface and is typically only observed within the first 200 
nm range, and only strongly within 50 nm, from the surface of the grating [1]. If the cells 
do not attach correctly, the fluorophores on the surface of the cell are unlikely to display 
significant enhancement. A test was devised, whereby MCF-7 cells that were stained 
with anti-EpCAM AlexaFluor®647 were placed on plane gold and gold grating surfaces 
either unmodified or after modification with a thiolated RGD peptide. Thiolated RGD 
has been used to bind cells to the surface of gold previously [14,15]. 
    
                                                                               124 
Images were taken, on the manual microscope, of cells after 30 mins of incubation on 
the surface of the substrates in both cases and the average fluorescence of the cells was 
established. Care was taken when imaging the cells to focus on the cell surface that was 
closest to the gold substrate. The fluorescence results were compared between the 
thiolated and unmodified gold substrate and also compared between samples that were 
prepared on a glass slide. 
 
Fig  8.4: MCF-7 cells stained with AlexaFluor®647 attached to unmodified or thiolated plane 
gold (Gold) or gold grating (Grating) substrates 
Fig. 8.4 summarises the results of this experiment where it was found that no statistically 
significant difference was present between the fluorescence intensity from samples that 
were placed on thiolated RGD or unmodified substrates from the student’s t-test. This 
indicates that the cells can adhere to the gold surface without the use of RGD peptide. 
Samples that were placed on gold substrates, both plane and thiolated, were statistically 
significantly brighter than the cells imaged on glass with P<0.05 in all cases. The grating 
samples were then compared to samples on plane gold and it was discovered that they 
were not significantly more fluorescent with P>0.05 for the two cases. This would 
indicate that KLx, is not matching KSPP and more work was carried out to investigate this 
further. See Fig 8.5 below for sample images of cells take on each of the substrates. 
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Fig  8.5: Bright field and Cyanine5 filter cube imaging of MCF-7 cells stained with 
AlexaFluor®647 anti-EpCAM on glass, gold and grating surfaces unmodified or thiolated. 
 
8.3.2 Investigation of coupling of light into the grating surface 
As mentioned in the previous section, it is necessary to investigate whether the excitation 
source of the microscope can couple into the grating. The criteria needed to do this 
includes that the light is linearly polarised along the Bragg vector of the grating and also 
that the momentum of the incident light matches that of the SPPs. The fluorescence 
source in the manual microscope was an X-Cite series 120 excitation lamp which uses 
a mercury lamp to illuminate the filter cubes. This light source is unpolarised, and so a 
polariser was introduced in this system. The microscope has a slot at the back where the 
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light source is coupled to the microscope and in this slot was placed a linear polariser 
which was free to rotate 360o in the vertical plane. The polariser was rotated every 45
o in 
order to attempt to observe enhanced fluorescence which would indicate the light was 
linearly polarised to the Bragg vector of the grating. In theory, there should be a 
maximum every 180o. MCF-7 cells were stained with anti-EpCAM AlexaFluor®647 and 
were allowed to adhere to either a grating or a plane gold substrate, which was used as 
a control since there should be no observable maxima with the gold substrate. An image 
was taken of the same cell every time the polariser was rotated 45o. The images were 
then analysed in image J and the average pixel grey value of the fluorescence emitted 
from the cell was obtained and displayed in Fig 8.6. 
 
Fig  8.6: Mean grey value of stained MCF-7 cell through rotated polariser on a plane gold or 
gold grating substrate 
It is clear from the data, that for both substrates, the fluorescence intensity was unaltered 
by the light polarisation angle. This implies that the polarisation is not being maintained 
within the microscope. As the light passes through the filter cube, it must transmit 
through three surfaces that possibly do not keep the polarisation introduced by the linear 
polariser. Because of this, a laser source microscope such as a laser scanning confocal 
microscope should be easier to achieve this. Also as the beam of light hits the substrate 
at a range of angles, only a finite distribution of these angles will satisfy the momentum 
conditions for a fixed period grating. It was reported previously that the coupling angle 
for a grating pitch of 581nm and wavelength of 630 nm is approximately 5-7o [1]. The 
range of angles at which a 20x lens illuminates a sample on the microscope can be 
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calculated using the numerical aperture equation (Eq. 8.6). Knowing the numerical 
aperture of the 20x lens (NA) of 0.4 and refractive index, η, of 1.52 for glass it can be 
substituted into the following equation: 
NA= ηsinθi     (Eq.  8.6) 
to find that the lens allows for angles from 0o to 15.1o and covers the coupling angle 
needed. 
To ensure that the gratings were functioning correctly and to investigate the response of 
the microscope to various concentrations of dye, two experiments were devised. The 
first employed dye-doped PVA that was coated on the surface of plane gold and grating 
substrates instead of imaging cells. These dye-doped substrates were measured on an 
instrument built by Dr. Daragh Byrne which has the capability of changing the coupling 
angle to the substrate and uses a diode laser. The results are presented below in Fig 8.7. 
 
Fig  8.7: Fluorescence response of dye doped polyvinyl alcohol on the surface of plane gold or 
grating substrates on the system built by Dr. Daragh Byrne as the laser couples into the 
grating. 
From the data in Fig 8.7, the base level from 65-95o of the two substrates refers to the 
dye concentration on each of the substrates. This base concentration was measured to be 
10x more dye on the grating than that on the gold surface before angle coupled 
enhancement is observed (100-130o). At the peak of the enhancement, ~115o, an 
enhancement factor of approximately 4x is clearly visible in Fig 8.7. This indicates that, 
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under appropriate coupling conditions, the gratings do produce a fluorescence 
enhancement which should translate to the microscope.  
Another microscope system, the Hamamatsu microscope, was employed that had better 
control over illumination, gain and camera settings to test the grating substrates and was 
tested for comparative purposes. 
These substrates were then measured on the two microscope systems, the manual and 
Hamamatsu, and the results are shown below in Fig 8.8. Three spots on each of the 
substrates were measured on both systems to ensure comparative results and it was 
expected to see these enhancements on the microscopes similar to the system built by 
Dr. Byrne. As the previous results did not show an improvement when using a polariser, 
no polariser was used with the manual microscope this time around. 
 
Fig  8.8: Results from measuring dye coated plane gold or grating substrates on a manual 
microscope (manual) compared with a Hamamatsu microscope at three different spots 
Results from these tests showed that there was slight enhancement in signal from the 
gold and grating samples on the two microscope systems.  However, this enhancement 
did not capture the difference in concentration of dye on the surface of the grating 
substrates that is accounted for when measuring on the laser angle coupling system. It 
was unclear if this was due to a difference between the response of the microscope 
camera compared to the camera used on Dr. Byrne’s system.  
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Another test was run to check the responsivity of the CCD camera on the Hamamatsu 
microscope in relation to increasing concentrations of dye. A 96-well microplate was 
used to attach increasing concentrations of DY647-P1 anti-human IgG antibody to the 
surface of the well plate. Simultaneously, the same antibody concentrations were placed 
on wells that were coated in silver nanoparticles to enhance the emission of the dye. A 
colloid solution of silver nanoparticles has been shown to enhance fluorescence emission 
previously through localised surface plasmon resonance [16]. The results of these tests 
are summarised in Fig 8.9. 
 
 
 
Fig  8.9: human IgG labelled with DY647 on a silver nanoparticle plate well surface (top) and 
on a normal plate well surface (bottom) on a microplate reader (left) compared with readings 
from the Hamamatsu microscope (right). 
The microscope measures fluorescence on a scale from 0-255 whereas the Tecan can 
output values up to 50,000 units. As a consequence, the graphs were not plotted together 
and a general comparison of trend was observed instead. For the assay performed on the 
silver nanoparticle coated surface of the well plate; both the Tecan microplate reader as 
well as the microscope system displayed a similar trend in fluorescence emission. This 
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implies that the camera should be able to detect the enhancement that is associated with 
imaging on the gold gratings. However, looking at the normal assay that was performed 
on both systems, the response from the microscope is not as sensitive. It is possible that 
this was caused by optimising the exposure time of the camera on the Hamamatsu 
microscope for the brightest well i.e. the highest concentration of antibody on the silver 
nanoparticle well surfaces. If the secondary assay exposure time was reoptimized a more 
sensitive response may have been achieved. However, as the microplate reader data was 
measured on the same gain settings, a like for like experiment was carried out. The 
conclusion drawn is that if significant coupling was taking place, an enhanced emission 
should be observable and that the Hamamatsu microscope camera is sensitive enough to 
distinguish the enhanced signal.  
8.3.3 Use of Cyanine5 nanoparticles with grating coupled SPR 
Although a large enhancement was not visualised previously using the gratings and 
AlexaFluor®647, it was decided to test nanoparticles on the microscope system. Anti-
EpCAM conjugated 0.168% NPs were incubated with cells and compared with the 
performance of an AlexaFluor®647 stain. Both were tested on glass, plane gold and gold 
grating substrates and images were taken of cells with a 20x lens and measured using 
image J. A summary of the results is displayed in Fig 8.10 and can be visualised in Fig 
8.11. 
 
Fig  8.10: Data analysis of images obtained for MCF-7 cells labelled with anti-EpCAM 
AlexaFluor®647 or NPs that were placed on either glass, gold or grating substrates. 
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Cells on the grating substrate had an overall higher average than that of the cells on the 
gold and glass substrates. A 1.6x enhancement was obtained between grating and gold 
substrates using AlexaFluor®647 and 1.3x for NPs, which was an overall 6.3x and 1.8x 
increase from grating substrates compared to glass in both cases for AlexaFluor®647 and 
the NPs respectively. However, statistical significance testing in the form of a student’s 
t-test was performed on the data set and it found that the nanoparticle stained cells on 
the grating, in comparison to the gold substrate, was not statistically significant (P>0.05) 
nor was it significant in comparison to glass. Interestingly, the cells stained with 
AlexaFluor®647 on grating substrates were statistically significant (P<0.05 in all cases) 
compared to gold substrates and similarly to the glass. It was found that the increase in 
fluorescence on the gold was also statistically significant compared to the glass 
substrates. Comparing AlexaFluor®647 to NPs on the same type of substrate, both plane 
gold and grating substrates were not significantly different but the comparison on glass 
was significant. This implies that the nanoparticles outperform the AlexaFluor®647 
when used with glass substrate but that significant enhancement is not observed when 
using the NPs with plane gold or grating substrates which is observed when using 
AlexaFluor®647. There was a large overall variability in mean grey value, generally due 
to the variance in cell size being measured, but also another contributing factor was the 
EpCAM expression across the cell membrane. 
Previous papers using silver coated gratings have observed an enhancement of 
fluorescence from cell staining, as mentioned in the introduction [7,9]. One paper in 
particular observed an 8-fold enhancement using the silver gratings compared to plane 
silver. However, some scepticism into this result is held as this increase is obtained from 
taking a line scan across a cell image of one particular cell on a silver grating and 
compared it to the line scan of one cell that was on a plane silver surface or glass 
substrate [7]. It is unclear from the report whether this was repeated for any more than 
one cell and so, does not infer that this was the result for all cells that were found on the 
substrates. Having said this, other groups have been successful in enhancing the 
fluorescence of cells grown on a silver grating but this was only compared to a glass 
substrate and did not measure the cells grown on a plane silver substrate to view pure 
metal enhanced fluorescence effects [9]. This is particularly important given that the use 
of a reflective substrate effectively doubles the intensity of light passing through the 
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fluorophore stained cell.  The data in Fig 8.10 for AlexaFluor®647 is comparable to the 
14-17-fold increase in signal that was obtained in this paper, taking into account that 
gold has a reduced ability to produce SPR. It is hypothesised that it would be possible 
to observe real fluorescence enhancement from the grating substrates with the use of a 
laser confocal microscope or an angle coupling instrument, like Dr. Byrne’s. These 
instruments will both have linearly polarised light sources and also, in the case for Dr. 
Byrne’s system, would definitely be able to keep a large portion, if not all, of the light 
at the angle required to couple into the gratings. 
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Fig  8.11: MCF-7 cells stained with anti-EpCAM AlexaFluor®647 or NPs on glass, gold or 
gold grating substrates. 
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8.4  Conclusions 
Gold coated gratings were investigated for the enhancement of cell imaging compared 
to plane gold and glass substrates. A small enhancement of 1.6x, grating to gold and 
6.3x grating to glass was achieved using AlexFluor®647 dye and 1.3x, and 1.8x 
respectively for NPs. This would indicate that the NPs are best suited for use in glass 
substrate staining to get maximum differentiation compared to AlexaFluor®647. 
Challenges have emerged in detecting statistically significant enhancements on a 
microscope system that was previously measured on a laser diode angle coupling system 
devised by Dr. Byrne. However, camera response does not appear to interfere with the 
ability to detect these enhancements as was investigated by means of increasing dye 
labelled antibody concentrations and measuring on a microscope and microplate reading 
system. The other issue with using a microscope system is that the angle of illumination 
is fixed and not necessarily linearly polarised as is required to see large enhancements. 
Microscope illumination operates generally in a wide range of angles with only one of 
those angles able to couple into the grating. With the use of a laser confocal microscopy 
system it may be possible to see more of the enhancement and if the angle of excitation 
could be adjusted, such as per Dr. Byrne’s system or even tested on this system, then I 
believe that an enhancement should be attainable. 
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Chapter 9:  Conclusions and outlook 
 
9.1  Conclusions 
In conclusion, the overarching aim of this research project, which was ‘to demonstrate 
the specific staining of circulating tumour cells from blood with fluorescent silica 
nanoparticles for cell staining, both in flow cytometry and imaging, in comparison to 
single dye molecules’ was successfully achieved. 
Cyanine5-doped silica nanoparticles were synthesised using a modified reverse 
microemulsion method. Two sets of NPs, doped with different weight percent dyes, were 
approximately 40 nm in size immediately after synthesis and were characterised 
quantitatively in terms of size, zeta potential and number of dye molecules inside the 
NPs. Their size was measured using TEM at stages throughout the synthesise steps and 
shows that with the addition of functionalisation steps that they become no larger than 
66 nm before the addition of an antibody. The number of dye molecules that was 
measured on average per NP, was found to be 137 and 155 dye molecules for the 0.168 
(w/w%) and 0.279 (w/w%) dye loaded NPs respectively.  Models that were produced 
based on homo-FRET interactions between dye molecules within the nanoparticle 
matched well with experimental results and showed that the fluorescence emission 
peaked at 0.4 (w/w%) loading of dye and that after this amount there was no benefit 
from the addition of more dye as it induced greater FRET effects. 
The conjugation of antibody was first verified using Cyanine3 labelled anti human IgG 
which was conjugated to the surface and subsequently used to estimate the number of 
antibodies that were bound via monitoring the supernatant of the solution. This number 
was found to be 79 ± 5 antibodies per NP. Also, 100% of the antibodies on the NPs were 
available to bind to analyte that was in solution phase. Knowing this, CTC specific anti-
EpCAM antibody was confidently conjugated to the surface using the same method 
knowing that it would retain specificity. 
Both sets of NPs were incubated with an EpCAM positive breast cancer cell line and a 
cervical cancer EpCAM negative cell line, MCF-7 and HeLa. The NPs showed 
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specificity to the MCF-7 line and were compared to commercially available anti-
EpCAM APC and AlexaFluor®647. Flow cytometry results showed that the 0.168% NPs 
were twice as bright as the APC and almost three times as bright as AlexaFluor®647. 
Good specificity was also observed using image analysis methods. Using laser confocal 
microscopy, NPs were confirmed to be on the surface of the MCF-7 cells where the 
EpCAM protein is expressed and not endocytosed in the time frame of a few hours. 
Good specificity was also achieved for a lower EpCAM expressing cancer cell line, 
LNCaP, which is a prostate cancer line and compared with a healthy cancer line PNT1A. 
Patient blood samples were mimicked by spiking the cultured cells into healthy donor 
blood at different ratios of CTCs to WBCs. NPs were able to distinguish spiked MCF-7 
cells up to ratios of 50:1, WBC: CTC, using 0.168% NPs and 20:1 with spiked LNCaP 
cells. Despite non-specific binding of the NPs to WBCs the number of NPs bound to 
CTCs was an order of magnitude higher and so via flow cytometry the CTC cell cloud 
could be identified above the WBC cloud in the red2 channel of the flow cytometer. 
Comparison of the performance to AlexaFluor®647 shows that the AlexaFluor®647 is 
more sensitive as it can detect the CTCs at levels of 127:1 and 115:1 for MCF-7 and 
LNCaP cell lines respectively, indicating that the NPs do need to be improved in terms 
of non-specific binding. Imaging of the cells complimented the flow cytometry data 
showing more NPs bound to the CTCs than the WBCs. 
Work was carried out to investigate the use of a secondary antibody-antibody labelling 
system that, when used with dye labelled antibodies, produced a more sensitive detection 
system. Results from using a secondary system with NPs showed that they were specific 
as they bound to MCF-7 cells well, compared to HeLa cells. An issue with non-specific 
binding of the control goat anti-mouse AlexaFluor®647 antibody made it difficult to 
assess the comparability of the performance of the NPs in this system. There appeared 
to be no real advantage of using the secondary system over primary staining methods as 
the overall increase in fluorescence was not larger. 
Cell staining was carried out on gold grating surfaces with the intention of showing 
enhancement on these substrates compared with plane gold and glass substrates. An 
increase of signal was produced from AlexaFluor®647 labelled MCF-7 cells on the gold 
grating surfaces but only by an increase of 1.6x compared to the plane gold surface and 
not nearly the enhancement that was observed on a laser diode system where an 
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enhancement of up to 30-fold can be observed with the correct conditions. Cells labelled 
with NPs did not produce as much an enhancement as the dye labelled cells and so there 
appears to be no real advantage of using NPs over dye labelled antibodies in this 
application. Despite this, with a more optimised system a greater enhancement could be 
produced. 
9.2  Conclusions in relation to CTC detection 
The use of nanoparticles as a viable detection stain for CTCs must be addressed on a 
number of levels in order to realise them as an enabling technology. Key points of 
interest are: the number and type of antigens that need to be stained, and, what end goals 
could be achieved using NP labels, in terms of the challenges in relation to CTC 
detection. These are discussed below with relevance to studies that have been conducted 
on patient CTCs. 
As CTCs originate in epithelial tissue, it would appear that epithelial markers, such as 
EpCAM, would be the ideal candidate markers to detect all CTCs of different cancer 
types. However, the expression of EpCAM on CTCs is not consistent within its lifetime 
and has been shown to be heterogenous [1,2]. This is due to epithelial to mesenchymal 
transition (EMT) whereby the cancer cell starts to downregulate the expression of 
epithelial surface proteins, to promote its preservation from the immune system, 
chemotherapy and targeted therapy [3,4]. This allows the CTC to stay in circulation long 
enough to move to another location in the body and upon reversal of the EMT process, 
the phenotype switches from mesenchymal to epithelial once again via the mesenchymal 
to epithelial transition (MET)  [3,5]. Following this, the tumour cells express epithelial 
proteins once more, which promotes the ability of the CTCs to form secondary cancer 
tumours [3,4]. This implies that CTC detection instruments, that use EpCAM as the main 
distinguishing antigen, may fail to correctly enumerate the CTCs in patients and 
underestimate those in the circulating system [6]. This is true also for the nanoparticle 
CTC detection system, where, if EpCAM was to be the sole target antigen, it would fail 
to enumerate the actual number of CTCs in blood samples.  
One study looked at the enumeration of EpCAM between different cancer cell lines 
which included an example of breast, colon, bladder and prostate cancer cell lines [7]. 
Across the different cell lines there was a large variance in expression of EpCAM, with 
the MCF-7 cell line expressing approximately 500,000 molecules per cell, closely 
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followed by colo205 colon cancer and SKBr-3 breast cancer [7]. LNCaP expressed 
approximately a third less EpCAM molecules than the other cells lines and the T24 
bladder cancer cell line only expressed 2,000 molecules. The number of EpCAM 
molecules on CTCs, from various metastatic carcinoma cancer patients, was found to be 
in the range of 30,000-60,000 molecules, exhibiting EMT downregulation of epithelial 
markers [7]. This data strengthens the argument to test CTC systems on patient samples, 
and not only cell lines, to get a true picture of how robust the EpCAM detection method 
is. It also points out a flaw in the EpCAM detection method, as not all cell lines are 
highly EpCAM expressive. If this nanoparticle CTC detection system were to continue, 
it would be imperative that tests on patient blood samples should be a next step in the 
development process. Another study, that also came to the same conclusion, showed that 
using EpCAM for the detection of CTCs in prostate cancer patients was successful 57% 
of the time. This was compared with the detection of EpCAM positive CTCs from non-
small cell lung cancer where the successful detection rate was only 20% [8,9]. It is clear 
from this study that EpCAM cannot be used for the detection of all types of CTCs. 
EpCAM can be used for certain carcinomas, like prostate and breast cancers but that for 
lung and bladder cancer, alternative markers and methods must be applied [9,10]. If this 
is the case the nanoparticles could only be used on certain types of carcinomas and that 
other antibodies would have to be conjugated to the nanoparticles to detect other types 
of CTCs.   
As EpCAM is a marker that cannot be relied upon alone, a panel of markers, that are a 
combination of epithelial and non-epithelial based must be envisaged that should 
indicate the presence of CTCs in a sample. One negative control that is routinely used is 
the anti-CD45 negative stain [11]. This is a marker for WBCs that is not expressed by 
CTCs, however, the expression of CD45 is quite varied between WBCs and some have 
low/no expression of CD45, particularly neutrophils, myeloid-derived suppressor cells 
(MDSCs) or other immature myeloid cells [12-15]. The challenge is combing a number 
of these antigens together to form a panel of antigens to categorise the CTCs. 
CellSearch®, which was FDA approved, have chosen four steps to categorise a cell as a 
CTC. These are: that it must be EpCAM positive, cytokeratin positive, have a nucleus 
and be negative for CD45 [16]. Such a range of markers have been successful in the 
identification of breast cancer CTCs. Using the nanoparticles as stains would have to 
follow the same protocol as CellSearch®, in identifying a number of criteria or stains to 
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identify CTCs in blood. In order to complete this challenge, a range of dyes at different 
wavelengths would have to be synthesised and antibodies specific to the desired antigens 
would have to be conjugated to them. This would provide a panel of markers from which 
the NPs could be used to doubly or triply verify that the EpCAM positive cells are 
actually CTCs. This would require an investment in time and any issues with non-
specific binding would have to be addressed, particularly when dealing with false 
positives or false negatives. Some suggestions to improve non-specific binding of 
nanoparticles are suggested in section 9.3.  
If these challenges can be overcome, such as; detection of low EpCAM expression on 
patient CTCs, designing of a CTC antigen identification panel and non-specific binding 
of nanoparticles, then I believe that nanoparticles could be used as a viable stain to 
identify CTCs from the blood of cancer patients.  
9.3  Outlook 
Overall, the potential for dye-doped silica nanoparticles to be used as a new type of 
antibody label was realised throughout this work. The NPs offer a viable alternative to 
single dye labels for cell staining and, with some optimisation, have the potential to be 
a very powerful tool in the applications of CTC detection via flow cytometry and 
microscopy. It is hoped that the work will continue in this field of nanoparticles to 
improve sensitivity of the NPs and allow the synthesis of highly sensitive cancer 
detection tools which can improve patient outcome by detecting these rare cells in low 
numbers. 
This is just one application of the NPs, but they could be used for many more specific 
applications such as rare antigen tagging. This work has shown that NPs containing 
cheaper dyes with lower quantum yields can be comparable to antibodies conjugated 
with more expensive dyes of higher quantum yields. Doping the NPs with dyes of higher 
quantum yield would increase the photon emission of each nanoparticle allowing for 
brighter emission signal for the detection of those rare surface antigens. Not only can 
these NPs be used to incorporate red dyes but they can be substituted for most dyes 
throughout the spectral range thus allowing the development of a large set of 
nanoparticles for different excitation and emission wavelengths. This could allow for 
multiple antigen imaging with different dye-doped silica nanoparticles. However, due to 
the issues regarding non-specific binding that were encountered in this project, time 
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would need to be invested in optimising the NPs so that there is a reduction of non-
specific binding. Some suggestions that have come to light recently include using 
binding/capping agents such as polyvinylpyrrolidone (PVP) to block the surface of the 
NPs. Also, upon the advice of researchers in flow cytometry development, a suggestion 
has been to use low molecular weight linear or branched PEGs in solution to improve 
the stability of the NPs in biologically viable media. Other possibilities that could lead 
to more specific staining rather than modifying the staining buffer, include the use of 
aptamer conjugated nanoparticles or those that use a streptavidin and biotin system 
instead of antibodies. The use of recognition molecules that have a high binding affinity, 
such as biotin-streptavidin, should improve the specificity of the NPs by reducing non-
specific binding through Fc regions on conjugated antibodies.  
There are many possibilities to expand the research of these dye-doped silica 
nanoparticles into other applications such as drug delivery or single cell analysis. As the 
NPs synthesised by this method can incorporate not only dye, they could be used as a 
system of drug delivery. Some modifications to the NPs would have to be made in terms 
of additional shells of silica and functionalisation but it does have a potential for this 
application. Also, if the specificity of the NPs can be improved using aptamers or similar 
then it could be used for high resolution imaging for individual cells such as STED or 
stochastic optical reconstruction microscopy (STORM) to gain a better understanding 
of the positioning of rare antigens or cell structures. 
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Appendix A: Programming codes for 
homo-FRET models 
A1: Codes for calculation of Forster radius: 
% script for calculating Forster radius between Cy5 and Cy5 (homofret) 
ext_Cy5= load('ext_Cy5.txt'); % M^(-1)*cm^(-1) 
em_Cy5 = load('em_Cy5.txt'); 
step=1; 
lambda = 500:step:850; %in nm units 
ex= spline(ext_Cy5(:,1),ext_Cy5(:,2),lambda);   
em= spline(em_Cy5(:,1),em_Cy5(:,2),lambda); 
dl= step*ones(size(lambda)); 
 
J = (em.*ex.*lambda.^4*dl')/(em*dl') % in M^(-1)*cm^(-1)*nm^4 
 
kappa = 2/3  % isotropic orientation 
fiD = 0.20 % quantum efficiency of Cyanine5 
n = 1.5 % refractive index of the surrounding medium  
Na = 6.023*10^23 % Avogadro constant in mol^(-1) 
 
R = (9*log(10)/(128*pi^5*Na)*10^17*kappa^2*fiD/n^4*J)^(1/6) % in nm 
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A2 Radius vs FRET models 
% script for calculating the homo-fret in high brightness NPs 
 
R0 = 5.5525; % forster radius for homo-fret of given dye in nm 
fi = 0:0.01:1; % range quantum efficiency of the dye 
r = 0:0.1:10; % distance in nm 
 
Eff = R0^6./(R0^6 + r.^6); % FRET efficiency equation rearranged 
[EFF, FI] = meshgrid(Eff, fi); 
Ft = (1 - EFF)./(1-FI.*EFF); % equation from paper 
 
fi = 0.20; % QY for cyanine5 
n=1:3:3000; % no. of fluorophores 
R=0.5:0.5:30; % radius of NP in 0.5nm steps 
 
[nn,RR] = meshgrid(n,R); 
% Total fluorescence from one NP 
r6= 16/9*pi^2*RR.^6./nn.^2; 
Ef= R0^6./(R0^6 + r6); 
nFt= nn.*(1-Ef)./(1-fi*Ef); 
 
md= 616.19 % mol. weight of dye 
Na= 6.022*10^23 % Avogadro const 
% Calculation weight percent dye loading 
j=41; 
Rw = R(j) % specific radius of the NP 20.5 nm radius 
wt = n*md/Na./(n*md/Na + 4/3*pi*Rw^3*1.6*10^(-21))*100;  %mass of dye/total mass NP 
 
 
 
figure(3) 
    
                                                                               150 
plot(wt, nFt(j,:)); 
xlabel('wt [%]'); 
ylabel('relative fluorescence by homofret') 
title(['Radius of HB NP = ' num2str(Rw) 'nm (forster radius =5.55 nm, fi=0.20 )']) 
 
assignin('base','x_values',wt.'); 
assignin('base','y_values',nFt(j,:).'); 
 
save Cy5_20.5nm_r_fluorescencetestsave.out nFt -ASCII 
save weightCy5testsave.out wt -ASCII 
 
figure(4) 
plot(wt,n); 
xlabel('wt [%]'); 
ylabel('# of molecules') 
title(['Fluorphores inside HB NP = ' num2str(Rw) 'nm (forster radius =5.55 nm, fi=0.20 )']) 
 
assignin('base','x_molecule_values',wt.'); 
assignin('base','y_molecule_values',n.'); 
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Appendix B: Supplementary figures for 
chapter 4 
 
Fig B1: 1% NPs (a) as synthesised radius of 20.4 ± 1.0 nm and (b) PEGylated radius 29.0 ± 
1.3 nm. The scale bar represents 100 nm. 
 
 
 
 
Fig B2: Absorbance of 0.5 w/w% and 1 w/w% Cy5 NPs after dissolution (t=60 min) of the 
silica matrix using carbonate buffer at pH 10.0. The absorbance of each set was background 
subtracted to reflect a true change in the absorbance at 650 nm. 
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Fig B3:Graph of fluorescence of NP labels 0.168% (top) and 0.279% labels (bottom) in blue 
compared to free cyanine5 dye molecules in red using a cascade dilution of concentrations for 
each label. 
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Appendix C: Supplementary figures for 
chapter 5 
 
 
Fig C1: Optimisation of 0.279% NP concentration for incubation with cells to minimise non-
specific binding with HeLa cells. (A) represents HeLa cells only (B) HeLa cells with 20 µg of 
NPs (C) with10 µg of NPs and (D) with 7.5 µg of NPs 
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Fig C2: Enlarged and enhanced (3a) image from Fig 5.4 showing NPs on HeLa cell (in white 
box) 
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Appendix D: Supplementary figures for 
chapter 6 
 
 
Fig D1: Absorbance spectra for pure silica (Si) NPs, Cyanine5 (Cy5) dye and Cyanine5 doped 
silica NPs 
 
 
Fig D2: Fluorescence emission of pure silica (Si) NPs, Cyanine5 (Cy5) dye and Cyanine5 
doped silica NPs at a fixed wavelength over a range of excitation wavelengths. 
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